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INTRODUCTION 
 
The stem cell transplantation (SCT) program started 40 years ago as a highly 
experimental procedure and has progressively become a common treatment for a wide variety 
of diseases. In the beginning, severe aplastic anemia was the main indication for allogeneic 
SCT (allo-SCT). Currently, poor prognosis leukemia, other malignant and non malignant 
hematological disorders, together with advanced or relapsed solid cancers are treated by allo-
SCT (1). Today, between 30,000 and 40,000 transplants are performed world-wide per year 
(2). Underlying diseases leading to allo-SCT are mostly acute or chronic leukemia and 
lymphoma. 
Autologous hemopoietic SCT is performed more frequently than any other type of 
allogeneic organ transplant world-wide. Underlying diseases leading to autologous stem cell 
transplant are mostly lymphoma, leukemia and multiple myeloma. 
As the number of long-term survivors after SCT is progressively increasing, more 
attention is now focused on early and late complications of this procedure which may worsen 
the quality of life and threaten the long-term outcome of transplant recipients (1).  
The majority of the data available on the late effects of SCT on the endocrine 
system concerns the pediatric population, whereas the studies in patients transplanted in 
adulthood are still scarce. The relative risk of endocrine complications was found to be 
influenced by the underlying diseases, previous therapies, the use of radiation treatment and 
the type of its schedule, post-transplant treatments and the age at SCT (3-5). Conditioning 
regimens that preceed SCT are designed to eradicate the underlying hematological disease 
(mostly a malignancy) and suppress the host immune system in the allogeneic setting. They 
consist of highly aggressive antiblastic treatments with or without total body irradiation 
(TBI). Most of the data concerning the endocrine function derive from the study of patients 
who underwent TBI as a part of pre-transplantation treatments. TBI has been reported as 
being responsible for a large part of post-transplant endocrinopathies. Only a few studies have 
been carried out in adults treated without TBI (6,7); consequently, the impact of 
chemotherapy alone and/or other possible risk factors in the functioning of the endocrine 
system is still not completely elucidated in SCT recipients. 
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The relationship between the endocrine and the immune system is well known; 
various endocrine glands are target organs that are frequently influenced by dysregulations of 
the immune system. As a matter of fact, large amounts of cytokines are released at the time of 
transplantation (8), and immune deficiency occurs because of delayed and incomplete 
recovery of the immune system, particularly as a consequence of allo-SCT. Graft-versus-host 
disease (GVHD) simultaneously causes both stimulation and suppression of the immune 
system, the latter one due to either direct immunosuppressive effects or as a consequence of 
the treatments of this disorder (9). The prevention and treatment of GVHD consist of high-
dose immunosuppressive therapies including mostly glucocorticoids, methotrexate, 
cyclosporine A and mofetile mycophanolate. Consequently, the integrity of several systems 
and tissues, including the endocrine, reproductive and skeletal system function, may be 
affected by multiple exogenous and endogenous damaging factors.  
When concerning with bone loss consequent to allo-SCT, many authors have 
described it as being more persistent and severe at cortical bone (femoral neck) when 
compared to trabecular sites (lumbar spine) (1-7). Damaging effects on bone mass were 
attributed to hypogonadism, immunosuppressive and myeloablative treatments, 
immobilization, increased cytokine release and dietary and metabolic changes concerning 
with calcium and vitamin D (5,6). One of the most important risk factors for bone loss is 
represented by precocious ovarian failure (POF), which is also the most common 
complication of allo-SCT (8-10). Calcium and vitamin D supplementation, and hypogonadism 
replacement are commonly used in clinical practice after SCT, while bisphosphonates are 
added only in patients with osteoporosis. Until today, little data is available on the effects of 
preventive or therapeutic interventions on post-transplant bone loss (1,11-13). No systematic 
evaluation has been performed yet in comparing the effects of different agents for prevention 
or treatment  of osteoporosis consequent to SCT. All commonly employed antireabsorptive 
treatments have been shown to improve bone mineral density (BMD) and decrease the rate of 
fractures in post-menopausal and glucocorticoid-induced osteoporosis (14-17). However, the 
use of these treatments in transplanted patients may be limited by the general health 
conditions and by the simultaneous presence of other complications, including acute and 
chronic GVHD. The liver, skin and gastrointestinal tract are the most common localizations of 
cGVHD (18), which  in the active phase may represent a contraindication for the use of oral 
or trans-dermal therapies; even a mild chronic GVHD  may reduce gastrointestinal or dermal 
drug absorption. Furthermore, allo-SCT patients usually run into long-lasting and complex 
  5 
therapeutic regimens in order to prevent or treat other complications; thus, the management of 
osteoporosis can be difficult in some of them. 
 
 
Endocrine consequences of the allogeneic stem cell transplantation in adults  
 
 
The hypothalamus-pituitary-gonadal (HPG) axis 
 
Women 
Gonadal failure is the most frequent endocrine consequence of high dose 
chemotherapy and radiotherapy for any malignancy; recovery is rare and age-dependent, and 
it is more frequent in girls than in adult women (10,11). Loss of ovarian function occurs as a 
result of cytotoxic agents and TBI used before transplantation in a dose-dependent manner (6, 
12-15). In fact, the LD50 (the radiation dose causing the death of 50% of cells) for the human 
oocyte has been estimated to be less than 4 Gy (16). Sanders et al. (14) studied 144 women 
transplanted for leukemia after conditioning with cyclophosphamide and TBI; they reported 
hypergonadotropic amenorrhea in 100% of the women for the first years after SCT, and only 
6% experienced late ovarian function recovery. All alkylating agents have toxic effects on the 
ovaries (17), they damage oocytes and supporting granulosa cells of both proliferating and 
resting follicles in a dose-dependent way (18). The older you get towards the transplant, the 
lesser the probability of ovarian function recovery; it decreasess by a factor of 0.8 per year of 
age (14). 
In women receiving chemotherapy only, single agent cyclophosphamide was 
associated with ovarian function recovery in 31% (6 out of 16 women) of patients 
transplanted < 26 years, but in none of those over 26 yrs (14). The addition of busulphan to 
cyclophosphamide in either "little" BU/CY (BU 16mg/kg, CY 120 mg/kg) or "big" BU/CY 
(BU 16 mg/kg, CY 200 mg/kg) regimens caused permanent ovarian damage in everyone apart 
from some exceptions (19,20). 
In a study by Chatterjee et al. (21), acute effects on ovarian function of high dose 
multiagent chemotherapy did not differ if they were administred with or without TBI.  The 
severity of the acute damage did not predict the probability of the late recovery of ovarian 
cycles. 
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In our experience, all but two women had ovarian insufficiency following SCT. About 
one third of the women became menopausal several months before allografting consequently 
to previous chemotherapies, while in the remaining patients, the cycles disappeared after 
conditioning regimens (22). The youngest patient, 13 yr at SCT, and another treated for 
aplastic anemia (without previous antiblastic agents) experienced a spontaneous recovery of 
ovarian function with regular menstrual cycles after 12 and 18 months of amenorrhea. 
Premature menopause has serious psychological and medical effects (23) and requires 
treatment. Hormonal replacement therapy (HRT) should be initiated after complete 
hematological reconstitution but can be contraindicated for long periods in women with 
severe chronic liver GVHD. In fact, estroprogestins may induce liver toxicity, and they 
interfere with the hemostatic balance. Moreover, HRT may not be fully effective because of 
reduced intestinal or cutaneous absorption, as found in 30% of women in our cohort (22). 
During secondary hypergonadotropic amenorrhea, PRL levels are usually normal and 17-β-
estradiol is often undetectable. We have also found reduced androgen circulating levels, likely 
due to either ovarian damage or adrenal suppression by immunosuppressive treatments of 
cGVHD (24). In particular, ovarian contribution to lower serum androgens was suggested by 
the correlation between ovarian volume  and patients’ estradiol and androgen levels; however, 
lower DHEAS values in patients with cGVHD were related to longer and more recent 
corticosteroid use. The impact of a low residual androgen steroid secretion after allo-
transplantation on women’s health, especially in terms of osteoporosis, cardiovascular risks 
and quality of life remain to be established as well as any future potential therapeutic 
implications. 
A serious complication in the peri-transplantation period is the polymenorrhea, 
which can be dangerous due to a suppressed hematopoiesis and the difficulty in controlling 
the bleeding. The treatment most commonly used is norethisterone acetate which has been 
shown to be the major risk factor for liver veno-occlusive disease (25). Recently, the use of 
gonadotropin releasing hormone analogues (aGnRH) with suppressive effects on the 
hypothalamic-pituitary-gonadal axis, has been shown to prevent peri-transplant vaginal 
bleeding,; moreover, they do not interfere with the hemostatic balance or cause liver toxicity 
(26). However, aGnRH administration should be started one month before the conditioning 
regimen (27) because of initial mild stimulatory effects on the HPG axis. While it has been 
established that hypogondadism induced by GnRH analogues administration prevent peri-
transplant bleeding, there is no sufficient evidence that it can be effective in preventing 
ovarian damage related to the antiblastic treatments. 
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Men 
Germinal epithelium of the testis is more vulnerable to the effects of chemotherapy 
and irradiation than the Leydig cells (28) in both childhood and adulthood. A return of 
elevated FSH levels to the normal range has been occasionally observed in patients treated by 
high-dose chemotherapy and a single-fraction TBI of 7.5 Gy. This observation has been 
explained by a recovery of germ-line function (29). Conversely, a very rare recovery of 
spermatogenesis has been described in adults after fractionated TBI (30). Molassiotis et al. 
(31) observed persistently increased FSH and LH levels in the majority of transplanted males, 
regardless the use of TBI. Concerning the Leydig cell function, normal testosterone levels 
were found in most of the patients following SCT by Littley et al. (30), whereas Chatterjee et 
al. (21) reported a subtle, but persistent Leydig cell dysfunction. More recently, the same 
group of authors have focused attention on libido and erectile dysfunction in men who had 
previously been treated by high-dose chemotherapy and TBI conditioning for myeloma; the 
athors attributed the sexual dysfunction to cavernosal arterial insufficiency (30). Van Basten 
did not confirm the presence of arterial dysfunction in a population that was only treated by 
chemotherapy (32) and thus, this seems to be mainly a consequence of TBI. 
We have found a persistent increase in FSH values in 47% of men after allo-SCT, 
suggestive of spermatogenesis damage. However, azoospermia was also found in men with 
FSH levels within the high-normal range (22). This finding suggests that germinal tissue 
damage cannot be ruled out by near-normal gonadotropin values, and a spermiogram is 
always necessary. Keilholtz et al. (12) and Mertens (33) found a similar FSH increase in long 
term survivors after autologous SCT (up to 92%); in those studies however, the patients had 
received radiation treatment. In a study by Grigg, cGVHD was associated with lower sperm 
count in male long-term survivors after busulphan/cyclophosphamide conditioning, 
suggesting some possible effects of this chronic complication on gonadal status (19). For 
men, the age during treatment seems to be less important than for women in the development 
of gonadal failure (4,12). In contrast, the underlying disease, the type of antiblastic drugs 
and/or the duration of their administration, all affect the likelihood of spermatogenesis 
damage. 
Testosterone production was unaffected in our long-term survivors out of treatments 
and nobody reported a regression of secondary sexual characteristics. On the other hand, all 
men evaluated during GVHD had low testosterone levels, likely due to an inhibitory effect of 
the immunosuppressive treatments on the hypothalamic-pituitary-gonadal axis. In fact, 
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glucocorticoids are known to suppress GnRH release and consequently the function of the 
whole axis. Moreover, the adrenal source of androgens is also inhibited by glucocorticoids. 
The role of CsA treatment for testicular injury cannot be excluded as it is known to damage 
the testicles in long term treatments (34). 
Testosterone replacement is rarely required given the mostly mild and transient 
nature of sexual steroid decrease in men after SCT. There is one case report describing the 
failure of preventing TBI-induced testicular germinal cell damage by GnRH analogue 
administration (35). Currently, the only possibility to achieve a certain conceivement after 
allo-SCT is by sperm cryopreservation. 
  
Reproductive function  
The majority of patients experience gonadal damage after SCT and a consequent 
infertility. Thus, options to preserve fertility have been searched. Sperms and embryos 
conceived by in vitro fertilization can currently be well cryopreserved, but oocyte banking, in 
the absence of a male partner, is more difficult and still an experimental procedure (36). Not 
only the conservation but also the pick up of germinal cells is technically more complex in 
women. For a satisfactory oocyte pick up, women have to undergo ovarian stimulation for 
several weeks before starting high-dose chemotherapy, monitoring the follicular growth by 
ultrasonography. Following these procedures, an aspiration of the follicles should be 
performed. All of this is often difficult to achieve due to the severity of the underlying 
malignant disease and the urgency to start antiblastic treatment as soon as possible. 
Furthermore, women affected by cGVHD can be predisposed to vulvo-vaginal infections, 
vaginal and even cervical stenosis and dysfigurement of the internal and external genitalia 
including the perineum. All of these disorders make it difficult for these women to have 
sexual intercourse, they can suffer from dyspareunia, reproductive failure and difficult birth 
labor (37-39). 
Sporadically, successful pregnancies have been reported in recent decades, especially 
in women who underwent autografting (40); however, most of the information regarding this 
issue derived from two large surveys conducted in Europe and the USA (20,41). In each 
population, partners of male patients had uncomplicated pregnancies and normal children, 
whereas women after allografting had a high incidence of miscarriage, pre-term labor and low 
birth weight babies, indicating the difficulty to carry out their pregnancy due to damage of 
both the ovaries and uterus. The rate in congenital malformation, developmental delay and 
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malignant disease was just as high in the offspring of SCT recipients as in the general 
population. Nevertheless, lower pregnancy rates and crude birth rates were revealed among a 
mixed population of transplanted patients than in the general population and they were worse 
in women that were previously treated by TBI. Germinal cell damage, endocrine dysfunction 
and disorders of pelvic vascularization can all contribute to a worse outcome of the 
reproductive function after SCT (42-44). 
In our experience of a total of 106 patients who had undergone allo-SCT in this 
center, only two pregnancies occurred: one was reported in a wife of a male patient who had 
received allograft 3 years earlier. One woman delivered two healthy twins 5 years after allo-
SCT with hormonally fully assisted pregnancy with oocytes donated by a sister. 
On the other hand, some reports have shown evidence of relapse of leukemia during 
pregnancy. However, it cannot be excluded that the patients have relapsed independently from 
pregnancy, and it is uncertain whether the natural history of the primary hematological 
disease can be influenced by pregnancy. Since the relationship between underlying diseases 
and pregnancy is still unclear, Salooja et al. (41) recommended that pregnancy would be 
delayed for more than 2 years after a SCT, especially in patients with CML. Moreover, they 
should  have a persistently negative Philadelphia chromosome and bcr/abl transcriptase. 
 
The hypothalamus-pituitary-adrenal (HPA) axis  
In accordance with a previous hypothesis on relative radio-resistance of adrenal tissue 
(3), post-allografting secondary adrenal insufficiency due to suppression of the HPA axis, 
seems to be related to the duration and cumulative dose of corticosteroid treatments received. 
Only the initial report by Sanders et al. (45) had described a high incidence of adrenocortical 
dysfunction following TBI and SCT, but subsequent studies have found rare evidence of 
permanent post-transplant cortisol deficiency (22,46). All of the patients who have developed 
secondary adrenal insufficiency in our center had previously been treated with corticosteroids 
for ≥ 10 months for chronic GVHD, at a cumulative dose > 10 gr/m2. Nevertheless, some 
variable individual sensitivities of the HPA axis to exogenous suppression can be speculated.  
Patients with chronic GVHD, in whom corticosteroid treatment is suddenly 
withdrawn because of the onset of an important infection, are at a high risk in developing an 
acute adrenal crisis that can further worsen their clinical condition. However, the prevalence 
of mild (or dynamic) temporal adrenal insufficiency is still likely to be an underestimated 
condition, therefore, a stimulation test should be performed to exclude any mild degree of the 
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HPA axis insufficiency. This procedure is still uncommon, unless thoroughly and specifically 
investigated by endocrinologists. In our experience, all of the patients recovered from adrenal 
insufficiency after 3 to 18 months. 
 
The hypothalamus-pituitary-growth hormone axis 
Results of previous studies on GH secretion in adults concluded that the pituitary 
gland is less vulnerable to irradiation damage in adulthood than in childhood. In particular, 
Littley et al. (30) found a normal GH peak response to a GH stimulation test, 17-55 months 
after SCT with TBI conditioning. Kauppila et al. (47) found normal IGF-1 levels in all 
transplanted patients, but 20% of them showed an impaired response to a provocative test 
following TBI for a SCT (<5 mcg/l with GHRH administration).  
When concerning with growth hormone secretion in children, a reduction in growth 
and GH secretion have previously been described after cranial irradiation. Height loss after 
TBI alone resulted less important (48,49). On the other hand, discordant results were obtained 
in children transplanted for leukemia following BU/CY conditioning alone: Sanders (50) 
reported a significant incidence of growth hormone deficiency, while Wingard et al. (51) 
found similar growth rates after BU/CY and CY/TBI over the first two post-transplanted 
years. In contrast to these reports, Liesner (52), Giorgiani et al. (53), Michel et al. (54) Leiper 
et al. (55) and Afify et al. (56) did not find any significant growth impairment up to 5 years 
after BU/CY and SCT. More data on the impact of BU/CY on growth are still needed to draw 
any final conclusion. GVHD has also been found to be associated with impaired growth by 
Sanders et al. (57). Glucocorticoids used for the treatment of this complication have acute 
growth-suppressive effects, however, decreased growth rates were reported also in untreated 
patients with cGVHD, suggesting that other factors directly related to the presence of cGVHD 
contributed to their decreased growth (57). The hypothalamus-pituitary-IGF-I axis function 
has been poorly investigated in adult allo-SCT recipients and our group has studied this 
condition after BU/CY conditioning alone. In contrast to the previous findings in adults, we 
have shown that IGF-I levels were lower than the age-reference values in 38% of patients who 
were affected by cGVHD, whereas IGF-1 resulted reduced in only 7% of subjects who were 
free of cGVHD. This finding can in part explain the previous observation made by Sanders et 
al. (57); in fact, cGVHD represents a condition of a multiorgan injury and is associated with a 
lower BMI. It is well-known that IGF-I reduction is associated with chronic diseases 
accompanied by situations such as starvation or reduced nutrition (58). The hypothesis of a 
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possible influence of the general health conditions on the GH-IGF status is further supported 
by results of Adan et al. (59), who have further investigated the effects of post-transplant 
complications on growth, showing that children with no complication have normal growth in 
contrast to children with any complications who had decreased growth rates (0.5±0.3SD vs. –
1.6±0.3SD), all of these children were conditioned with chemotherapy alone.  
 
The hypothalamus-pituitary-thyroid axis 
The thyroid dysfunction consequent to TBI occurred both in children and adults 
(4,31) and may be transient (60). It is well known that external irradiation to the neck may 
lead to abnormal thyroid function and predispose to thyroid neoplasm. The incidence of 
thyroid dysfunction following fractionated TBI (15-16%)(46,50,61) appears significantly less 
than that following single-dose TBI (46-48%)(50,62,63). The long-term natural history of 
irradiation-induced thyroid dysfunction is still unknown as well as the timing and the peak 
incidence for TBI schedules (4). 
After a TBI dose of 10-12 Gy, the typical biochemical finding is a subclinical 
hypothyroidism characterized by mildly elevated basal TSH levels and a thyroid hormones 
within the normal range (46,50,60,63) with overt hypothyroidism being a rare finding. As a 
matter of fact, Al-Fiar et al. (64) has observed a trend with an increase in the incidence of 
thyroid dysfunction associated with increasing TBI doses. 
On the other hand, an eightfold increase in the incidence of hyperthyroidism has 
been found following neck irradiation for Hodgkin’s disease (65), being dose-related and 
affected by latency period.  
Chemotherapy-only conditioning regimens (BU/CY) were also implicated in thyroid 
dysfunction and TSH increase, with an 11% incidence reported by Al-Fair et al. (64) vs. 
16.7% for 12 Gy TBI. Most of the patients were evaluated within 2 years after SCT. Similar 
frequency was reported by Toubert et al. (14%)  in a cohort of patients not treated by TBI (6).  
The type of transplant may play some role in the development of thyroid disorders. In fact,  
sub-clinical and overt thyroid function impairment has been more frequently reported after 
allo-BMT (6,66,67) but less in autologous BMT recipients (12). Kauppila et al. (47) have 
reported exaggerated TSH response to TRH in 35% of patients after a mean of 3.2 years 
following allo-SCT. Sub-clinical hypothyroidism was revealed late after allo-SCT in our 
experience (> 5 years after SCT), all but one had normal baseline TSH levels. L-thyroxin 
replacement treatment was given to both patients.  
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Although increased frequency of transient thyreotoxicosis has been described early 
after allografting and immune induced injury has been claimed as the pathogenetic factor 
(22,66), hypothyroidism can be discovered years after transplant and has been ascribed 
principally to TBI and busulphan therapy (57,60,68,69). The prevalence of transient sub-
clinical hyperthyroidism in our patients (15%) was in line with data from a recent longitudinal 
study by Kami et al. (12.3%)(66). Antibodies toward thyroid were not necessarily present in 
patients with sub-clinical hyper- or hypothyroidism. We reported at first a biochemical and 
ultrasonographic evidence of chronic thyroiditis associated with normal thyroid function in 
allo-BMT recipients, occurring 2 to 10 years after allo-SCT.  
Toubert et al. (6) have found low T3 syndrome (FT4 and TSH within, and FT3 
below their respective ranges of normality) in 48% of patients at 3 months decreased to 19% 
at 14 months after allo-SCT, while Schulte et al. (70) described this condition in 100% of 
patients at day 14 after SCT, and its persistence to day 28 was associated with a higher 
probability of fatal outcome. We have found persistence of the low T3 syndrome in patients 
with chronic extensive GVHD even 12-48 months after BMT, likely due to decreased extra-
thyroidal conversion of thyroxin to 3,5,3’ triiodothyronin induced by either chronic disease or 
glucocorticoid treatment (71,72). 
An increase in the prevalence of thyroid papillary carcinoma was found in SCT 
recipients compared to the general population by two major multicenter studies (one 
European and one American) on late cancer complications (1,73). However, the number of 
events are few (5/3182 children). The risk of thyroid tumors following TBI seems to be dose- 
and age-related (65,74). This is in line with a recent experience of Chernobyl (75), suggesting 
that the thyroid gland is highly sensitive to the radiation effects at a very young age. The 
latency period between thyroid irradiation and clinical presentation of the tumor can be many 
years. As there is a body of evidence from animal studies that TSH increase can be a risk 
factor for thyroid tumorigenesis, the patients with subclinical hypothyroidism should be 
treated with a substitutive levothyroxin dose in order to normalize TSH levels. Nevertheless, 
there is not yet any  evidence of reducing thyroid cancer risk by longitudinal studies of 
irradiated patients. The only thyroid malignancy in our population was a case of thyroid 
lymphoma 8 months after BMT. The pre-existing thyroid nodules were stable over time in all 
patients during the observational period up to 36 months in terms of size and consistence.  
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Risk factors for endocrine disorders 
The risk factors for gonadal damage are summarized in the Table 1. There are some 
gender difference in gonadal damage and recovery: males are less frequently affected and are 
more likely to experience gonadal recovery than females. In cases of gonadal function 
recovery, male gonads tended to recover more quickly than those female (33,43,76). Total 
dose and modalities of TBI administration seem to play an important role in damaging 
endocrine system.  
          Table 1. Risk factors for gonadal damage after allogeneic SCT 
 Risk factors 
Patients’ factors  
Pubertal status Post-pubertal> pre-pubertal 
Age at SCT in women >30 yrs 
Gender  Female > male 
Underlying disease, tendency to infiltrate gonads  ALL, lymphoma 
 
Treatments’ factors 
 
Radiotherapy/type Local, inverted Y 
     Multiple doses 
 Chemotherapy Multiple alkylating agents> single agent 
 Alkylating agents > other chemotherapy 
Type of transplant Allogeneic following TBI > autologous 
 Presence of graft-versus host disease 
  
While multiple fractionating of radiation treatment seems to be less dangerous for the thyroid 
gland than a single dose TBI, gonads injury and GH deficiency are more frequently caused by 
repeated radiation doses (Table 2 and 3). 
 
Table 2. Risk factors for growth hormone deficiency  
 Risk factors 
Patients’ factors Childhood > adulthood 
Treatments’ factors  Cranial irradiation > TBI 
 Radiotherapy > chemotherapy 
 Single dose > fractionated 
radiotherapy 
 Intrathecal chemotherapy 
 TBI: total body irradiation 
 
Type of transplant seems to be important also for other endocrine dysfunction. In particular, 
thyroid and adrenal functions, and IGF-1 impairment occur more frequently in patients after 
allografting than in those who have underwent auto-SCT.  
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Table 3. Risk factors for thyroid dysfunction after hematopoietic stem cell transplant 
Condition Risk factors Time since SCT 
Hypothyroidism  Neck irradiation > TBI Late effect (years after SCT) 
 Single dose TBI > fractionated TBI  
 Allogeneic > autologous SCT  
 Chronic GVHD  
Subclinical hyperthyroidism Allo-SCT Earlier effect (within 12 months) 
Low T3 syndrome General conditions, nutritional status Variable (days – years after SCT) 
 Immunosuppressive treatments  
   
Papillary carcinoma Radio-chemotherapy > chemotherapy Late effect (years after SCT) 
 Childhood > adulthood  
 
 
Among allo-SCT patients, those affected by chronic GVHD had more frequent disorders in 
IGF-1 secretion and in thyroid and adrenal function (22) (Table 4). However, thyroid 
disorders occurred also in 35.7% of our allo-transplanted patients without chronic GVHD. As 
thyroid is one of the most frequently involved target organs in the autoimmune disorders also 
in the general population, its more frequent involvement is present also in the population of 
patients transplanted with SCT. In our experience, men and women were equally affected by 
chronic GVHD, while cGVHD presence was associated with older age at SCT and 
significantly higher cumulative doses of corticosteroids and cyclosporine A compared with 
patients not affected by this complication. Nevertheless, it is difficult to separate clinical 
effects of immune system damage and immunosuppressive treatments. No significant 
difference in thyroid, IGF-I and adrenal impairments was found regarding age at SCT in our 
adult population (22).  
Table 4. Occurrence of endocrine disorders according to chronic graft-versus-host-disease (GVHD)  
in 40 adult patients treated with allo-SCT following little BU/CY conditioning for leukemia (22).  
Variable GVHD +  GVHD –  
Thyroid disorders  14 (53.8%) 5 (35.7%) 
     Persistent low T3 syndrome$ 4 (15.4%) - 
     Chronic thyroiditis* 9 (34.6%) 4 (28.6%) 
     Subclinical hyperthyroidism 4 (15.4) 2 (14.2%) 
     Subclinical hypothyroidism 2 (7.7%) - 
     Thyroid lymphoma 1 (3.8%) - 
Adrenal insufficiency 4 (15%) - 
IGF-I impairment  10 (38%) 1 (7.1%) 
Total of patients affected 18 (69%)# 4 (28.6%) 
The values express number of patients affected and percentage of the subgroup with or without GVHD. $: 
persistent low T3 syndrome means the presence of normal FT3 and FT4 values and TSH levels below the 
low limit of the normal range at least 12 months after allo-BMT; *: diagnosis of chronic thyroiditis was 
based on autoantibodies to thyroid presence and typical ultrasound pattern; **: p< 0.001 vs group without 
GVHD by Mann-Whitney test; #: χ2 = 6.078; p = 0.048 vs group without GVHD. 
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Conclusions 
High prevalence of endocrine dysfunction in allo-SCT recipients have been 
described world-wide by groups performing SCT. Gonadal failure was found in 95-99% of 
women and in 60-92% of men, both related prevalently to TBI and alkylating agents 
administration. On the other hand, thyroid, adrenal and IGF-I impairments were late events 
occurring in up to 47.5%, 10% and 27% of all patients, respectively, being related to 
antiblastic treatments, immune system derangement and to immunosuppressive treatments.  
Allogeneic SCT has become a successful treatment for different hematological 
malignancies and other diseases as well, and is generally performed in young patients 
(1,3,77). Multiple late complications have already been described but few data on risk factors 
of these long term effects of SCT are available, except for gonadal failure. Endocrine 
disorders were mostly ascribed to highly aggressive chemotherapy and TBI. However, 
multiple disorders were found in the endocrine system function of patients not treated by TBI, 
even years after SCT. In particular, we have recently demonstrated that cGVHD profoundly 
impairs endocrine functions in allo-STC recipients, even in absence of TBI. While the toxic 
effects of antiblastic agents have been widely described, the impact of immune system 
damage on endocrine function is less clear. Allogeneic bone marrow/blood derived stem cell 
transplantation is the only case of great amount of donor immunocompetent cells infused to a 
host recognizable as “nonself”, and thus causing graft-versus–tumor reaction, and GVHD. 
While the first is necessary for disease disappearance, the second represents a frequent 
complication that requires immunosuppressive treatments further compromising immune 
system function (78,79). GVHD is divided into acute and chronic disease based upon the time 
of onset. Skin, liver and gastrointestinal tract are principally affected (80-82); however, more 
target organs can be involved in the chronic disease and autoantibody formation – usually 
related to autoimmune disorders-, is more frequently described in the chronic disease 
(79,81,82). Patients developing cGVHD seem to be at greater risk for endocrine dysfunction 
and increased frequency of thyroid disorders, adrenal insufficiency and IGF-I. This findings 
suggest that immunosuppressive treatments and immune system derangement play an 
important role in the development of endocrine dysfunction after allografting. This hypothesis 
is further supported by a previous finding of normal thyroid and adrenal function 5 years after 
autologous bone marrow/blood-derived progenitor cell transplantation (12). 
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Survival for malignant diseases might have as consequence endocrine failure and this 
can be even more relevant considering that patients undergoing allo-BMT are younger than 
recipients of autologous BMT and other organ transplants. Therefore, they require life-long 
attention to detect, prevent and treat symptoms and disorders of endocrine dysfunction. 
Furthermore, important fertility problems remain still to be resolved (35-37,83). A 
multidisciplinary management to patients after allogeneic bone marrow-derived hemopoietic 
stem cells is mandatory. 
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Endocrine disorders during the first year after autologous stem 
cell transplant 
 
 
Introduction  
Autologous hemopoietic stem cell transplant is performed more frequently than any 
allogeneic type of organ transplant world-wide. The endocrine system is one of the most 
common targets of post-transplant complications (1,2). The relative risk of developing 
endocrine disorders was found to be related to underlying diseases, previous treatments, use 
of radiation therapies and type of irradiation schedule, post-transplant treatments and age 
(3,4). It may be difficult for physicians operating outside specialized centers to decide on the 
timing of investigating endocrine disorders. Moreover, it is also essential to identify the type 
of disorders that need treatment, as opposed to those that can only be followed up. 
Underlying diseases leading to autologous stem cell transplant are mostly lymphoma, 
leukemia and multiple myeloma. The transplant is preceded by conditioning regimens that 
consist of high dose antiblastic treatments, with or without total body irradiation, designed to 
eradicate the underlying hematological disease. 
Most of the data currently available on post-transplant endocrine disorders concern 
the pediatric setting, whereas studies in transplanted adults are still scant. Moreover, in 
previous studies (5,6) data from patients submitted to allogeneic or autologous transplant were 
frequently pooled together, with most patients having undergone radiotherapy as a part of 
conditioning regimens (6-8). Currently, no prospective data  exist on endocrine dysfunction in 
adult survivors from autologous stem cell transplant. Subsequently to our finding of a high 
prevalence of persistent endocrine dysfunctions in allogeneic setting (9), in 1999 we began 
endocrine screening in patients undergoing autografting. 
The aim of this study was to assess the function in multiple areas of the endocrine 
system in adult patients with functioning marrow autograft, in disease remission lasting at 
least one year after transplant, in the attempt to clarify the management of post-transplant 
endocrine disorders. 
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 Patients and Methods  
  Patients  
Between 1999 and 2002, 110 adult patients received autologous stem cell transplant 
in our institution. Primary diseases included Hodgkin’s disease and non-Hodgkin’s 
lymphoma, acute or chronic myeloid leukemia, chronic lymphocytic leukemia and multiple 
myeloma. The data relative to 15 patients who had relapsed or died during the first 12 months 
were excluded; the study sample consisted of the remaining 95 patients. The clinical features 
of these patients are summarized in Table 1.  
Table 1. Clinical characteristics of the 95 patients evaluated for endocrine dysfunction after 
autologous stem cell transplant 
 
  Characteristic  Number (%) or 
Median (range) 
Age at stem cell transplant (years) 39 (17-55) 
Women/men 48 (51%)/47 (49%) 
Disease:   
      Hodgkin disease 29 (31%) 
      acute myeloid leukemia 27 (28%) 
      non Hodgkin lymphoma 25 (26%) 
      multiple myeloma 10 (11%) 
      chronic lymphocytic leukemia 4 (4%) 
Previous radiotherapy 
     upper/lower half body 
26 (27%) 
16 (17%)/10(11%) 
Conditioning regimen:  
    Busulphan (16 mg/kg in 4 days) and cyclophosphamide (120       
      mg/kg in 2 days) 
29 (31%) 
    Carmustine (300 mg/m2 in 1 day), etoposide  
     (200 mg/m2 in 4 days), cytarabine (400 mg/m2 in 4 days),   
      melphalan (140 mg/m2 in 1 day) 
56 (59%) 
    High dose melphalan (200 mg/ m2  in 1 day) 10 (11%) 
Corticosteroid treatment:   
    duration (days) 128.5 (30-730) 
    cumulative dose (g/m2)* 6.5 (0.8-13) 
*: cumulative dose of corticosteroids is expressed as equivalents of prednisone. 
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Informed consent was obtained by all subjects and the study was designed in accordance to 
the Helsinki II Declaration on human experimentation. 
The source of the stem cells was an unmanipulated marrow (n=50) or mobilized 
peripheral blood progenitors (n=45). Mobilization was achieved by chemotherapy and a 
granulocyte colony-stimulating factor at a dose of 16 µg/kg daily by subcutaneous injection. 
No patient underwent radiotherapy as part of the conditioning regimen. The conditioning 
regimen for myeloid leukemia consisted of busulphan  and cyclophosphamide administration. 
The combination of carmustine, etoposide, cytarabine and melphalan was used in patients 
with lymphomas and chronic lymphocytic leukemia. Patients with myeloma received only a 
single high dose of melphalan. Twenty-six patients (16 women/10 men) received radiotherapy 
as a part of lymphoma and myeloma treatment, 16 of them over the neck/thorax, the other 10 
over the abdomen/pelvis. 
 
Study protocol 
Patients were evaluated 3±0.4 and 12±0.9 months after autografting for all endocrine 
functions except for the adrenocortical one, which was investigated during the peritransplant 
period, 7-20 days after corticosteroid withdrawal and monitored as appropriate in patients 
with adrenal insufficiency. Thyroid function was evaluated again after 6 months, due to the 
high prevalence of abnormalities found in the 3rd month. Blood samples were obtained 
between 08:00 and 10:30 a.m. Circulating free thyroxine, free triiodothyronine, thyroid-
stimulation hormone (TSH) and autoantibodies toward thyroid, follicular stimulating hormone 
(FSH), luteinizing hormone (LH), prolactin, adrenocorticotropin hormone, 17-β-estradiol, 
testosterone, cortisol, dehydro-epiandrosterone sulphate (DHEAS) and insulin-like growth 
factor I (IGF-I) were measured in a single sample, whereas prolactin was measured as a 2 hr 
profile (6 samples taken every 20 min). All measurements were performed by commercially 
available kits: cortisol, testosterone, estradiol and DHEA-S using Immulite, solid phase 
chemoluminescent enzyme immunoassay (DPC, Los Angeles, CA, USA);  FSH and LH with 
Biodata S,p.A. kit (Rimini, Italy). Serum TSH was measured using an immunoradiometric 
assay (Delfia, Wallac, Inc. Finland) and free thyroid hormones were determined by 
radioimmunoassay Lisophase kits (Technogenetics, Milan, Italia). Antithyreoglobulin 
antibodies were measured with an Ares Serono kit (Milan, Italy) and antiperoxidase 
antibodies by a DiaSorin kit (Saluggia, Italy). The intra-assay variation coefficient was <3.6% 
and the inter-assay one <7.8% for all the measurements.  
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An ultrasound scan of the thyroid gland was performed in all patients using a 7.5 
MHz linear transducer. Transparietal pelvic ultrasound was performed in all women, using a 
3.5 MHz linear transducer. Spermiogram was performed in 35 men 12 months after 
autografting; the remaining 12 men refused seminal fluid analysis. 
 
Statistical Analysis  
Statistical analysis was performed by the SPSS Inc. (Chicago, Ill.) package. Due to a 
skewed distribution of most of the data, median and range were used through the text and in 
the tables. The Mann-Whitney test was used to compare the differences at 3 and 12 months. 
Age, sex, diagnosis and treatments received were investigated as possible risk factors for 
endocrine disorders by χ2 test and by linear or logistic regression analysis, as appropriate. 
Two-sided P values <0.05 were regarded as significant.  
 
Results 
Early abnormalities (at 3 months) 
Serum IGF-I levels were lower than age-reference values in 53 (56%) of patients 
(Table 2). 
Among the 48 women, 42 were in reproductive age: all had had a normal age at 
menarche, followed by regular periods. Two women underwent bilateral ovariectomy because 
of ovarian lymphoma or leukemia infiltration; 37 of the remaining 40 women (93%) had 
secondary hypergonadotropic amenorrhea. Cycles disappeared 3-12 months before 
autografting in 12 women (32%), consequently to previous antiblastic treatments, and in 25 
women (68%) after the conditioning regimens. Only three women (7%) reported normal 
cycles before and after autografting. 
Among the 47 men, one was excluded due to hypogonadotropic hypogonadism of 
unknown onset. High FSH values were found in 39 out of 46 men (85%) and low testosterone  
levels in 17 of them (37%). LH levels were normal in all men. Testosterone (p=0.05) and LH 
(p<0.05) levels were lower in patients with lymphoma than in those with leukemia or 
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myeloma, likely due to a greater inhibition of the reproductive axis by a prior greater 
exposure to corticosteroids.  
 
Table 2. Endocrine evaluation in the 95 patients at 3 and 12 months after autologous stem cell transplant 
Variable 3 month 12 month Normal range 
 Median (range) or number (%)  
IGF-I 120 (67 – 430) 170 (143 –540)* 100-625 ng/ml† 
Women‡ 40 (83%)  40 (83%)  
   FSH 65 (5.8 – 111) 49.5 (4.9 – 103) 2-13 U/L 
   LH 28 (2.4 – 77) 17 (3.2 – 60) 2-15 U/L 
   Prolactin 11 (7 – 16.2) 12.5 (8 – 17.3) 5-20 ng/ml 
   17β-estradiol 15 (8 - 68) 29.2 (8 – 78)* 40-250 pg/ml 
Men   46 (98%) 46 (98%)  
    FSH 22 (2.1 – 59) 16.4 (2.1 – 22) * 2-11 U/L 
    LH 7.5 (2.3 – 40) 6.2 (2.2 – 12) 2-10 U/L 
    Prolactin 6.9 (5 – 29) 7 (4.5 – 23) 5-20 ng/ml 
   Testosterone 3.0 (1.8 – 7.9) 4.8 (2.0 – 8.1)* 3.0-10.0 pg/ml 
TSH 1.56 (0.25 – 7) 1.6 (0.8 -10.5) 0.3-3.5 mUI/ml; 
Triiodothyronine 3.2 (1.9 – 4.4) 3.7 (2.9 – 5.2)* 2.8-5.6 pg/ml 
Thyroxine 10. 5 (7 – 15.4) 10.8 (7.3 – 14.8) 6.6-18.0 pg/ml 
Subclinical hyperthyroidism 15 (16%) 0* - 
Subclinical hypothyroidism 9 (9%) 11 ( 12%) - 
“Low T3” syndrome 29 (30.6%) 0 * - 
Patients with antibodies to thyroid 11 (12%) 16 (16.8%) - 
Number of subjects with antibodies 
antiperoxidase / antithyreoglobulin / both  
5 /5/1 7 /6/3 <10 U/ml and <100 
U/ml 
Ultrasonographic evidence of chronic 
thyroiditis 
4 (4.2%) 3 (3.15%) - 
† : the normal IGF-I range in men was 180-625 µg/l for <20 yrs of age, 118-475 µg/l for ages 21-30 yrs, 
102-400 µg/l for 31-40 yrs, 100-306 µg/l for 41-50 yrs and 95-270 µg/l for 51-60 yrs. In women <20 yrs of 
age it was 151-530 µg/l, 21-30 yrs: 118-450 µg/l, 31-40 yrs: 100-390 µg/l, 41-50 yrs: 96-288 µg/l and 51-60 
yrs: 90-250 µg/l. ‡: only women in reproductive age with ovaries were considered; *: p<0.01 vs. values at 3 
months. 
Prolactin was within the normal range in all patients. 
Secondary adrenal insufficiency was diagnosed in 28 out of 95 (30%) patients; all of 
them had been treated with corticosteroids as a part of previous treatment protocols, at a 
median cumulative dose of 7 g/m2 for an average period of 130 days. However, a cumulative 
dose of corticosteroids (7±5 vs. 6±4 g/m2, p=0.3) and the duration of the treatment (126±130 
vs. 141±200 days; p=0.7) were similar in patients who had or had not developed adrenal 
insufficiency, suggesting some individual variability in the adrenal axis suppression. 
Pre-transplant thyroid function was normal in the 40 patients tested. After the 
transplant, the “low T3 syndrome” (thyroxin and TSH within, and  triiodothyronine below the 
normal range) was found in 29 patients (31%). Sub-clinical hyperthyroidism (normal 
triiodothyronine and  thyroxine with TSH below the normal range) was diagnosed in 15 
patients(16%). Subclinical hypothyroidism (normal thyroid hormones and TSH 4-7 µU/ml) 
was diagnosed in nine patients (10%): in one it was transient, while in eight it progressively 
worsened. Pre-existing thyroid nodules had been reported in 10 patients (11%), while in 
another 5 cases (5%) the nodules were detected after the transplant; their diameter ranged 
between 0.7-2 cm (median, 1 cm). 
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Late abnormalities (at 12 months) 
Serum IGF-I levels normalized in 17 out of 53 (18%) patients and remained low in 
36 cases (38% of 95). 
Four women (11% of 37) experienced a spontaneous recovery of the ovarian 
function. Estradiol was significantly higher in patients aged <35 yrs than in the older ones 
(41±19 vs. 12±35 pg/ml; p=0.003) and lower in women conditioned by 
busulphan/cyclophosphamide when compared to other conditioning regimens (15±5 vs. 
35±22 pg/ml; p<0.0001). No predictors of recovery for menstrual cycles were found within 
the first year after autografting. Among the 33 women with persistent amenorrhea, 10 (30%) 
had a further increase in gonadotropin levels (by 30-100% of baseline) and had no 
ultrasonographic evidence of ovarian follicles. In 13 other women (39%) ovarian follicles 
were detected, FSH levels reduced and estradiol increased.  
Testosterone levels normalized in 15 men (88%) and remained low only in two. FSH 
remained above the normal range in 38 (83%) of men. Patients previously treated by pelvic or 
abdominal radiotherapy had significantly higher FSH levels (22±8 vs. 14 ±4 UI/L; p<0.0001). 
There were no other predictors of gonadal axis function improvement in men. Abnormalities 
of seminal fluid analysis were found in all 35 patients: 32 had azoospermia (91%) and three 
had oligospermia with reduced motility (9%). 
Adrenal insufficiency recovered after 3 to 7 months in all patients. Interestingly, 
cortisol and DHEAS values were still significantly lower in 10 patients previously treated by 
abdominal/pelvic irradiation, compared to those who had never received radiotherapy 
(cortisol: 117±54 vs. 162±47 ng/ml, p=0.002; normal range, 50-250 ng/ml; DHEAS: 98±59 
vs. 210±98 mcg/dl, p<0.001; normal range, 80-560 mcg/dl). 
The “low T3 syndrome” disappeared invariably, and  triiodothyronine levels 
normalized in all subjects. Sub-clinical hyperthyroidism diagnosed in the 3rd month was also 
transient, and had disappeared by the 6-month evaluation. A mild increase in thyroid 
autoantibodies which is a biochemical evidence of chronic autoimmune thyroiditis, was found 
in 11 (12%) patients at 3 months and in 16 (17%) at 12 months, all of them had normal 
thyroid function. The ultrasound showed a non-homogeneous hypoechoic pattern typical of 
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thyroiditis in only four of them. Three new cases of subclinical hypothyroidism were detected, 
accounting for a total of 11 (12%) hypothyroid patients. As expected, the frequency of 
hypothyroidism was higher in patients previously (15-36 months earlier) treated by 
neck/thoracic radiotherapy than in untreated ones (50% vs. 1.3%; p<0.0001). Pre-existing 
nodules disappeared after transplant in two patients and remained stable in all the others, in 
terms of size and consistency.  
Discussion 
This prospective study aimed at investigating endocrine dysfunctions during the first 
year after autologous stem cell transplant; it shows an equal distribution of endocrine 
disorders among men and women, with multiple glands involved in most cases. Persistent 
gonadal insufficiency was the most frequent abnormality (>90%).  Persistent IGF-I deficiency 
(38%) and hypothyroidism (12%) were observed less frequently, while peri-transplant 
hypocortisolism (29%) was transient. A significant prevalence of transient hyperthyroidism 
(16%) was also documented. Since we do not have data on endocrine function before 
transplant for all patients, except for adrenal function and menstrual disorders, we cannot 
exclude that some dysfunctions preceded the transplant procedure. Since radiotherapy was not 
used in conditioning regimens and only few patients had previously received irradiation, we 
are unable to speculate as to whether endocrine system damage may have been due to 
different doses or regimens of radiotherapy. 
While large studies on growth hormone-IGF-I axis disorders have been reported in 
children (12-14), scarce data are available in adults. In this study we did not perform any 
stimulation test to evaluate the growth hormone secretory potential, therefore, we cannot 
discuss this issue. We measured, however, circulating IGF-I levels and we found them 
significantly decreased in 56% of patients 3 months after the transplant, with a recovery in 
18% of them, within 12 months. The recovery can likely be explained by the loss of the 
inhibitory effect of previous glucocorticoid treatment on the somatotropic axis, and by an 
improved metabolic state late after autografting (15). 
Gonadal damage affected virtually all patients, with a few exceptions. The dominant 
manifestation was hypergonadotropic amenorrhea in women and spermatogenesis injury in 
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men. Both alkylating agents and irradiation cause germ cell injury and damage to Leydig cells 
in men, and to the follicular pattern in women (3,18). Indeed, women conditioned by 
busulphan/cyclophosphamide had lower estradiol levels than those conditioned by the other 
regimens. Menstrual cycles recovered in only 7 (18%) out of 40 women within the 12th 
month, while later recovery may be possible in some of the other 13 women with ovarian 
follicles at pelvic ultrasonography (10,20). Younger age has often been associated with higher 
likelihood of reproductive function recovery (9,10,21); this finding did not emerge clearly in 
our cohort up to 12 months after transplant. However, higher estradiol levels in younger 
patients indicate better residual ovarian function. 
Impaired spermatogenesis was documented in all patients who underwent seminal 
fluid analysis at 12 months, 91% of them showed germinal aplasia with azoospermia. 
Increased FSH levels were found in 85% of men, indicating that spermatogenesis damage was 
not always associated with FSH increase. Increased FSH levels up to 5 years were previously 
found in 2/3 of auto-transplanted men (22), and spermatogenesis resumed later than 12 
months after allografting (23); thus, some patients will likely have spermatogenesis recovery 
later on. In our cohort, radiotherapy was associated with significantly higher FSH levels, 
suggesting a greater testicular injury in patients treated by abdominal/pelvic irradiation. 
Similarly, a greater cumulative probability for germ cell injury was previously found in 
patients treated by radiotherapy than in those treated by chemotherapy only (6,24). When 
concerning with the hormonal pattern, the data is controversial, indicating either persistently 
low or normal testosterone levels in long-term survivors to autografting (17,25,26). 
Overt adrenal insufficiency was principally related to corticosteroid treatment as part 
of previous cytotoxic regimens for the underlying diseases. No stimulation test was performed 
in this study; therefore, a milder degree of adrenal insufficiency cannot be excluded in other 
patients. Although serum cortisol recovered within the normal range after a period of 
appropriate replacement therapy, previous radiotherapy was associated with lower cortisol 
and DHEAS levels after 12 months. Only the initial report by Sanders et al. (27) described a 
high incidence of adrenocortical dysfunction following total body irradiation and stem cell 
transplant; subsequent studies found rare evidence of permanent post-transplant cortisol 
deficiency (4,28). Other authors have reported a persistent (up to 5 years) decrease in adrenal 
androgens in children conditioned by radiotherapy, despite their normal cortisol values (29). 
In the light of these findings, radiotherapy, although not causing permanent adrenal 
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insufficiency, can cause long-lasting partial injury  to the adrenocortical tissue, expressed 
principally as reduced androgen production. 
Thyroid abnormalities were more frequent in our sample (66%) than in those of 
previous studies (28,30,31) where thyroid dysfunctions were mostly ascribed to radiotherapy. 
Carlson et al. described thyroid disorders in only 18% of patients, 3 to 60 months after 
autografting (30). In our cohort, subclinical disorders were also considered. Subclinical 
hyperthyroidism was transient, i.e., limited to the period of  immunological reconstitution 
occurring within 3 months after the transplant. Transient thyreotoxicosis was reported during 
the same period (peak, 100 days) after allografting, and an immune induced injury was 
claimed as the major pathogenic factor (31). A similar disorder, although less expressed, may 
also occur after autografting and the difference in severity can be related to a milder degree of 
immune system derangement after autologous transplant (32,33). Subclinical hypothyroidism 
was mostly related to previous radiotherapy and worsened progressively in all but one patient. 
In analogy with our  finding,  other authors also described busulphan/cyclophosphamide 
conditioning to be linked to thyroid dysfunction  and TSH increase, with a similar incidence 
(11%)(34). Biochemical evidence of thyroiditis was found in 17% of patients, while a typical 
ultrasonographic pattern was observed in only 4%. Further investigation is needed to clarify 
this discrepancy. Elevated thyroid antibody titers also appeared up to 12 months in 4/111 
auto-transplanted patients (30). 
Transient “low T3 syndrome” was likely part of the negative metabolic condition that 
persisted several months after transplant, and disappeared thereafter. Corticosteroid and 
antiblastic treatments may also contribute to this thyroid dysfunction (35-39). Thyroid 
nodules were mostly small and stable over follow-up. 
Frequent post-transplant endocrine disorders raise an important clinical question of 
when and how to treat them. Transiently low IGF-I does not always mean growth hormone 
deficiency in transplanted patients. The deficiency should be investigated after resolving the 
post-transplant negative metabolic situation and after an adequate interval from corticosteroid 
withdrawal. It is still unclear whether replacement treatment may be helpful in growth 
hormone deficient adults after transplant. Hypergonadotropic amenorrhea often seems 
irreversible, and should be treated by hormone replacement or oral contraceptive therapies in 
all reproductive aged women, unless contraindicated. As spontaneous pregnancies have been 
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reported in auto-transplanted women on hormonal replacement therapy (40), these patients 
should be advised to use other contraceptive measures, especially in the presence of ovarian 
follicles. Hormone therapy should be withdrawn for a period of 2-3 months a year, monitoring 
the reproductive axis function. It is still unclear to which extent mild transient male 
hypogonadism may influence general health condition and whether replacement treatment 
may be helpful. Generally, it is left untreated, although some reports indicate a relationship 
between transient low testosterone levels and bone mass decrease (41,42). Spermatogenesis 
hardly recovers within 12 months after autografting and should be monitored every 6-12 
months thereafter. Adrenal insufficiency is still an underestimated condition; albeit transient, 
it can impair post-transplant recovery. Replacement therapy with short-acting steroids is 
mandatory, with a progressive reduction of the dose, in order to enable the adrenal axis to 
gradually recover. When concerning with thyroid function, we recommend to perform the 
first evaluation within 3 months after autografting. Patients with a completely normal picture 
should undergo annual assessment of thyroid hormones, thyroid specific autoantibodies and 
ultrasonography. Transient hyperthyroidism is usually non symptomatic in auto-transplanted 
patients, and does not require any treatment; the same is true for the “low T3 syndrome.” 
Nevertheless, these patients should be monitored every three months until their endocrine 
values are normalized. Patients with thyroiditis and normal thyroid function should be 
monitored every 3-4 months, due to their risk in developing hypothyroidism. Hypothyroidism 
needs replacement treatment, since TSH increase is considered as the main regulator of 
thyreocyte differentiation and proliferation (43). While it is well established that external 
irradiation of the neck may predispose to hypothyroidism and thyroid neoplasms, the natural 
history, timing and peak incidence in adults are still unknown (3,44-46). This issue is even 
less clear for patients who have undergone chemotherapy and transplant procedures. 
Therefore, all patients should undergo life-long yearly evaluations of thyroid function and 
morphology. 
In conclusion, this study documents frequent endocrine disorders during the first year 
after autologous stem cell transplant. Despite the tendency to improve, in more than half of 
the cases, the complications persist over one year. Multiple factors including previous 
antiblastic, corticosteroid and radiation treatments, an abnormal immunological condition and 
general health status are likely responsible for the onset of endocrine disorders. Precocious 
gonadal failure, adrenal insufficiency, thyroiditis and hypothyroidism require specific 
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monitoring and treatment by specialized operators. Therefore, endocrine screening is 
necessary during the first year after autologous stem cell transplant. 
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High prevalence of endocrine dysfunction in long-term 
survivors after allogeneic bone marrow transplantation for 
hematological diseases 
 
 
Introduction 
 
Bone marrow transplantation (BMT) programs started in Europe in the early 
1970s as highly experimental procedures and have now progressed to become the 
treatment of choice for a wide variety of diseases. While in the beginning severe aplastic 
anemia was the main indication for allogeneic BMT (allo-BMT), currently leukemia, 
followed by other hematological and non hematological diseases is the most frequent 
disorder treated by this procedure (1). 
As the number of long-term survivors after allo-BMT is progressively 
increasing, attention is now focused on early and late complications of this procedure 
which may worsen the quality of life and/or threaten the long-term outcome of transplant 
recipients (1). A high risk of bone complications (2), thyroid (3-5) and gonadal 
dysfunction (6,7) has been described in adult survivors. The relative risk of these 
complications is likely to be influenced by the underlying disease, previous treatments, 
post-BMT treatments and age at BMT (7). Marrow transplant conditioning regimens are 
designed to eradicate the underlying hematological disease (mostly a malignancy) and to 
suppress the host immune system. They consist in highly aggressive antiblastic 
treatments. Moreover, great amounts of cytokines are released at the time of 
transplantation (8), and immune deficiency occurs due to delayed and incomplete 
recovery of the immune system. Graft-versus-host disease (GvHD) causes both 
stimulation and suppression of the immune system, the latter due to either direct 
immunosuppressive effects or consequence of the drugs administered to treat the disease 
(9). Prevention and treatment of GvHD consist in high-dose immunosuppressive 
treatments including glucocorticoids, methotrexate and cyclosporine A. Consequently, 
the integrity of several systems and tissues, including the endocrine function may be 
affected by multiple exogenous and endogenous damaging factors. 
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Most of the data concerning the endocrine function derive from the evaluation of 
patients who underwent total body irradiation (TBI) as part of pre-transplantation 
treatments. At present, the combination of busulphan and cyclophosphamide is largely 
employed in conditioning regimens. However, only a few studies have been carried out in 
adults treated without TBI (5,10); consequently, the impact of chemotherapy and immune 
system derangement on the endocrine function in present allo-BMT recipients is still not 
completely elucidated. 
As transplanted patients may ask for medical attention outside the highly 
specialized institutions where they were transplanted, cross sectional or prospective 
studies are essential to evaluate the actual prevalence of non hematological late effects. 
The main aim of this study was to assess the function in multiple areas of the endocrine 
system in adult long-term survivors with functioning donor marrow graft transplanted for 
hematological diseases and conditioned without the use of TBI. 
 
 
Patients and Methods 
 
Patients 
One hundred and six patients received bone marrow-derived stem cells from 
HLA-identical siblings in our institution since 1994. Only patients surviving more than 1 
year after BMT, disease-free and with complete hematological reconstitution at the time 
of the endocrine evaluation and giving informed consent, were included in the study. 
Forty consecutive patients (21 F, 19 M) met the inclusion criteria and entered the study. 
Their age at transplantation ranged between 13 and 45 years (median, 29) and their post-
BMT follow-up lasted from 12 to 62 months (median, 38). Primary diseases were acute 
(n=17) or chronic (n=16) myelocytic leukemia, acute lymphoblastic leukemia (n=5), and 
severe aplastic anemia (n=2).  
 
Treatments  
All patients received the myeloablative conditioning regimen BUCY2 including 
busulphan (16 mg/kg in 4 days) and cyclophosphamide (120 mg/kg in 2 days). Acute 
GvHD prophylaxis was performed with cyclosporin A (1 mg/kg i.v. from day –1 to +21, 
then 10 mg/kg p.o. for 6 months) and “short course” methotrexate (10 mg/kg for 4 doses). 
  37 
Acute GvHD was treated by high-dose methylprednisolone (2-10 mg/kg for 10 days), 
followed by slow dose tapering in the following 6 months, monitoring patients’ clinical 
conditions. Chronic GvHD was treated by prednisolone at doses of 1-2 mg/kg, associated 
with CsA at doses ranging from 1 to 8 mg/kg/day. The median cumulative dose of 
prednisone equivalents was 10 g/m2 (range 0.9-24 g/m2). Previous treatment history 
included alkylating agents only for patients with ALL, while radiotherapy before 
transplant was an exclusion criteria (Table 1). 
Table 1. Clinical characteristics of 40 patients evaluated for endocrine dysfunction     
               after allogeneic bone marrow transplant 
Patient characteristics  N=40 
Age at transplant (years) 29 (13-45) 
Women/men 21/19 
Basic disease:   
    acute myeloid leukemia (AML) 17 
    chronic myeloid leukemia CML) 16 
    acute lymphoblastic leukemia (ALL) 5 
    severe aplastic anemia (SAA) 2 
Previous treatment history:  
    AML  IDA/MIT/CYT/ETO 
    CML HYD/IFN- 
    ALL VCR/DNR/CYC/CYT/MTX/MIT/ASP
    SAA No therapy 
Conditioning regimen:    
   BUCY2 
 
38 
   CY 2 
Follow-up duration (months) 38 (12-62) 
N° of patients with acute GVHD  13 
N° of patients with chronic GVHD 26 
    limited/extensive form 15/11 
Corticosteroid treatment:   
    Duration (months) 9 (3-36) 
    Cumulative dose (g)* 10 (0.9-24) 
Cyclosporine A  treatment:  
    Duration (months) 6.65(3.3-26.3) 
    Cumulative dose (g)  59.5(36-300) 
The values are expressed as median and range. Abbreviations: BU: busuphan, CY: 
cyclophosphamide, IDA: idarubicin; MIT: mitoxantrone; CYT: cytarabine; ETO: 
etoposide; VCR: vincristine; DNR: daunorubicin; CYC; cyclophosphamide; MTX: 
methotrexate; HYD: hydroxyurea; ASP: asparaginase; GVHD: graft vs host disease. *: 
cumulative dose of corticosteroids is expressed as prednisone equivalents.  
 
Acute GvHD was graded according to the Glücksberg system (11), and chronic GvHD 
was graded as either limited or extensive, based upon clinical severity and target organ 
involvement (12). Thirteen patients had been affected by acute GvHD, and twenty-six 
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patients were affected by chronic GvHD (15 limited and 11 extensive form) at time of 
evaluation. All these patients were treated by corticosteroids for a period ranging from 6 
to 36 months. Eleven patients with extensive chronic GvHD were also treated with 
cyclosporine A at a median cumulative dose of 59.5 gr (range, 36 to 790 gr), in order to 
reduce the corticosteroid maintenance dose. 
 
Methods  
More than 75% of the patients included in the study were transplanted after 1995 
and were prospectively evaluated since transplantation. The remaining patients were 
investigated in a cross-sectional way at first, then they were followed-up prospectively. In 
order to combine the data of these two groups of patients, the first evaluation of those 
transplanted before 1995 and the evaluation at 12 months in those transplanted since 
1995, were pooled. However, some data obtained in the prospective study were also 
included, when a more complete information could be obtained on the endocrine 
function. For the same reason, when some previous medical record on endocrine function 
was available and gave important insight on patient outcome, this was also considered.  
Blood samples were obtained between 08:00 and 10:30 a.m.  To assess the thyroid, 
gonadal, adrenal and somatotroph axes, circulating free thyroxine (FT4), free 
triiodothyronine (FT3), thyroid stimulation hormone (TSH) and circulating 
autoantibodies toward thyroid, FSH, LH, ACTH, 17-β-estradiol, testosterone, cortisol, 
dehydroepiandrosterone sulphate (DHEA-S) and insulin-like growth factor I (IGF-I) were 
measured in a single sample while prolactin (PRL) and GH were measured during a 2 hr 
profile (6 samples taken every 20 min). All measurements were performed by 
commercially available kits: cortisol, testosterone, estradiol and DHEA-S using Immulite, 
solid phase chemoluminescent enzyme immunoassay (DPC, Los Angeles, CA, USA);  
FSH and LH with RIA Biodata S,p.A. (Rimini, Italy). ACTH was tested by double-
antibody 125I radioimmunoassay (DPC Los Angeles, CA 90045-5597, USA). Serum TSH 
levels were measured using an immunoradiometric assay (IRMA) (Delfia, Wallac, Inc. 
Finland) which has a detection limit of 0.03 mU/L. Serum concentrations of FT3 and FT4 
were determined by RIA Lisophase kit (Technogenetics, Milan, Italia). 
Antithyreoglobulin antibodies were measures with an immunoradiometric technique 
(Ares Serono kit set, Ares Serono, Milan, Italy), while antiperoxidase antibodies were 
assayed by a RIA kit (DiaSorin, Inc, Saluggia, Italy). Serum GH levels were measured by 
IRMA using commercially available kits (Sorin, Saluggia, Italy); the sensitivity of the 
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assay was 0.2 µg/L. IGF-I was measured by IRMA after ethanol extraction; the 
sensitivity of the assay was 0.8 µg/L. The normal IGF-I range in our laboratory was 141-
680, 130-625, 110-450 and 100-300 µg/L for patients pubertal (13-16 yrs), adolescent, 
and aged 20-40, 41-59 yrs, respectively. 
Ultrasound scan of the thyroid gland was performed in all patients using a 7.5 
MHz linear transducer. Previous medical records were reviewed to obtain complete 
information on patients’ outcome including data on menstrual history pre- and post-
transplantation. At least one measurement was performed for GH/IGF-I, thyroid and 
adrenal function determination. The gonadal function was investigated at least twice in 
both genders; in women one baseline measurement and another on HRT treatment were 
performed, while in men two baseline measurements were performed in order to 
distinguish a transient from a persistent damage. When multiple samples were available 
for the same patient, the mean value was calculated. Informed consent was obtained from 
all patients and the design was made in accordance with the Helsinki II declaration. 
 
Statistical Analysis  
Because the data had a skewed distribution, median and range were used 
throughout the text and in tables. The Mann-Whitney test was used to compare the 
differences between the groups with and without GVHD; the χ2 test was used to assess 
association of endocrine disorders with particular clinical features. Two-sided P values 
<0.05 were regarded as significant. 
 
 
Results 
 
The hypothalamus-pituitary-gonadal axis 
Women enrolled in the study had previous history of normal age at menarche 
followed by regular periods. Following BMT, all but two women had permanent ovarian 
insufficiency (secondary hypergonadotropic amenorrhea). Two of them had became 
menopausal several months before allografting due to previous intensive chemotherapy. 
During amenorrhea, PRL levels were normal, FSH and LH values were high and 17-β-
estradiol was often under the detection limit of the assay (Table 2).  
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Table 2. Hypothalamus-pituitary -ovarian axis evaluation in 21 transplanted women 
Variable Baseline HRT* Normal range 
FSH 120 (50 – 259) 2,65 (0.3 – 30) 2-13 U/L 
LH 78 (16 – 151) 4.2 (0.5 – 20) 2-15 U/L 
Prolactin 11 (7 – 16.2) 12.5 (8 – 17.3) 5-20 ng/ml 
17β-estradiol < 20 62 (35 – 88) 40-250 pg/ml 
Values are expressed as median and range; *: values on cyclic hormone replacement therapy 
(HRT) with estrogens and progestins were obtained in 20 women. 
 
The youngest woman, 13 yr at BMT, experienced a spontaneous recovery of the ovarian 
function with regular menstrual cycles after 12 months of amenorrhea. Another woman 
had transient hypergonadotropic polymenorrhea (FSH = 59.6 UI/l; LH = 32.3 UI/l). In all 
ameno-rrhoic patients cyclic oral hormone replacement treatment (HRT) was initiated 
within 12 months after BTM unless controindicated.  In the patient with polymenorrhea 
consequent to BMT, regular cycles were obtained by norethisterone acetate 
administration for 6 months (10 mg/day for 12 days a month), then permanent 
amenorrhea occurred and HRT was initiated. Gonadotropin and 17-β-estradiol levels 
improved significantly in all women on HRT. Fifteen women assumed estradiol (2-3 
mg/day) and dihydrogesterone (Table 2). Five women, aged >40 yr, were treated by 
transdermal estradiol administration (50-100 µg delivered/day) associated with oral 
medroxyprogesterone acetate or nomegestrol (10 and 5 mg/day respectively) 12 
days/month. No difference in gonadotropin values was found between women treated by 
oral or transdermal estradiol administration (data not shown). However, 3 women could 
not be treated for 20-34 months following allografting because of severe or recurrent 
chronic liver GVHD, and other 4 women were likely under-treated probably due to 
reduced intestinal absorption for a mild chronic intestinal GVHD that was confirmed by 
biopsy in 2 of them. One woman had endometrial damage: no menstrual cycles occurred 
after cyclic HRT and no endometrium was shown by endovaginal pelvic ultrasound 
study. One pregnancy was obtained with complete pharmacological assistance and 2 
healthy twins were born to a woman 5 years after BMT. 
Men had normal LH and testosterone levels, while 9 of 19 (47%) presented FSH 
values above the upper limit of the normal range (Table 3), indicating spermatogenesis 
damage. By seminal fluid analysis azoospermia was diagnosed in 3 men, one of them 
having FSH within the normal range. The remaining men refused seminal fluid analysis. 
No relationship was found between FSH levels increase and age. One pregnancy was 
  41 
reported in a wife of a man who received allograft 3 years earlier and resulted to have 
normal FSH levels. 
Table 3. Hypothalamus-pituitary-testis axis function in 19 transplanted men 
Variable Baseline Normal range 
FSH 15.1 (3.2 – 20) 2-15 U/L 
LH 5.05 (3.5 – 9) 2-10 U/L 
Prolactin 10.6 (6 – 15.1) 5-20 ng/ml 
Testosterone 5.07 (4 – 11) 3.0-10.0 pg/ml 
 Values are expressed as median and range.  
 
The hypothalamus-pituitary-adrenal (HPA) axis 
Secondary adrenal insufficiency was diagnosed in 4 subjects, all of whom had 
been treated with corticosteroids for ≥ 10 months for chronic GVHD, at a cumulative 
dose > 10 gr/m2. A severe herpes zoster infection occurred in two patients with chronic 
GVHD causing corticosteroid treatment withdrawal; these patients subsequently showed 
further worsening of their clinical condition due to acute adrenal crisis. In the four 
patients with insufficiency, serum cortisol, ACTH levels and urinary cortisol excretion 
were significantly lower than  those of the remaining patients. Adrenal insufficiency 
recovered after 6 to 18 months in all patients. Cortisol and ACTH levels were within the 
normal range in 22 patients who were evaluated 30-180 days after corticosteroid 
treatment withdrawal (Table 4). DHEA-S levels were low in the patients with adrenal 
insufficiency and within the normal range in the remaining patients. No significant 
difference was found in the dose of prednisone equivalents administered or treatment 
duration between patients developing or not adrenal failure. 
Table 4. Hypothalamus-pituitary-adrenal axis evaluation 
Variable Adrenal insufficiency 
(n=4)* 
No insufficiency 
(n= 36)** 
Normal range 
Cortisol 5 (2 – 39) 188 (120 – 350) 50–250 ng/ml 
ACTH 44.9 (33 – 183) 29 (8 – 58) 9- 50 pg/ml 
DHEA-S 57 (39 – 89) 241 (157 – 378) 80 – 560 µg/dl 
Cortisol urinary excretion 50 (29 – 50) 105 (60 – 140) 50-150 mcg/24h 
Prednisone cumulative dose (g) 15 (11 – 24) 8.9 (1.2 – 15) - 
Corticosteroid treatment duration (mos) 18 (12 – 36) 10 (5 – 15) - 
DHEA-S: dehydroepiandrosterone sulphate; *: the values were obtained 10 to 30 days after corticosteroid 
withdrawal; **: values were obtained 30 to 180 days after corticosteroid withdrawal. 
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The hypothalamus-pituitary-growth hormone axis 
GH profile showed levels within the normal range in all subjects in study, 
whereas IGF-I levels were lower in the group of 26 patients affected by chronic GVHD 
(Table 5). IGF-I levels were lower than age-reference values in 10 (38%) patients who 
were affected by chronic GVHD and only in one (7%) who was not affected by the 
complication. 
 
Table 5. Hypothalamus-pituitary-growth hormone axis evaluation  
Variable Patients Normal range 
GH (all patients) 1.2 (0.9 – 2.1) 0.1 – 7 ng/ml 
IGF-I (all patients) 154 (50 – 240) 100-685 ng/ml# 
IGF-I (GVHD + patients) 94 (50 – 160)* 100-685 ng/ml# 
IGF-I (GVHD – patients) 184 (82 – 240) 100-685 ng/ml# 
The data are expressed as median and range. GH: growth hormone; IGF-I: insulin-
like growth factor –I; #: the normal IGF-I range was 141-685, 130-625, 110-450 and 
100-300 for patients pubertal (13-16 yrs), adolescents, and aged 20-40 and 41-59 yrs, 
respectively. *: p<0.05 vs GVHD negative patients. 
 
 
The hypothalamus-pituitary-thyroid axis 
Twenty of 40 patients had had a pre-transplant thyroid function evaluation that 
resulted normal. After BMT, low T3 syndrome (FT4 and TSH within, and FT3 below their 
respective ranges of normality) was found in 4 patients with chronic extensive GVHD 12 to 
48 months after BMT. Sub-clinical hyperthyroidism (normal FT3 and FT4 levels and TSH 
values below the normal range) was diagnosed in 6 patients between the 12th and 18th month 
after BMT. Three of them were re-evaluated after a subsequent period of 4 to 7 months, and 
TSH normalized. Thyroid ultrasound revealed non-homogeneous hypoechoic pattern in 2 of 
them. Thyroid autoantibodies were present in only one patient at the diagnosis of sub-clinical 
hyperthyroidism. Post-transplant thyroid ultrasound showed non-homogeneous hypoechoic 
pattern in 9 patients, in 6 of them associated with a mild increase in autoantibodies toward 
thyroid that suggested chronic autoimmune thyroiditis (Table 6).  
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Table 6. Hypothalamus-pituitary-thyroid axis evaluation  
Variable Transplanted patients  
(n = 40) 
Normal range 
TSH 1.35 (0.1 – 7) 0.3-3.5 mUI/ml; 
FT3 3.05 (1.9 – 5) 2.8-5.6 pg/ml  
FT4 11 (6.7 – 13.5) 6.6-18.0 pg/ml 
N° of subjects with antibodies 
antiperoxidase/antithyreoglobulin  
5/2 < 10 U/ml/<100 U/ml 
N° of patients with  antibodies to thyroid 6/40 (15%)  
The data are expressed as median and range. The values are those obtained from the prospective 
and cross- sectional study; those obtained from medical records are non included in this table. 
 
Sub-clinical hypothyroidism (thyroid hormone within the normal range; TSH 7 µU/ml) was 
revealed in one of them 5 years after BMT. A similar abnormality was revealed also in 
another woman with negative autoantibodies (TSH, 5.6 µU/ml) 6 years after BMT. L-thyroxin 
replacement treatment was given to both patients. Pre-existing thyroid nodules were detected 
in 2 patients (single nodule in one and 2 small nodules in other). They were stable over time 
in both patients (follow-up, 18 and 24 months) in terms of size and consistence. One patient 
developed thyroid lymphoma 8 months after BMT.  
Thyroid function, adrenal function and IGF-1 impairments occurred more frequently 
in patients with than in those without chronic GVHD (Table 7).  
Table 7.  Occurrence of endocrine disorders according to chronic graft-versus-host-disease (GVHD) 
Variable cGVHD + 
(n = 26) 
cGVHD –  
(n = 14) 
Age at transplant (years) 35.2 (19 – 45) 22 (13 – 45) 
Men/women 13/13 6/8 
Follow-up duration (months) 32 (12 – 60) 34 (12 – 62) 
Prednisone cumulative dose (g) 11.2 (1.2 – 24)** 4.5 (0.9 – 9) 
Cyclosporine A cumulative dose (g) 63 (39 –300)** 55 (32 – 98) 
Thyroid disorders  14 (53.8%) 5 (35.7%) 
     Persistent low T3 syndrome$ 4 (15.4%) - 
     Chronic thyroiditis* 9 (34.6%) 4 (28.6%) 
     Subclinical hyperthyroidism 4 (15.4) 2 (14.2%) 
     Subclinical hypothyroidism 2 (7.7%) - 
     Thyroid lymphoma 1 (3.8%) - 
Adrenal insufficiency 4 (15%) - 
IGF-I impairment  10 (38%) 1 (7.1%) 
Total of patients affected 18 (69%)# 4 (28.6%) 
The values are number of patients affected and percentage of the subgroup GVHD. $: persistent low 
T3 syndrome means presence of normal FT3 and FT4 values and TSH levels below the low limit of 
the normal range at least 12 months after allo-BMT; *: diagnosis of chronic thyroiditis was based on 
presence of autoantibodies and typical ultrasound pattern; **: p< 0.001 vs group without GVHD by 
Mann-Whitney test; #: χ2 = 6.078; p = 0.048 vs group without GVHD. 
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Given the small number of patients, the difference became significant only when disorders 
were considered altogether (p= 0.048). Men and women were equally affected by chronic 
GVHD, while older age at BMT and significantly higher cumulative doses of corticosteroids 
and cyclosporine A (p<0.05, both) were shown in patients affected by chronic GVHD than in 
patients not affected by this complication. It is difficult to separate clinical effects of immune 
system damage from those due to immunosuppressive treatments. Thyroid disorders were 
more frequent in men than in women, but the difference did not reach statistical significance 
(χ2, 4.945; p=0.08). No significant difference in thyroid, IGF-I and adrenal impairments was 
found regarding age at BMT (patients transplanted <29 yr and > 29 yr; χ2, 0.44 to 2.25; 
p=0.32 to 0.09). No influence of acute GVHD occurrence was shown on the  endocrine 
dysfunction. Thyroid disorders occurred also in 35.7% of patients without chronic GVHD. 
 
 
Discussion 
Allogeneic BMT has become a successful treatment for various hematological 
malignancies and other diseases as well, and is generally performed in young patients with 
long life expectancy (1,3,7). Several late complications have already been described, but only 
a few data on risk factors of these long term effects of BMT are available. The disorders are 
likely attributable to highly aggressive chemotherapy and immune system derangement. 
While the toxic effects of antiblastic agents have been widely described, the impact of 
immune system damage on endocrine function is less clear. Allogeneic bone marrow/blood 
derived stem cell transplantation is the only case of great amount of donor immunological 
cells infused to a host recognizable as “nonself” to these cells, and thus causing graft-versus–
tumor reaction and GVHD. While the first may be beneficial for the eradication of the basic 
disease, the second represents a serious complication that requires immunosuppressive 
treatment further compromising the immune system function (9). GVHD may presents as 
acute or chronic disease based upon the time of onset. Autoantibody formation  was more 
frequently described in the chronic disease, while cellular immunity is usually responsible for 
the acute forms (9,14,15). Skin, liver and gastrointestinal tract are the tissue mainly affected 
by the acute form; any tissue can virtually  be involved in the chronic disease (13). 
The most relevant finding of this study is the high prevalence of endocrine dysfunction 
in allo-BMT recipients who had not been treated by TBI, even years after BMT. Ovarian 
failure was found in 95% of women and spermatogenesis damage was likely in 47% of men; 
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both were considered to be related to alkylating agents administration. On the other hand, 
thyroid, adrenal and IGF-I impairments were late events occurring in 47.5%, 10% and 27% of 
all patients, respectively, and were considered to be related to immune system derangement 
and to immunosuppressive treatment. In particular, the hypothalamus-pituitary-IGF-I axis 
function has never been investigated in adult allo-BMT recipients, being lower than normal 
more frequently in patients with chronic GVHD (38%) than in those without this complication 
(7.1%).  
Gonadal failure is the most frequent endocrine consequence of high dose 
chemotherapy and radiotherapy for any malignancy, and recovery is rare. Loss of the ovarian 
function is found in almost all women immediately after allogeneic and autologous BMT 
(5,16-18), as a result of cytotoxic agents and TBI used before transplantation. All alkylating 
agents have toxic effects on the ovaries (19). High dose therapy damages oocytes and the 
supporting granulosa cells of both proliferating and resting follicles in a dose-dependent 
manner (20). In this study, immediate onset of menopause with hypergonadotropic-
hypoestrogenic hormone profile was observed in all women but one, who experienced 
polymenorrhea. Only the youngest woman had spontaneous recovery of ovarian function. 
According to previous data, age at BMT seems to play an important role, with increased 
incidence of irreversible ovarian failure with increasing age (21). Premature menopause has 
serious psychological and medical effects (22) and necessitates treatment. However, HRT can 
be contraindicated for long periods in case of chronic liver GVHD, or it may not be fully 
effective because of reduced intestinal or cutaneous absorption, as found in 7 of 21 (30%) 
women in our cohort. One woman had also permanent complete atrophy of endometrium 
consequent to BMT.  
Forty-seven percent of men had increased FSH levels, suggestive of spermatogenesis 
damage. Azoospermia was found in all three men tested, one of them with normal FSH levels. 
This finding suggests that germinal tissue damage can not be excluded by normal 
gonadotropin values. Unfortunately, only a few men agreed to perform a seminal fluid 
analysis, and thus sperm parameters were not available in the whole men population. On the 
other hand, testosterone production was unaffected in our long-term survivors and nobody 
reported a regression of secondary sexual characteristics. Keilholtz et al. (16) similarly found 
FSH increase in long term survivors after autologous BMT; in their study however, the 
prevalence of high FSH levels was higher than in our cohort, likely because our patients did 
not receive radiation treatment. For development of gonadal failure, age at treatment seems to 
be less important for men than for women (21). In fact, no difference in the prevalence of high 
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FSH levels was found according to patient’s age in our men cohort. In contrast, underlying 
disease, type of antiblastic drugs and/or duration of their administration, all affected the 
likelihood of spermatogenesis damage. 
In accordance with previous hypothesis pointing out a relative radio-resistance of the 
adrenal tissue (7), post-allografting adrenal insufficiency was present even in our cohort of 
non irradiated patients; it seems related to duration and cumulative dose of corticosteroid 
treatment received. Autoantibodies to adrenal cortex (ACA, indirect immunofluorescence) 
and to 21-hydroxylase (immunoprecipitation assay) were assayed in our patients with adrenal 
insufficiency and were absent. However, some patients with preserved normal function of the 
adrenal glands had assumed similar cumulative doses for similar periods as patients who 
experienced adrenal insufficiency. Thus, variable individual sensitivity of the HPA axis to 
exogenous suppression can by speculated. No stimulation test was performed in the current 
study; therefore, some minor degree of HPA axis insufficiency could have been overlooked. 
Indeed, adrenal insufficiency is still an underestimated condition, unless specifically 
investigated by endocrinologists. 
Concerning growth hormone secretion, reduced growth and GH insufficiency has been 
previously described in children treated by cranial irradiation, but not in those who did not 
received prophylactic radiotherapy (23). Our results are in keeping with these findings, 
although GH secretion would have been better investigated by dynamic testing. IGF-I 
impairment seem to be related to chronic GVHD, that represents a condition of multiorgan 
injury and is associated with lower BMI. It is well-known that IGF-I reduction is associated 
with chronic diseases accompanied by conditions as starving or reduced nutrition (25), and 
this can be the most likely explanation for our results. 
Frequent sub-clinical or overt thyroid function impairment has been reported after 
allo-BMT (4,5,24), less frequently in autologous BMT recipients (16). Increased frequency of 
transient thyrotoxicosis has been described early after allografting and immune induced injury 
has been claimed as the pathogenetic factor (4); by contrast, hypothyroidism can be 
discovered years after transplant and has been ascribed principally to TBI and busulphan 
therapy (26-28). The prevalence of sub-clinical hyperthyroidism in our patients is in line with 
data from a recent longitudinal study by Kami et al. (4), and lower than those reported by 
Toubert et al (5). Since a half of our patients was evaluated for thyroid function only once 
post-BMT, some transient sub-clinical dysfunction could have been missed. We have 
observed a case of chronic thyroiditis associated with normal thyroid function, an event 
unreported till now in allo-BMT recipients. Antibodies toward thyroid were found only in one 
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patient; however, it but it is known that autoantibodies are not necessarily present in patients 
with sub-clinical hyper- or hypothyroidism. Low T3 syndrome was present in patients with 
chronic extensive GVHD even 12-48 months after BMT. This could be due to decreased 
extra-thyroidal conversion of thyroxin to 3,5,3’ triiodothyronin induced by either chronic 
disease or glucocorticoid treatment (29,30). None of our patients developed overt 
hypothyroidism probably because they had not been treated by TBI. Although an increase in 
the prevalence of thyroid papillary carcinoma was found in BMT recipients by two major 
multicenter studies on late cancer complications (1,31), the only thyroid malignancy in this 
study was a case of thyroid lymphoma.  
A limit of our study is the small sample size, which may have obscured some possible 
influence of factors different from chronic GVHD on the endocrine dysfunction. Moreover, 
patients in this study were relatively younger than those reported in other similar studies. 
Since chronic GVHD is more frequent  in older patients, we may have underestimated the real 
risk of endocrine disorders in an average population of transplanted patients.  
While a previous study documented thyroid and adrenal function 5 years after 
autologous bone marrow/blood-derived progenitor cell transplantation (16), our data suggest 
that immunosuppressive treatment and immune system derangement play an important role in 
the development of endocrine dysfunction after allografting. In fact, a high rate of thyroid 
disorders, adrenal insufficiency  and IGF-I decrease was found in patients affected by chronic 
GVHD. On the other hand, the most frequent endocrine dysfunction was ovarian insufficiency 
(95%), while spermatogenesis damage was likely in about half of men; gonadal failure is 
attributed to alkylating agents administration (19,21). Long survival after malignant disease 
may be associated with endocrine disorders and this is even more relevant for patients 
undergoing allo-BMT, who are younger than recipients of autologous BMT or other organ 
transplants. Therefore, these patients deserve life-long attention to detect, prevent and treat 
symptoms and disorders of endocrine dysfunction. A multidisciplinary management for 
patients who underwent allogeneic bone marrow-derived hemopoietic stem cells is 
mandatory. 
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Gonadal status in reproductive age women after stem cell 
transplantation for hematologic malignancies 
 
Introduction 
In recent years, autologous (auto-) and allogeneic (allo-) stem cell transplantation (SCT) 
have consistently improved disease-free and overall survival of haematological and non-
haematological malignancies, and an increasing number of young women can expect to become 
long-survivors (1). However, improvement in a disease control is associated with significant early 
and delayed side-effects, one of the most frequent being gonadal damage. 
 Ovarian failure associated with SCT has been generally ascribed to total body irradiation 
(TBI) and antiblastic alkylating agents, both widely used for the treatment of haematological 
malignancies and in conditioning regimens to transplant (2-4). Ovarian damage results in 
immediate menopause in most women; recovery is rare, being less frequent at older age (3,4). The 
conditioning regimen aims at eradicating the underlying malignant disease and, in the allogeneic 
setting, at suppressing the host immune system. Conditioning regimens avoiding TBI, such as the 
combination of busulphan and cyclophosphamide, have been employed more frequently in the 
recent years: such a combination, however, still confers a consistent risk for developing ovarian 
failure, by altering germ cell viability and gonadal hormone production (5-7). Additionally, a 
“cytokines storm” is released in the peri-transplantation period (8), and a prolonged immune 
deficiency usually occurs due to delayed and incomplete recovery of the immune system in both 
allogeneic and autologous SCT recipients.  
Allogeneic graft compromises the host immune system more severely than the autologous 
one due to a prolonged treatment by immunosuppressive drugs needed to avoid the “reverse” 
rejection. Indeed, acute or chronic graft-versus-host disease (aGVHD, cGVHD) – a complication 
affecting more than 50% of patients after allografting - induces additional relevant alteration in the 
immune system (9). 
We have recently demonstrated that cGVHD profoundly impairs endocrine functions in 
allo-STC recipients, even in absence of TBI (10). Moreover, cGVHD was associated with lower 
sperm count in male long-term survivors after busulphan/cyclophosphamide conditioning (11). It 
should be emphasized that most previous studies focused on the etiopathogenetic role of 
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chemotherapy and TBI  in inducing ovarian failure and infertility  and considered allo- and auto-
SCT patients as one group (2,5,6,10-13). Conversely, we observed more frequent recovery of 
menstrual cycles in women after auto-SCT that in those all-transplanted.  
To investigate whether differences in ovarian residual function exist in the allogeneic and 
autologous setting treated with similar conditioning regimen without TBI, we designed this 
observational, analytical, prospective, controlled study.  
 
Materials & Methods 
Subjects 
Fifty consecutive reproductive age women (24 allo- and 26 auto-transplanted, aged 21 to 
45 yrs, median 29) who had received SCT for malignant haematopoietic disorders in our 
institution were enrolled in this pilot study between 12–24 (median, 17) months after SCT. 
Inclusion criteria were: 1) disease-free at the time of evaluation with complete haematological 
reconstitution; 2) at least 12 month period elapsed since SCT. Exclusion criteria were: 1) history 
of radiation therapy, 2) previous history of menstrual cycle disorders or endocrine diseases and 3) 
previous hormone replacement therapy.  
Five women were excluded because of hyperthyroidism (n=1), delayed puberty (n=1), 
history of oligomenorrhea prior to the disease (n=2) and radiation treatment (n=1). In the 
remaining 45 patients, primary diseases were acute or chronic myelogenous leukaemia (AML; 
n=19 and CML; n=7, respectively), acute lymphoblastic leukaemia (ALL; n=4), chronic 
lymphocytic leukaemia (CLL; n=3), Hodgkin disease (HD; n= 8) and non-Hodgkin lymphoma 
(NHL; n=4). Allo- and auto-transplanted patients with AML received SCT in their first complete 
remission, patients with ALL, HD, NHL and CLL were transplanted in second complete 
remission. Profile at study entry of the patients is summarized in Table 1.  
Forty-five healthy pre-menopausal women age- and BMI-matched with the patients agreed 
to participate in this study and were included as controls. All of them had regular menstrual 
cycles. Exclusion criterion for control women was the use of estrogen/progesterone use as 
contraceptive or replacement treatment.  
Informed consent was obtained by all patients and the study was designed in accordance 
with the Helsinki II Declaration. 
 
  52
 
 
 
 
Table 1. Clinical features in 22 women after allogeneic stem cell transplantation (SCT), 23 women after autologous SCT and in 45 healthy women as controls.  
 Allo-SCT 
(n= 22) 
Auto-SCT 
(n= 23) 
Controls 
(n=45) 
Age at evaluation (years) 27.6±2.3 28.2±2.6 28.5±2.4 
Time from transplant (months) 18.9±1.2 17.8±1.7 - 
BMI (kg/m2) 23.4±0.9 25±1.0 24.2±0.8 
Diagnosis:    
AML 9 10 - 
ALL 4 - - 
CML 7 - - 
HD 2 6 - 
NHL - 4 - 
CLL - 3 - 
Previous treatment history:    
AML Idarubicin/mitoxantrone (MIT)/cytarabine (CYT)/etoposide  
ALL Vincristine/daunorubicin/cyclophosphamide/methotrexate/MIT/CYT/asparaginase  
CML Hydroxyurea/ interferon-α  
HD Vincristine/adriblastine/bleomycin/etoposide  
NHL Methotrexate/adriblastine/cyclophosphamide/vincristine/prednisone  
CLL Chlorambucil/fludarabine  
Previous use of alkylating agents   
  (n. of patients) 
6/22 (27%) 13/23 (56.5%)  
Prednisone cumulative dose (g/m2) 7.7  ± 1.8 8.2 ± 0.9 - 
           treatment duration (months) 8.4 ± 1.8* 5.9 ± 0.7 - 
Values are expressed as mean ± SEM. Corticosteroid cumulative dose is expressed as prednisone equivalents. Abbreviations: BMI: body mass index; AML: Acute 
myeloid leukemia; ALL: acute lymphocytic leukemia; CML: chronic myeloid leukemia; HD: Hodgkin disease; NHL: non Hodgkin lymphoma; CLL: chronic 
lymphocytic leukaemia; *: p<0.001 vs. autologous setting 
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Treatments 
 Both allo- and auto-transplanted patients for AML, CML and ALL received the same 
conditioning regimen BUCY2, including busulphan (16 mg/kg in 4 days) and cyclophosphamide 
(120 mg/kg in 2 days).  Patients with HD, NHL, and CLL were conditioned with the BEAM 
protocol, consisting of carmustine (300 mg/m2 in 1 day), etoposide (200 mg/m2 in 4 days), 
cytarabine (400 mg/m2 in 4 days) and melphalan (140 mg/m2 in 1 day). Allo-SCT recipients 
received bone marrow-derived stem cells from HLA-identical siblings. After allografting, aGVHD 
prophylaxis was performed with cyclosporin A (1 mg/kg i.v. from day –1 to +21, then 10 mg/kg 
p.o. for 6 months) and short course methotrexate (10 mg/kg for 4 doses). Acute GVHD was 
treated by high-dose methylprednisolone (2-10 mg/kg for 10 days), followed by slow dose 
tapering in the following 6 months, monitoring patients’ clinical conditions. Chronic GVHD was 
treated by prednisolone at doses of 1-2 mg/kg, associated with CsA at doses ranging from 1 to 8 
mg/kg/day. Previous treatment history included alkylating agents  for patients with ALL, CLL, 
HD and NHL (Table 1) and consisted in a mean 6-month duration of chemotherapy for all 
diagnoses. Acute GvHD was considered according to the Glucksberg grading system (14), and 
cGVHD was graded as either limited or extensive, based upon clinical severity and target organs 
involvement (15). Nine women had been affected by aGVHD of global grade 1-3 and 13 women 
were affected by cGVHD (six limited and seven extensive form). Three women with the limited 
form had liver involvement and other three skin manifestation. Liver, skin, intestine and eyes were 
the most common cGVHD sites in the extensive form with variable combination (liver and 
gastrointestinal [n=2], liver and eyes [n=2], skin, gut, and eyes [n=2], skin, gut, and kidney [n=1].  
Liver  manifestation included an increase of liver enzymes in all women (ALT: 50-1100 U/L; 
AST: 82-761 U/L; γ-glutamyl-transferase: 90-350 U/L) and reversible cholestasis with alkaline 
phosphatase (487-785 U/L) and bilirubin increase (5 -9 mg/dl) associated with icterus in two. Skin 
lesions included lichen planus and focal epidermal atrophy. Ocular dryness (Sjogren-like 
syndrome) was the major ophthalmologic manifestation, while oral mucosa dryness and lichenoid 
lesions were the upper gastrointestinal tract symptoms. Diarrhoea and malabsorption were present 
in two women. One woman developed reversible membranous glomerulonephritis with nephrotic 
syndrome. All these patients were treated as stated above for a period ranging 6-24 months (Table 
1). After evaluation, hormone substitutive treatment with estradiol and medroxyprogesterone  was 
initiated in all women with amenorrhea unless contraindicated or refused.  
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Study design 
Previous medical records were reviewed to obtain complete information on patients’ 
outcome, including data on menstrual history pre-transplantation. Post-transplantation data were 
recorded prospectively. Body-mass index (BMI, kg/m2) was determined in all subjects. In the 
control group the endocrine and ultrasonography was performed in the early follicular phase of the 
menstrual cycle (2-3 day). 
Endocrine evaluation 
In all subjects, blood samples were obtained between 08:00 and 10:00 a.m. Circulating 
FSH, LH, prolactin, 17-β-estradiol, testosterone and ∆4-androstenedione levels were assayed to 
assess the hypothalamic-pituitary-ovarian function. Dehydroepiandrosterone sulphate (DHEAS) 
was also measured as the major androgen of adrenal origin. All measurements were performed by 
commercially available kits: 17-β-estradiol by RIA  (Nichols Institute Diagnostics, San Juan 
Capistrano, CA), total testosterone and DHEAS using Immulite, solid phase chemiluminescent 
enzyme immunoassay (DPC, Los Angeles, CA, USA); FSH and LH with RIA Biodata S,p.A. kits 
(Rimini, Italy); androstenedione using RIA Diagnostic Systems Laboratories kit (Webster, TX, 
USA); at least 2 different samples were taken in all subjects and the average value was calculated 
for each hormone. Detection limits were 3 pg/ml for 17-β-estradiol, 5 ng/dl for testosterone, 10 
ng/dl for ∆4-androstenedione and 2 µg/dl for DHEAS. Intra-assay and inter-assay coefficients of 
variation were below 7% and 15%, respectively, for all endocrine determinations.  
Ultrasonographic evaluation 
Pelvic ultrasonography was performed in all patients and controls using a 7.5-MHz 
transvaginal transducer. The study was performed by a single well-trained operator (S.P.), blind in 
respect to patient or control exam. Ovarian and uterine volumes were estimated using the ellipsoid 
formula (longitudinal x antero-posterior x transversal diameter x 0.523) (16). The mean ovarian 
volume for each woman was calculated. Number of follicles and endometrium thickness were also 
recorded. 
Statistical analysis  
Student’s t test for paired and unpaired data was used to compare the group of patients and 
controls, and different subgroups of patients, respectively. The nonparametric Mann-Whitney U 
test was used to compare hormone levels in patients and controls as well as in allo- vs.  auto-SCT 
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patient group, when Wilk-Shapiro’s  test was not consistent with the Gaussian distribution of the 
data. To assess the dependence between endocrine and ultrasonographic features of the patients, 
the Pearson’s correlation coefficient was calculated. As possible predictor variables of menstrual 
cycle recovery were considered age at transplant, BMI, time from SCT, previous use of alkylating 
agents and type of transplant. Univariate and regression analysis was performed using the cycle 
recovery as a binary outcome variable. Two-sided P values <0.05 were taken as statistically 
significant. Data are expressed as mean ± SEM. 
 
Results 
Menstrual history data indicated that the disappearance of menstrual cycles was caused by 
the myeloablative conditioning therapy in 30 women, while other 15 had amenorrhea after 
conventional chemotherapy shortly before SCT. Recovery of menstrual cycles was slightly, but 
not statistically, more frequent in the group of auto-transplanted patients (4/23 vs. 2/22 in the allo-
SCT group). Women who experienced recovery of the ovarian function were younger than those 
who did not, and were transplanted from a longer period (p<0.05). BMI, corticosteroid cumulative 
dose and duration of treatment did not differ in women with or without cycle recovery (Table 2).  
Table 2. Univariate predictors of cycle recovery  
 Cycle recovery No cycle recovery P 
Age at SCT (years) 21.7± 2.3 28.5 ± 2.5               0.013 
BMI at SCT (kg/m2) 23.6±1.6 23.9±0.9 NS 
BMI at evaluation (kg/m2) 22.8 ± 1.8 24.7± 1.4  NS 
Corticosteroid dose (mg/m2) 
 8.9 ± 2.7 8.1 ± 1.1 NS 
Corticosteroid duration (mos) 9.6 ± 2.2 7.3 ±1.9 NS 
Time from SCT (mos) 20.2 ± 1.7 17.1 ± 1.8 0.047 
    
Patients previously treated 
with alkylating agents 
(n./total)# 
3/6 (50%) 16/39 (41%) NS 
BMI: body mass index; SCT: stem cell transplantation, corticosteroid dose was calculated as prednisone 
equivalents. Students’ t-test was used to compare mean values; # χ2 test was used for comparison of the 
frequency. 
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By the logistic regression, however, only young age at SCT was a positive predictor of 
cycle recovery (p<0.05), while previous use of alkylating agents, type of transplant, BMI and time 
elapsed from transplant did not reach statistical significance (Table 3).  
 
 Table 3. Predictors of cycles recovery by regression analysis 
 Odds ratio (95% C.I.) P 
Age at SCT <21 yrs  6.8 (0.191 - 0.829) <0.05 
Allogeneic setting 0.47 (-0.337 – 0.116) NS 
Previous alkylating treatment 0.72 (-0.303  - 0.143) NS 
Time from SCT > 18 months 2.1 (-0,116 -  0,336)  NS 
SCT: stem cell transplantation 
 
At study entry, the groups of allo- and auto- transplanted women had similar age and 
follow-up period after transplantation, while they differed in the underlying haematological 
disease. Patients with AML and CML were not treated by alkylating agents, all patients with CML 
received allogeneic  SCT, while patients with AML were treated by allo- or auto-SCT in a similar 
proportion (9 vs. 10). Consequently, before transplant alkylating agents were more frequently used 
in the auto-SCT group. The dose of corticosteroids was similar in both patient groups, although 
most allo-transplanted patients were treated for longer periods, and treatments were stopped more 
recently, as in the auto-SCT group steroid treatment took a part of chemotherapeutic regimens 
previous to the transplant (Table 1).  
 
Endocrine evaluation  
Endocrine parameters of the two patients’ groups and controls are shown in Table 4. 
Serum gonadotropin levels were significantly higher (P<0.001) while 17-β-estradiol, ∆4-
androstenedione, testosterone (P<0.001) and DHEAS (P<0.05) were lower in allo-SCT patients 
than in controls. The auto-SCT women had significantly higher (P<0.001) gonadotropin values 
and lower 17-β-estradiol (P<0.001) than controls while ∆4-androstenedione and testosterone levels 
were similar. Serum gonadotropin levels were significantly higher (P<0.001) and 17-β-estradiol, 
∆4-androstenedione and testosterone  significantly lower (P<0.05) in the allo-SCT compared to the 
auto-SCT group. Prolactin levels were within the normal range in all subjects, without any 
difference between patients and controls. Similar results with the same statistical significance 
were obtained when only women affected by AML were compared (10 auto- and 9 allo-
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transplanted, data not shown). When allo-SCT patients were divided according to presence of 
cGVHD, ovarian failure resulted to be slightly more severe in women with cGVHD (Table 5).  
 
Ultrasonographic evaluation 
Ultrasonographic results in the patients’ groups and in controls are shown in Table 4. 
Ovarian size in our control group was within the normal range of pre-menopausal women with 
similar age (16-18). Volumes of ovaries and uterus were lower in the patients, both allo- and auto- 
transplanted, when compared to the controls (P<0.001). Furthermore, either uterine or ovarian 
volumes were significantly (P<0.001) smaller in the allo-  than in the auto-SCT group.  
In the patient group, the mean number of follicles resulted significantly (P<0.0001) lower in 
comparison with controls; and allo- transplanted women had less follicles than those auto-
transplanted (p<0.0001). In particular, 4 to 12  small and larger follicles (diameter, ≤12 mm) per 
ovary were observed in the control group, several small ovarian follicles (diameter ≤6 mm) were 
found in 12 women after auto-SCT and in only four after allo-SCT. In the allo- and auto-SCT 
groups, without difference between groups, the mean endometrial thickness were significantly 
(P<0.05) lower in comparison with controls (Table 4). In fact, endometrial thickness was very low 
or undetectable in most SCT patients.  
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Table 4.  Endocrine  and ultrasound findings in women after allo- or auto- stem cell transplantation (SCT) and in controls. 
 Allo-SCT 
(n= 22) 
P 
vs. controls 
Auto-SCT 
(n= 23) 
P 
vs. controls 
Controls 
(n=45) 
Reference intervals 
FSH  127±16b <0.001 63.6±7.9 <0.001 6.8±3.2 2-13 U/L 
LH  75±10b <0.001 28.2±3.7 <0.001 10.6±2.6 2-15 U/L 
17-β-estradiol  48.8±6.7a <0.001 73.05±8.8 <0.001 183.6±19.2 140-734 pmol/L 
Testosterone  0.55±0.07a <0.001 1.32±0.14 0.551 1.35±0.14 0.68-2.8 nmol/L 
∆4-Androstenedione  1.74±0.14 a <0.001 3.84±0.17 0.947 4.1±1.22 3.4-10 nmol/L 
Dehydroepiandrosterone sulphate   3.3±0.29 <0.05 4.3±0.7 NS 4.7±0.3 1.4-7 µmol/L 
Prolactin  8.8±0.89 NS 9±1.2 NS 9.5±1.3 2-15 µg/L 
       
Ovarian volume (cm3)  1.35±0.14c <0.001 3.3±0.14 <0.001 8.2±0.17 5.7-10 cm3  *  
Uterine volume (cm3) 27.2±0.76c <0.001 47.3±1.56 <0.001 53.0±1.9 - 
N° of follicles per ovary 0.4±0.7 c  <0.001 3±2 <0.001 8±2 - 
Endometrial thickness (mm) 3.5±0.15 <0.05 3.9±0.14 <0.05 6.4±0.16 5-8 mm* 
Values are expressed as mean ± SEM. Ovarian and uterine volumes were calculated according to the ellipsoid formula (multiplication of 3 diameters x 1/3pi). *: data 
relative to the early follicular phase of menstrual cycle. NS: not significant; a: P<0.05, b: P<0.01 and c: P<0.001  vs. auto-SCT. 
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According to the presence of cGVHD, ovarian and uterine volumes were significantly 
lower in women with than in those without GVHD (P<0.001; Table 5). 
 
Table 5.  Clinical features, endocrine and ultrasound evaluation in women after allogeneic SCT 
according to chronic GVHD occurrence.  
 Chronic GVHD 
(n= 13) 
No chronic GVHD 
(n= 9) 
P 
Age (years) 26.6 ±3.1 25.2 ±3.8 NS 
Time since transplant (mos) 18.5 ± 1.1 19 ± 1.3 NS 
BMI (kg/m2) 21.2 ± 2.2 24.1 ± 1.9 NS 
FSH (IU/L) 140 ± 22.3 106.3 ± 6.6 <0.05 
LH (IU/L) 78.6 ± 12.5 66.3 ± 2.4 NS 
17-β-estradiol (pmol/L) 37.4 ± 4.26 58 ± 5.1 <0.05 
Prolactin (µg/L) 7.65 ±  1.4 7.9 ± 1.5 NS 
Testosterone (nmol/L) 0.4 ±  0.1 0.55 ± 0.11 NS 
∆4-androstenedione (nmol/L) 1.57 ±  0.17 1.85 ± 0.23 NS 
DHEAS (µmol/L) 2.7 ± 0.32 3.5 ± 0.23 <0.05 
Ovarian volume (cm3) 1.05 ±  0.14 1.4±  0.15 <0.001 
Uterine volume (cm3) 23.1 ±  0.9 34±  1.9 <0.001 
The values are expressed as mean ± SEM. GVHD: graft-vs-host disease; BMI: body mass index; 
DHEAS: dehydroepiandrosterone sulphate; Ovarian and uterine volumes were calculated according 
to ellipsoid formula (multiplication of 3 diameters x 1/3pi).  
 
As expected, in the patient group considered as a whole, 17-β-estradiol (r= 0.51; P<0.05)  
and ∆4-androstenedione (r= 0.55; P<0.05) values correlated with ovarian volume, 17-β-estradiol 
was also inversely correlated with FSH levels (r= ―0.67; p<0.05). Uterine volume correlated with 
ovarian volumes (r=0.77; P<0.01). On the other hand, no correlation was found between age, 
BMI, time elapsed from transplantation and endocrine or ultrasonographic parameters. 
 
Discussion 
The results of the present study show that reproductive age women undergoing allogeneic 
or autologous SCT have a premature ovarian failure (secondary hypergonadotropic amenorrhoea), 
that persists up to 24 months after transplant in most cases (87%). Only younger age (<21 yrs) at 
SCT was an important predictor of ovarian function recovery. Although cycles recovered more 
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frequently in auto-SCT women, the difference when compared with the allo-SCT group was not 
significant.  The longer period elapsed between SCT and evaluation in women who experienced 
recovery of ovarian function, suggests that recovery is not an early event and may occur even long 
time after SCT. By regression analysis, the type of transplant, BMI, previous use of alkylating 
agents and steroids were not associated with a different probability of spontaneous recovery of 
ovarian function.  However, some of these factors can become significant in larger populations of 
these peculiar patients. In fact, age, weight gain, disease stage and use of systemic chemotherapy 
resulted important predictors of menopause onset also in other female neoplastic populations (19).  
Ovarian failure is reported to be a rather frequent event after myeloablative therapy 
followed by SCT in postpubertal patients (3,4,6,11,12). However, whether it is due to high-dose 
alkylating agents and/or TBI used in the conditioning regimens, to conventional chemotherapy 
before myeloablative treatment, to the combination of all three treatment approaches (2,20) or to 
other unknown factors is still to be fully elucidated. Most previous studies (2,5,6,10-13), having as 
endpoints spontaneous recovery of ovarian function, infertility or pregnancy rates, have focused 
on the role of different treatments, such as TBI and chemotherapy, in inducing ovarian failure. 
Additionally, in previous studies no distinction between allo- and auto-SCT subjects has been 
performed, and different conditioning regimens, also including TBI, were considered altogether.  
In the attempt to overcome these limitations, we included patients receiving a similar conditioning 
treatment, excluding TBI, and analyzed auto- and allo-SCT patients also separately.  
One of the relevant finding of the current study, is that allo-transplanted recipients had 
lower 17-β-estradiol and androgen circulating levels and lower ovarian volume than in the auto-
transplanted ones. Importantly, among allo-transplanted women those who developed cGVHD had 
lower 17-β-estradiol, ∆4-androstenedione, testosterone and DHEAS and higher FSH and LH levels 
than those who did not develop GVHD. The potential role of a lower BMI (indicating less fat 
mass after cGVHD) in inducing androgen aromatization to estrogens seems to be negligible, 
considering the lower circulating androgen levels and the absence of correlation between BMI and 
endocrine parameters. It should also be noted that auto-transplanted women had an ovarian 
volume similar to that observed in women after a corresponding interval from physiological 
menopause; in contrast the ovarian volume of allo-SCT was lower (16-18). 
The differences in endocrine and ultrasound parameters between auto- and allo-
transplanted patients were similar in the subgroup including only women with AML, indicating 
that results did not depend on the underling disease, but likely on different transplant procedures. 
Chemotherapy is known to induce ovarian failure by apoptotic changes in pre-granulosa cells 
causing follicle loss (21,22). In particular, alkylating drugs have been shown to alter base pairs, 
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leading to DNA cross-links and single-strand breaks (23). The combination of high-dose 
cyclophosphamide and busulphan is one of the most potent conditioning regimens often inducing 
ovarian failure (24). Primordial follicles were absent in some patients at ovarian biopsy, likely due 
to damage of oocytes and proliferating as well as resting follicles supporting granulosa cells (22). 
Additional finding in our cohort of patients was that, beside having lower 17-β-estradiol levels, 
allo-SCT women had lower testosterone levels than both auto-SCT and control women. The 
ovarian secretion of estrogens is reported to decline faster than that of androgens after 
physiological menopause, likely due to progressive follicular athresia with persistent androgen 
production from stromal ovarian tissue (25). Consequently, the ovaries were hypothesized to 
become primarily androgen-producing glands, able of maintaining gonadotropin responsiveness 
for many years (25). As a matter of fact, different studies had shown that ovarian testosterone 
production remains relatively constant, thereby increasing the relative ovarian contribution to the 
global testosterone production and androgen-to-oestrogen ratio (26,27). Conversely, absent 
gonadotropin receptors and insignificant 17-β-estradiol and androgen production has been recently 
shown in post-menopausal women after cessation of menstrual cycles for at least 5 years (28). The 
different period of time elapsing from menopause onset to evaluation could explain the difference 
between these apparently contrasting findings. Serum 17-β-estradiol, ∆4-androstenedione and 
testosterone levels in our cohort of allo-SCT patients were significantly decreased, indicating both 
follicles and stromal endocrine cells damage, with signs of more severe damage in women 
affected by cGVHD. Conversely, in auto-SCT patients only serum 17-β-estradiol levels were 
decreased, while ∆4-androstenedione and testosterone levels were normal 12-24 months after 
transplantation. The ovarian contribution to lower serum androgens is confirmed by the 
correlation between ovarian volume and 17-β-estradiol and androgen levels. However, since lower 
DHEA-S values were found in allo-SCT patients, particularly in those with cGVHD, effects of 
longer and more recent corticosteroid use on adrenal androgen secretion can not be ruled out. The 
degree of immune system involvement might be hypothesized as major difference between the 
two groups. 
While the toxic effects of antiblastic agents have been widely described as detrimental, the 
impact of immune system damage on endocrine function in transplanted women is not clear. 
Allogeneic SCT is an exceptional condition in terms that a massive amount of donor 
immunological cells is infused to a host, and they can recognize the host as “non-self”. The best 
known target organs for such a “graft versus host reaction” are skin, liver, gut and lung, but any 
other organ can be targeted including gonads, and the neoplastic tissue itself. The prophylaxis and 
treatment of GVHD require immuno-suppressive drugs, which further compromise immune 
system function and whose effects can not be separate from those of the immune system 
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dysregulation itself. Azoospermia related to cGVHD (10) was also reported in allo-SCT 
recipients, in line with our hypothesis on a possible involvement of the immune system 
derangement in the gonadal damage.  
In the current study, we did not investigate circulating autoantibodies against ovary since 
the existence of a correlation between anti-ovarian antibody titre, cellular immune dysfunction and 
histological evidence of inflammation in women with autoimmune ovarian failure is still 
undefined. Circulating anti-ovary autoantibodies are not correlated with clinical activity of 
autoimmune oophoritis and their pathogenetic role remains questionable (29,30). 
In conclusion, the results of the current study indicate that after autologous SCT ovaries 
have characteristics similar to those occurring after a similar period of physiological menopause, 
whereas allogeneic SCT is associated with a more severe injury, characterized by lower estradiol 
and androgen levels, and ovarian size. Chronic GVHD following allografting further worsen this 
condition. Ovarian failure in SCT recipients seems to be related principally to the myeloablative 
conditioning regiments, however, ovarian steroid levels and size can be further influenced in the 
allogeneic setting, likely by a major deregulation of the immune system and its treatments. The 
impact of a lower residual oestrogen and androgen steroid secretion after allo-transplantation on 
women’s health, especially in terms of osteoporosis, cardiovascular risks and quality of life 
remains to be established as well as any future potential therapeutic implication and pregnancy 
outcomes (31). 
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Estrogen-progestogen induced hematocolpometra following 
allogeneic stem cell transplant  
 
Introduction 
The most frequent and obvious complication of the reproductive system after 
allogeneic stem cell transplantation (allo-SCT) is ovarian failure, which occurs in over 
90% of female patients (1,2). While ovarian toxicity depends on age, type of transplant, 
conditioning regimens, previous use of alkylating agents and radiation treatment (1), some 
other gynecological complications have been described in association with extensive 
chronic graft-versus-host disease (cGVHD). In particular, propensity to develop vulvo-
vaginal infection, vaginal and cervical stenosis, and disfigurement of the internal and 
external genitalia, sometimes with peritoneal involvement, have been reported. All of 
these conditions may negatively influence sexual function, causing dyspareunia, 
reproductive failure and difficult labor (2-4). Chronic GVHD is a late complication after 
allo-SCT occurring in up to 50% of patients. Although skin, liver, eyes and the 
gastrointestinal system are most frequently involved, hypothetically any organ can be 
targeted by this disorder. Gynecological manifestation is relatively rare, but probably 
underestimated. Corson et al. have described a 10% prevalence of vulvovaginal lesion in 
the Seattle population, when systematically evaluated, including 41 women with cGVHD 
(4).  
As women undergoing allo-SCT are prevalently young (young age is one of the 
selection criteria), giving them estrogen + progestogen hormonal therapy (EPT) becomes 
mandatory in order to prevent the multiple negative effects of premature menopause. It 
should be underlined that, regardless sexual activity of the women, gynecological 
complications may become manifest after the introduction of EPT. 
 
Methods and Results 
We here describe our experience concerning gynecological complications in a 
population of 30 allo-transplanted women who were followed in a single center 12-120 
months after SCT. Their median age at transplant was 32 years (range, 12-40). All women 
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had been conditioned by “ BUCY 2” regimen including busulphan (16 mg/kg in 4 days) 
and cyclophosphamide (120 mg/kg in 2 days) and nobody had received any radiation 
therapy. The reasons for transplant included acute myeloid leukemia (n=10), acute 
lymphocytic leukemia (n= 6), chronic myeloid leukemia (n=12) and severe aplastic 
anemia (n=2). Fourteen women had been or were still affected by cGVHD: 6 by the 
limited form and 8 by the extensive one. 
Three women were found to have gynecological manifestation of cGVHD that became 
evident shortly after HRT introduction. Following are the reports of single cases: 
Case 1  
A 31-year old woman with acute myeloid leukemia had received SCT from a HLA 
identical brother in her first complete remission. She had had two previous pregnancies 
terminated with a cesarean section. Acute GVHD was mild and only dermal. On the other 
hand, extensive cGVHD involved multiple organs causing dermal, bucal (lichenoid 
lesions) and ophthalmic (Sjögren-like) lesions. Hypergonadotropic amenorrhea followed 
SCT and sequential EPT was introduced 18 months after allografting. The patient was 
married, sexually active, disease-free and had no sign of active cGVHD at the moment of 
EPT introduction. Cyclic withdrawal bleeding was mild and after the third cycle she 
complained of pelvic pain and dyspareunia. Gynecological examination revealed vulvar 
atrophy, a large, palpable and painful mass, and cervical adhesions. Transabdominal 
ultrasonography revealed the presence of hematocolpos. EPT was interrupted, cervical 
synecchiae were freed digitally and about 250 ml old blood was evacuated from uterus. 
Local treatment with equine conjugated estrogens (ECE) was continued for 6 months. 
Thereafter, when there was no evidence of cervical or vaginal adherence, she initiated 
sequential EPT again; a recent transvaginal ultrasonography (TV-US) has not detected any 
abnormal findings. 
Case 2  
A 24-year old patient (para 0) affected by chronic myelocytic leukemia received 
SCT from her brother in the first remission. After 15 months, she relapsed and received 
two lymphocyte infusions. Thereafter, she developed extensive cGVHD with liver, dermal 
(sclerodermatous lesions) and ophthalmic manifestation. She was surgically treated for 
obstruction of the lachrymal canal. Three years after SCT, she suffered from severe 
menopausal symptoms, osteoporosis and had no sign of active cGVHD. Sequential EPT 
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was initiated with very mild withdrawal bleeding. During the third treatment cycle she 
referred to a gynecologist because of a progressively increasing pelvic pain.  
A  
 
 
 
 
 
 
A.       B. 
Figure 1. Pelvic ultrasonography before EPT introduction (panel A) and 3 months later when 
hematocolpometra was diagnosed (panel B) 
 
 A hematocolpometra was revealed by ultrasonography (Figure 1) and treated during 
hysteroscopy in general anesthesia with digital lysis of multiple vaginal and uterine 
synecchiae, evacuating approximately 300 ml of old blood. Thereafter, local therapy with 
ECE was initiated with improvement of the picture. However, the patient reported that the 
adhesion tended to reoccur whenever she interrupted the treatment. Four months after 
hysteroscopy, a continuous EPT was introduced, under strict monitoring of the patient’s 
condition, continuing also the local treatment. 
Case 3  
A 22-year old (gravida 2 para 2) patient with chronic myeloid leukemia received 
allo-SCT from a HLA-identical sister. She developed acute liver GVHD and veno-
occlusive like disease, continuing as severe cGVHD at the same site. Eleven months after 
SCT she was treated with decompression surgery because of bilateral femoral head 
avascular necrosis. Because of severe menopausal symptoms consequent to SCT, she 
started a sequential EPT 26 months after grafting. No withdrawal bleeding occurred at the 
end of the first cycle. At the gynecological examination, an extensive vulvar atrophy was 
found, with quite complete vaginal obliteration. EPT was withdrawn and vaginal dilatators 
with local application of ECE were prescribed to maintain vaginal patency. When asked, 
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the patient, although married, reported no sexual activity after SCT. Improvement but not 
the disappearance of local symptoms was observed after 2, 4 and 16 weeks of local 
treatment. 
Other findings 
Another woman affected by chronic myeloid leukemia experienced no withdrawal 
bleeding with cyclic EPT despite otherwise normal gynecological examination. Her 
gonadotropin values decreased from post-menopausal levels to the normal range and 
vasomotor symptoms disappeared, findings that indicated satisfactory absorption of 
hormonal treatment. However, the woman had no evidence of endometrium at TV-US 
repeated at different periods of sequential EPT cycles. Asherman’s syndrome consequent 
to chemotherapy was diagnosed and EPT has been resumed. She has no history of acute or 
cGVHD. 
 
Risk factors for gynecological disorders 
Three out of 30 allo-transplanted women followed up in our center had severe 
involvement of gynecological organs. The prevalence was 3 out of 14 patients affected by 
cGVHD. Chronic GVHD with dermal and mucosal localization was present in two women 
while the third had only liver involvement (Table 1). The age at SCT did not differ 
between women affected or not by the stenosis. None of our patient had a post-transplant 
history of infection, suggesting no infectious etiology of the dystrophic process observed. 
Fluids from evacuated uteri were cultured and resulted negative for Gram-positive or 
Gram-negative bacteria. Chronic GVHD seems to be the most plausible cause of 
gynecological disorders in the three patients described above. 
 
Discussion 
Quite a high percentage (3/14) of allo-transplanted women with cGVHD followed 
up in our center had severe involvement of gynecological organs. In contrast with the 
ovarian injury related to the type of antiblastic treatments, conditioning regimens and age 
(1,2,5), severe but not necessarily extensive cGVHD was the factor most closely related to 
the vaginal and cervical stenosis in our patients. Furthermore, permanently undetectable 
endometrium was observed in another woman, despite sequential EPT administration. 
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Although vulvo-vaginal infection had been described as causing vaginal and cervical 
stenosis, the post-transplant period was free of infection in the above described patients. 
Holm et al.(6) has found a severe impact of total body irradiation (TBI) in association 
with SCT on the internal female genitalia, causing a permanent reduction in uterine and 
ovarian volumes, even during either EPT administration or spontaneous pubertal 
development. Similar findings have been reported by Bath et al. (7) who has shown 
reduced blood flow and undetectable endometrium in adult women who underwent SCT 
during childhood. Contrarily to Holm, the study by Bath found that physiological EPT 
improved both uterine blood flow and endometrial thickness. Similarly, reduced vaginal 
elasticity and rugal folds, pale tissue, atrophic vulvovaginitis, introital stenosis, and loss of 
pubic hair were noted by Schubert et al. (2) as frequent finding after allo-SCT, being more 
frequent in women who had previously been treated by TBI (33/36 vs. 2/8 of not treated 
by TBI). However, none of the women in our population had undergone TBI or other 
radiation treatment.  
Two large studies on the reproductive outcome of SCT recipients were carried out 
(one in Europe, the other in the USA), both showing a high incidence of miscarriage, pre-
term labor and low birth weight babies in female recipients of allografting (8,9). On the 
other hand, congenital malformation,  developmental delay and malignant disease were 
similar in the offspring of SCT recipients compared to the general population. This 
suggests that mechanical problems or infections can cause the difference in the 
reproductive outcome between the allo-SCT setting and the general population. 
Interestingly, gynecological manifestation of cGVHD described in the literature 
were always associated with the extensive disease. One of our patients was affected by the 
limited cGVHD with only severe liver involvement. Chronic GVHD represents a complex 
disorder characterized by reaction of immunocompetent donor lymphocytes against 
histocompatibility antigens of the host. Cutaneous changes have been described as 
virtually always present (10). Immunologically, pathologically and clinically, cGVHD is 
similar to autoimmune diseases, sharing features with lichen planus, scleroderma and 
Sjögren syndrome. Although no clinically apparent cutaneous lesions were detected in 
case no. 3, we cannot exclude that she had some mild occult cutaneous involvement. 
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Table 1. Characteristics of the women with gynecological manifestation of cGVHD  
 Patient n. 1 Patient n. 2 Patient n. 3 
Diagnosis AML CML CML 
Age at transplant (years) 30 24 21 
Acute GVHD (grade) 0 1 1-2 
Chronic GVHD extensive extensive limited 
      sites involved Muco-cutaneous, 
ophthalmic 
Cutaneous, liver, 
ophthalmic 
Liver 
Introduction of EPT (mos. after 
transplant) 
18 36 26 
Glucocorticoid cumulative dose (g) 9.6 0.8 10  
     duration of treatment (days) 212 30  360  
Cyclosporine A cumulative dose (g) 37.5 70  70.9  
     duration of treatment (days) 135  180  750  
Abbreviations: GVHD; graft-versus-host disease; AML: acute myeloid leukemia, CML: chronic myeloid leukemia; 
HRT: hormone replacement therapy. Glucocorticoid dose is expressed as prednisone equivalents.  
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Progression or recurrence of lesions were previously observed in cases of extensive 
cGVHD, despite ongoing treatments (11). In our patients nos. 2 and 3, with extensive and 
limited cGVHD, respectively, who were sexually inactive, the withdrawal of local therapy 
with equine conjugated estrogens caused exacerbation of the vaginal lesions, even in the 
absence of any other sign of active GVHD. No systemic immunosuppressive treatment 
was given to our women because they were lacking any other manifestation of cGVHD, 
and vaginal dilatation with local application of estrogen improved consistently their 
condition. As a matter of fact, estrogen deficiency can contribute to the gynecological 
manifestation in SCT recipients, by worsening the atrophy of external and internal 
genitalia. 
Continuous regimen of EPT might be less risky for hematocolpometra 
development. An important issue is represented by the psychological problems related to 
the lack of menstrual cycles, which is perceived as a loss of femininity, further worsening 
the patient’s self-perception already damaged by the disease history and likelihood of 
infertility. Our young women preferred sequential treatment with periodical bleeding that 
made them feel not so different from “normal women”. Pre-transplant counseling to 
female patients should also include information on their possible gynecological 
complications and outcomes. 
 
Conclusion 
In conclusion, gynecological complications in allo-SCT recipients are likely 
multifactorial, including contribution of TBI, cGVHD, estrogen deficiency and infections. 
Women undergoing allo-SCT are mostly young and have more that 90% probability of 
ovarian failure with very little possibility of menstrual cycles recovery. Findings of 
previous studies and our experience indicate that, following SCT, both uterine and ovarian 
functional status need to be investigated before choosing the appropriate management for 
any single women. All women with cGVHD should undergo gynecological examination 
before introducing EPT, in order to avoid unpleasant complication as hematocolpometra. 
Vaginal and cervical synecchiae can be treated with prolonged local estrogen treatments; 
temporary use of continuous EPT regimens might be preferable in these women. 
Moreover, patients with cGVHD should be closely monitored by pelvic exam and 
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ultrasonography during the first months of EPT, to detect any complication caused by 
intrauterine adhesions undetected at previous gynecological examinations.  
 
 
References 
 
1. Brennan, B & Shalet, SM. Endocrine late effects after bone marrow transplant. [Review] Br J Haematol 
2002;118:58-66. 
2. Schubert, MA, Sullivan, KM, Schubert, MM, et al. Gynecological abnormalities following allogeneic 
bone marrow transplantation. Bone Marrow Transplant 1990;5:425-430. 
3. Delord C, Treleaven J, Shepherd J, Saso R, Powlers RL. Vaginal stenosis following allogeneic bone 
marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant 1999; 23:225-52. 
4. Corson, SL, Sullivan, K, Batzer, F, August, C, Storb, R, Thomas, ED. Gynecologic manifestation of 
chronic graft-versus-host disease. Obstet Gynecol 1982;60:488-492. 
5. Tauchmanovà, L., Selleri, C., De Rosa, G., et al. Gonadal status in reproductive aged women after stem 
cell transplantation for haematological malignancies. Hum Reprod 2003; 18:1410-1416. 
6. Holm, K, Nysom, K, Brocks, V, Hertz, H, Jacobsoen, N, Muller, J. Ultrasound B-mode changes in the 
uterus and ovaries and Doppler changes in the uterus after total body irradiation and allogeneic bone 
marrow transplantation in childhood. Bone Marrow Transplant 1999;23:259-263. 
7. Bath, LE, Critchley, HOD, Chambers, SE, Anderson, RA, Kelnar, CJH, Wallace, WHB. Ovarian and 
uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid 
replacement. British J Obstet Gynaecol 1999;106:1265-1272. 
8. Salooja, N, Szydlo, RM, Sociè, G, et al. Pregnancy outcomes after peripheral blood or bone marrow 
transplantation: a retrospective survey. Lancet 2001;358: 271-276. 
9. Sanders, JE, Hawley, J, Levy, W, et al. Pregnancies following high-dose cyclophosphamide with or 
without high-dose busulphan or total-body irradiation and bone marrow transplantation. Blood 
1996;87:3045-3052.   
10. Cordoba, S, Vargas, E, Fraga, J, et al. Lichen sclerosus et atrophicus in sclerodermatous chronic graft-
versus host disease. Int J Dermatol 1999;3:700-711. 
11. Anguenot, JL, Ibèchèole, V, Helg, C, Piacenza, JM, Dumps, P, Bonnefoi, H. Vaginal stenosis with 
hematocolpometra, complicating chronic graft versus host disease. Case report. Eur J Obstet & Gynecol 
Reprod Biol  2002;103:185-187. 
 
  73
 
High serum leptin in patients with  chronic graft versus host disease 
after hematopoietic stem cell transplantation 
 
 
Introduction 
Leptin, a protein encoded by the ob gene, is an adipocyte-derived hormone of the long-
chain helical cytokine family playing a regulatory role in the neuronal control of body weight 
by inhibiting food intake and stimulating energy expenditure (1).  The leptin receptor is 
expressed not only in the central nervous system, but also in several peripheral tissues, such 
as hematopoietic and immune systems (2,3). It is now becoming increasingly clear that leptin 
has important physiological functions in hematopoiesis, reproduction, immunity and 
inflammation (2-5). Clinical and experimental evidence also indicates that alterations in leptin 
levels and/or in the responsiveness to leptin may be involved in the development of several 
immune-related diseases such as diabetes, thyroiditis, rheumatoid arthritis, immune-mediated 
renal disease and multiple sclerosis (6-10).  Leptin production has been shown to be sustained  
by several inflammatory cytokines both in rodents and in humans (11,12). Recently, it has 
been also documented that leptin exerts a direct effect on T-lymphocyte responses, promoting 
T-helper 1 (Th1) and suppressing Th2 cytokine production.  In particular, leptin stimulates 
naive T-cell proliferation, enhances interferon-γ (IFN- γ and tumor necrosis factor-alpha 
(TNF-α production and decreases interleukin (IL)-4 secretion of memory T cells (10,13-15).  
Increased serum leptin values have been found after heart, liver, kidney and stem cell 
transplantation (SCT) (16-18).  However, the reasons and the mechanisms responsible for 
such a post-transplant increase are still unclear. In the SCT setting, only a single paper has 
appeared, dealing with serum leptin levels in relation with conditioning protocols  and growth 
hormone (GH) status (18). However, alterations in nutrition, endocrine and immune system 
functions occurring in SCT recipients might also influence leptin production. Changes in 
nutritional status can occur during the early post-transplant period due to a decrease in food 
intake and impaired gastrointestinal system function. The nutritional status can be further 
impaired after SCT due to treatments for acute or chronic graft versus host disease (aGVHD, 
cGVHD). A prolonged immune deficiency usually occurs, due to delayed and incomplete 
recovery of the immune system in both the autologous (auto-) and allogeneic (allo-) settings, 
which is negatively influenced by long-lasting treatments with immunosuppressive drugs in 
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allotransplanted patients (19,20). Indeed, glucocorticoids, the most often used 
immunosuppressive therapy, increase leptin production both in vitro and in vivo (21,22). 
Transient or permanent gonadal failure consequent to SCT may further increase leptin 
secretion (23).  
To better understand changes in leptin production in subjects undergoing SCT, we 
measured serum leptin concentration in a group of 60 transplanted patients and in 60 healthy 
subjects with similar age and body mass index (BMI). Moreover, 15 patients undergoing allo-
SCT were prospectively evaluated, with leptin determination prior to and after transplant. 
Relationship with age, gender, BMI, gonadal status, lymphocyte subpopulations, cytokine 
secretion, inflammation and time elapsed since transplant was investigated.  Based on the 
evidence that leptin increase may contribute to the onset of immune response, we also 
investigated in vitro consequences of leptin blockade on T cell activation in a mixed 
lymphocyte reaction (MLR).  
 
Materials & Methods 
Patients 
Sixty consecutive patients (36 allo-SCT and 24 auto-SCT, median age 35.4 years, range 
18-45 years) were enrolled in this study. All patients had received SCT for a hematological 
malignancy in our institution; they were enrolled in this study between 12 and 72  (median, 
26) months after SCT. All patients were disease-free at time of evaluation, in complete 
hematological remission. Patients in both transplant settings had similar age and  BMI. BMI 
was calculated in all subjects as weight divided by height square (kg/m2). No patient had 
received radiation as part of therapy before transplant. Patients’ profile at study entry is 
summarized in Table 1. Patients allo- or auto-transplanted for acute or chronic myeloid 
leukemia or acute lymphoblastic leukemia received the same conditioning regimen BUCY2, 
including busulphan (16 mg/kg in 4 days) and cyclophosphamide (120 mg/kg in 2 days); 
patients with lymphomas or chronic lymphocytic leukemia were conditioned with the BEAM 
protocol, consisting of carmustine (300 mg/m2 in 1 day), etoposide (200 mg/m2 in 4 days), 
cytarabine (400 mg/m2 in 4 days) and melphalan (140 mg/m2 in 1 day). Allo-SCT recipients 
received unmanipulated bone marrow cells from HLA-identical siblings, whereas auto-SCT 
recipients received mobilized peripheral blood stem cells. In the allogeneic setting, 21 patients  
were affected by cGVHD: 5 limited and 13 extensive skin cGVHD associated with liver, 
gastrointestinal and eye localization in 10, 9 and 8 patients, respectively; the other patients 
had isolated liver (n=2) and lung (n=1) localization. Liver manifestation included a reversible 
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increase in liver enzymes (ALT: 50-1000 U/L; AST: 81-760 U/L and -glutamyltransferase: 
90-360 U/L) and cholestasis with alkaline phosphatase (450-790 U/L) and bilirubin (5-9.5 
mg/dl) increase in all subjects  that was associated with transient icterus in three patients. Skin 
lesions included lichen planus and focal epidermal atrophy. Ocular dryness (Sjogren-like 
syndrome) was the major ophthalmological manifestation, while oral mucosa dryness and 
lichenoid lesions were the upper gastrointestinal tract symptoms. Diarrhea associated with 
malabsorption were present in five patients. The clinical diagnosis of cGVHD was confirmed, 
if indicated, by histopathology of skin, liver or mucous membranes. All these patients had 
been treated by prednisolone at doses of 1 mg/kg, associated with CsA at doses ranging from 
1 to 8 mg/kg/day  for a period ranging 6-24 months (Table 1). No patient was on 
corticosteroid treatment at study entry, the drug having been withdrawn since at least three 
months. In addition, no patients showed intestinal cGVHD and significant weight loss. The 
control group consisted of 60 healthy individuals, including 15 donors of stem cells and 45 
healthy subjects matched for age, sex and BMI. Informed consent was obtained by all subjects 
and the study was designed in accordance with the Helsinki II Declaration.  
 
Table 1. Clinical caracteristics of autologous (auto-SCT) and alloge-neic (allo-       
               SCT) transplanted patients 
 Auto-SCT 
(n=36) 
Allo-SCT 
(n=24) 
Age:  years 
        (range) 
33 ±12 
(16-48) 
34±11 
(18-45) 
Gender: female/male 17/19 11/13 
Diagnosis: 
         Acute Myeloid Leukemia 
         Acute Lymphoblastic Leukemia 
         Chronic Myeloid Leukemia 
         Hodgkin’s disease 
         Non Hodgkin’s Lymphoma 
 
           16 
4 
           14 
2 
0 
 
              12 
0 
0 
9 
3 
Conditioning regimen: 
         BU-CY2 
         BEAM 
 
36 
 0 
 
 
12 
12 
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Leptin, hormonal and biochemical evaluation 
Blood samples were obtained from all subjects between 08:00 and 10:00 a. m. after 8-10 h 
fasting. All samples were stored at –80° C until analysis. Measurements for serum leptin, C-
reactive protein (CPR), FSH, LH, testosterone/17β-estradiol and cortisol were determined in the 
same blood sample by commercially available kits. Leptin was measured using RIA (Linco 
Research, St Louis, MO, USA); the sensitivity was 0.5 ng/ml and was expressed both as absolute 
values and as leptin/BMI ratio. Cortisol, testosterone and estradiol were measured using 
Immulite, solid phase chemoluminescent enzyme immunoassay (DPC, Los Angeles, CA, USA); 
FSH and LH with RIA Biodata S,p.A. (Rimini, Italy). ACTH was tested by double-antibody 125I 
radioimmunoassay (DPC Los Angeles, CA, USA). Intra-assay and inter-assay coefficients of 
variation were below 7% and 15%, respectively, for all endocrine determinations. Gonadal 
insufficiency was considered in men when testosterone levels were below the normal range, and  
in amenorrhoic women when estradiol concentrations were lower and FSH higher than the 
normal range for reproductive aged women. 
 
Measurement of serum Th1 and Th2 cytokines   
Serum levels of IL-2, IL-4, IL-5, IL-10, TNF-α and IFN-γ  were measured on the same 
blood sample used for leptin and hormonal evaluation by a cytometric bead array kit (CBA kit, 
Becton-Dickinson, San Diego, CA, USA). Briefly, 50 µl of sample or standard reagent was 
mixed with 50 µl each of mouse anti-human cytokine-captured beads and specific phycoerythrin-
conjugated detection antibody reagent. The mixture was incubated subsequently for 3 h at room 
temperature prior to washing and data acquisition using flow cytometry (FACScan, Becton-
Dickinson). Data were acquired and analyzed using Becton-Dickinson, CBA software, according 
to the manufacturer’s instructions. 
CD4-to-CD8 ratio was analysed, using a FITC-conjugated murine anti-human CD4 combined 
with a PE-conjugated anti-human CD8 (both from Becton Dickinson), in uniformly set 
lymphocyte gates that usually contained >95% of lymphocytes.  Proper isotypic controls were 
used in all assays. At least ten thousand events were acquired in the live cell gates for analysis. 
 
Mixed lymphocyte reaction(MLR) 
Isolated peripheral blood mononuclear cells (PBMCs) were obtained from 5 SCT 
recipients (stimulator cells) and their corresponding unrelated HLA-mismatched donors 
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(responder cells) through density gradient centrifugation using Ficoll. Responder PBMNCs were 
monocyte-depleted (PBL) by plastic adherence for 2 h at 37°C in 100% humidity and 5% CO2. 
Stimulator cells were irradiated (30 Gy) before being cultured with responder cells.  Responder 
and stimulator cells were cultured for 5 days in RPMI 1640, supplemented with 10% fetal calf 
serum (FCS), antibiotics, and 5×10 5  β2-mercaptoethanol, at a concentration of 5×106 cells/mL 
and a ratio of 1:1, in a final volume of 200 µL/well, in flat-bottomed 96-well microculture plates. 
MLR was performed in absence and in presence of purified polyclonal rabbit anti-human leptin 
(anti-hOb, 10 µg/ml;  kindly provided by Dr. Radek Sokol, BioVendor Laboratory Medicine, 
Inc., Brno, Czech Republic); as control affinity purified rabbit polyclonal IgG was utilized.  T-
cell proliferation was measured on day 6  after a 18-hour pulse with 3H-thymidine (3H-TdR) 
(0.037 MBq/well [1 µCi/well], specific activity 24.79 × 10-10 Bq/mmol [6.7 Ci/mmol]) 
(Amersham, Buckingham, United Kingdom).  Thereafter, the cells were harvested on glass filter 
paper, and the counts per minute (cpm) were determined in a liquid scintillation counter 
(Betaplate, Wallac, Boston, MA).  Results are expressed as the mean of triplicate cultures for 
each experiment.  Ficoll, RPMI 1540, FCS, antibiotics and β2-mercaptoethanol were purchased 
from Life Technologies, Gaithesburg, MD,USA. 
 
Statistical analysis  
Data are expressed as mean ± SD throughout text and tables. Data were analyzed by the 
two-tailed Student t test. The Mann-Whitney U test was used to compare the differences between  
groups. To assess the relationship between leptin, cytokines, CRP, BMI, age and time since 
transplant the Pearson correlation coefficient was calculated. Two-sided P values <0.05 were 
taken as significant. 
 
Results 
Serum leptin, biochemical and  hormonal changes after SCT  
We compared serum leptin concentrations between 36 long term survivors after allo-SCT, 
24 survivors after auto-SCT and 60 age and BMI matched controls. Serum leptin was 
significantly higher in the patients compared to controls; in addition, it was higher in patients 
after allo- than after auto-SCT, expressed as absolute value and after normalization for BMI 
(Table 2, Figure 1A).  
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Table 2. Biochemical features in patients after allo- or auto-SCT, and in healthy controls 
 Allo-SCT 
(n= 36) 
Auto-SCT 
(n= 24) 
Controls 
(n=60) 
Age at evaluation (years) 34.9±11 36.1±12 35.5±2.4 
Female/Male 17/19 11/13 28/32 
Time from transplant (months) 28.9±15 23±16 - 
BMI (kg/m2) 25.99±4.7 25.6±3.45 25.2±0.8 
Leptin (ng/ml)   
- 
   Males  20.98 ± 13.3 *a 11.1 ± 8.35b 3.8  ± 1.2 
   Females  34.1 ± 12.6 *a 26 .53± 10.9 b 10 ± 2.5 
Leptin/BMI 
    
   Males 0.78 ± 0.54*a 0.475 ± 0.3 b 0.135 ± 0.05 
   Females 1.36 ± 0.7* a 1.03 ± 0.4 b 0.68 ± 0.1 
Patients with AML#    
   Leptin 23.6 ± 18 15.4 ± 14.5  
   Leptin/BMI 0.97 ±0.8 0.53 ± 0.42  
    
Cortisol (ng/dl) 151 ± 63 159 ± 52 160 ± 17 
C-reactive protein (mg/L) 0.6± 0.3 b 0.7 ± 0.4 b 0.35 ± 0.2 
Values are expressed as mean ± SD. Abbreviations: BMI: body mass index. #: 16 patients in the allo-
SCT and 12 in the auto-SCT group were affected by AML. Statistical analysis, *: p<0.05 vs. auto-SCT 
patients; a: p<0.001 vs. controls; b: <0.005 vs. controls. 
 
 
In 20 patients who were prospectively evaluated prior and after allo-SCT, pre-transplant 
levels overlapped those of controls, while after SCT serum leptin increased two-to ten fold 
(Figure 1B). When gender was introduced into the analysis, post-transplant leptin and 
leptin/BMI ratio displayed a better separation between the allo- and auto-SCT groups (Figure 
1A). The typical sexual dimorphism (higher leptin in females) persisted in both transplant 
settings but was set up at higher levels (Table 2, Figure 1 A).  
Significantly higher leptin values were found in 19 patients affected by cGVHD than in those 
free of this complication, also when men and women were considered separately (Table 3). The 
difference remained significant even when normalized for differences in BMI. BMI was similar 
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in patients with and without cGVHD and did not change significantly after SCT compared to 
pre-transplant levels (data not shown).  
 
Table 3. Serum leptin in patients after allogeneic SCT with or without chronic GVHD 
 Patients cGVHD+ 
(n=19) 
Patients cGVHD- 
(n=17) 
P value 
All patients     
  BMI (kg/m2) 25.6 ± 1.6 25.9 ± 1.7 NS 
  Leptin (ng/ml) 29 ± 15 19 ± 14 0.007 
  Leptin/BMI 1.14 ± 0.6 0.72 ± 0.5 0.006 
    
Females    
   Leptin (ng/ml) 35 ± 10 22 ± 9 0.012 
   Leptin/BMI 1.4 ± 0.6 0.8 ± 0.7 0.03 
    
Males    
   Leptin (ng/ml) 27.8 ±13 14.0 ± 10 0.027 
   Leptin/BMI 0.95 ±0.43 0.5 ± 0.4 0.03 
The data are expressed as mean±SD. BMI: body mas index. 
 
Therefore, the increase in serum leptin induced by SCT was not a function of BMI variations. As 
expected, a significant correlation was found between leptin and BMI in controls, donors, 
patients prior to transplant and  those auto-transplanted  (r=0.475–0.68; p<0.05 for all); by 
contrast, no correlation was revealed in patients after allo-SCT (r= 0.057; p=0.835) (Fig. 2). 
Significantly higher leptin level was present in 12 hypogonadic women (leptin and leptin/BMI 
ratio: 35.8±6.7 ng/ml and 1.38±0.19, respectively) compared to those with regular menstrual 
cycles or on hormone replacement therapy (HRT) (leptin and leptin/BMI ratio: 20.4± 4.6 ng/ml 
and 0.95±0.18, with p=0.003 and p=0.002, respectively). 
Although circulating C-reactive protein (CRP), an acute phase inflammatory reactant, was higher 
in patients than in controls (Table 3), their values did not differ between the allo- and auto-SCT 
settings and between patients affected or not by cGVHD (Table 3). No patient had clinical or 
laboratory evidence of acute or chronic infection at the time of evaluation.  By linear regression, 
leptin levels did not correlate with cortisol and CRP values, time since transplant and age when 
the patients were considered altogether, as subgroups (allo-/auto-transplanted) or women and 
men separately. 
Cytokines analysis and CD4-to-CD8 ratio after SCT  
Since a dysregulation of the type-1/type-2 cytokine balance may frequently occur 
following auto- and allo-SCT, we evaluated IL-4, IL-5, IL-10, IL-2, IFN-γ and TNF-α in the 
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same serum sample of auto- and allo-SCT patients used for measurement of leptin levels, using 
microparticle-based flow cytometric technology (Table 4). Mean level of IL-4, IL-5, IL-10 and 
IL-2 in auto- and allo-SCT patients did not differ from the baseline levels observed in 15 healthy 
subjects; there was no difference in the levels of these cytokines also between patients with and 
without cGVHD. As for IFN-γ and TNF-α their concentrations in auto-SCT patients were not 
different from those in normal subjects. In allo-SCT patients we found higher levels of 
circulating IFN- γ compared to auto-SCT patients and normal controls, whereas TNF-α 
concentrations did not differ among the three subgroups. Within allo-SCT patients, mean IFN-γ 
and TNF-α levels were higher in patients with than in patients without cGVHD. In addition, 
relationship between concentrations of TNF-α or IFN-γ and serum leptin levels were evaluated 
in allo-SCT patients. Patients with higher circulating IFN-γ concentrations, but not those with 
higher TNF-α levels, showed increased serum leptin levels. Indeed, using as a cut-off the median 
value of serum IFN- γ concentration (15 pg/ml that means the the median value of the patients’ 
cohort), there was a significant difference in serum leptin levels between the groups of patients 
with higher or lower serum IFN-γ levels (33 vs. 19 mcg/L, p=0.04). Moreover, a significant 
correlation between leptin and IFN-γ was found only when allotransplanted patients with IFN- γ 
values > 15 ng/ml were considered.  
As documented by the concomitant analysis of CD4-to-CD8 ratio, a significantly lower ratio was 
found both in auto-SCT (mean ± SEM: 0.95±0.1) and allo-SCT (mean ± SEM: 0.7±0.1) patients 
compared with normal individuals (normal range: 1.1-2.4; p<0.05). A majority of allo-SCT 
patients with cGVHD showed a CD4-to-CD8 ratio (mean ± SEM: 0.59±0.06) significantly lower 
than patients without cGVHD (mean ± SEM: 0.97±0.1; p=0.001). However, the correlation 
between serum leptin levels and degree of decrease of CD4-to-CD8 ratio did not reach statistical 
significance (p=0.09).  
 
Effects of leptin-blockade in the mixed lymphocyte reaction(MLR) 
In order to elucidate the involvement of serum leptin in alloreactivity, we tested the 
influence of a polyclonal rabbit anti-human leptin antibody in a one-way MLR in which PBMNC 
from 5 unrelated HLA-mismatched donors were stimulated with PBL from their corresponding 
recipients. As shown in the Figure 3, there was a significant reduction in T-lymphocyte 
proliferation when mixed cultures of T lymphocytes stimulated by irradiated allogeneic PBMNCs 
(1:1 ratio) were performed in the presence of  a leptin-blocking antibody (mean decrease of 
proliferative responses > 50%, range 40-60%, as measured by  3HTdR incorporation; p = 0.001).  
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Table 4 -  Mean serum cytokine levels in transplanted patients 
 
      IL-2     IL-4 
 
     IL-5 
 
    IL-10 
       IFN-α     TNF-γ 
Controls    (n=15) 2.5 ± 0.4 3.8 ± 0.7 2.5 ± 0.6  3.4 ± 0.9 6.5 ± 1.2 3.0 ± 0.5 
Auto-SCT (n=20) 1.9 ± 0.5 4.0 ± 1.0 2.1 ± 0.3 4.0 ± 1.1 8.8 ± 1.3 3.9 ± 1.1 
Allo-SCT  (n=35) 3.2 ± 0.2 5.0 ± 0.5 3.8 ± 0.6 6.7 ± 0.4 14.4 ± 1.1*° 4.7 ± 0.4 
 without cGVHD (n=14) 3.1 ± 0.2 4.4 ± 0.9 3.1 ± 0.9 4.0 ± 1.1 9.8 ± 1.5 3.5 ± 0.5 
 with cGVHD  (n=21) 3.3 ± 0.3 5.3 ± 0.5 4.3 ± 0.9 7.4 ± 1.2 17.1 ± 1.3 a 5.5 ± 0.3 b 
Values are expressed as mean pg/ml ± SEM. Statistical analysis, *: p=0.0001 vs. controls; °: p=0.01 vs. auto-SCT patients; a: p=0.001 vs. patients 
with cGVHD ; b: p =0.04  vs. patients with cGVHD. 
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Figure 3. Effect of leptin-blockade on T cell proliferation in a representative allogeneic mixed 
lymphocyte reaction (MLR). Freshly isolated peripheral blood lymphocytes (PBL) from a HLA-
mismatched recipient were cultured at 1:1 ratio with irradiated peripheral blood mononuclear cells 
(PBMNCs) from the donor as stimulators, in medium alone, with purified rabbit anti-human leptin (anti-
hOb) or with polyclonal rabbit anti-human IgG used as control (CTR-ab). Treatment with polyclonal anti-
hOb induced 50% decreased (7981±1969) proliferation in response to HLA-mismatched PBMNC 
stimulators compared to medium alone (16141±5393) and CTR-ab (14795±2325). Columns and error 
bars represent mean cpm values and standard deviation of triplicate cultures. 
 
 
 Little, if any, inhibition occurred in the presence of  a polyclonal rabbit anti-human IgG 
utilized as control in MLR (mean decrease of proliferative responses < 4%, range 0-8%; p = 0.1). 
 
Discussion 
In agreement with a previous report (18),  we found that serum leptin levels were 
significantly increased after SCT in our cohort of patients. In prospectively evaluated patients, 
two-to-ten fold increase in serum leptin was observed after allo-SCT, pointing out that increased 
leptin production was consequent to the SCT procedure and not due to the basic disease.  In the 
general population serum leptin is proportional to BMI; it is reduced by starvation and increased 
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by food intake (24,25). BMI is commonly used as an indirect index of fat mass in clinical 
practice. In our study, serum leptin correlated with BMI in controls and auto-transplanted 
patients, but not in allo-transplanted patients, suggesting that factors other than BMI can strongly 
influence leptin overproduction in this subgroup. Indeed, in these patients, leptin increase was 
not a function of the BMI changes, since BMI was similar in allo- and auto-transplanted patients 
as well as in allo-transplanted patients before and after transplant. The typical sexual dimorphism 
in leptin distribution was preserved in our patients’ population, although set at a higher level.  
In the previous study on leptin after SCT (18), the effects of radiation therapy on the 
hypothalamic-pituitary region and/or direct irradiation of the adipose tissue were hypothesized as 
possible causes of the leptin increase, and the negative relationship between growth hormone 
peak and leptin was explained by possible radiation-induced hypothalamo-pituitary lesions.  Our 
data do not support such hypotheses. In fact, none of our patients had received radiation therapy 
as part of treatment for the underlying disease before transplant or as part of their conditioning 
regimen. In addition, in a recent study from our group on endocrine function in allo-SCT 
recipients, no evidence of hypothalamic-pituitary lesion capable of  influencing leptin secretion 
was found (26). Leptin increase should not be caused by the underlying disease, as its levels were 
shown decreased in untreated patients affected by AML, without any significant change during 
chemotherapy-induced cytopenia and neutropenia (27). The differences in leptin levels in 
patients after auto- and allo-SCT were similar when the analysis included the whole group of 
patients or only patients with AML diagnosis. 
Recently, leptin  has been proposed to act as a link between nutritional status and cell-
mediated immunity (11). BMI was similar in controls and in auto- and allo-transplanted patients, 
indicating that the difference in leptin values was not caused by the host’s nutritional status. On 
the other hand, no patients showed signs of intestinal GVHD and alteration of the nutritional 
status. 
Chronic GVHD remains a major cause of morbidity and mortality in allo-SCT (28). 
Significantly higher leptin levels were found in patients affected by cGVHD compared to those 
free of this complication and the difference was even more evident when men and women were 
considered separately. This induced us to investigate more accurately the relationship between 
cGVHD and serum leptin. 
Chronic GVHD is associated with a state of profound immunodeficiency, which can easily 
lead to infections, particularly when prolonged immunosuppression is required for its treatment 
(29). However, no patient was on corticosteroid treatment or had adrenal insufficiency at time of 
testing, as documented by normal serum cortisol and plasma ACTH levels. Furthermore, the lack 
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of correlation between cortisol and leptin values suggests no significant influence of cortisol on 
serum leptin levels in our cohort. Stimulating effect of estrogens and progesterone on leptin 
production has previously been described (30,31), with leptin lowering after menopause (32). 
However, we found higher leptin levels in hypogonadal women compared to those with regular 
menstrual cycles or on HRT. In addition, all women with cGVHD suffered from ovarian failure 
and were not assuming HRT. Taken together, all these findings support the hypothesis that 
factors other than a dysregulation of the endocrine system may influence the increase of serum 
leptin levels in cGVHD patients after allo-SCT.  
Increase in circulating leptin was found during fever and systemic inflammation (4,33). 
No our patients had clinical evidence of acute or chronic infection at time of evaluation. As 
serum CRP positively correlates with leptin increase during systemic inflammation,  (34,35) we 
investigated this relationship in our patients. Lack of correlation between leptin and CRP further 
indicated that leptin increase in our cohort of patients was not caused by a systemic 
inflammatory state.  
Accumulating evidence documents that leptin play a role in several autoimmune 
diseases (6-10). Chronic cGVHD is a particular type of immune-mediated process. It may be 
caused by an immunological attack of target organs by transplanted donor lymphocytes as 
extension of the alloreactivity responsible for acute GVHD, or it can be a manifestations of an 
altered immune reconstitution with generation of autoreactive T-cell clones and dysregulation of 
post-thymic CD4+ effector memory cells (CCR7-/CD62low) and CD4+CD25+ cells (36,37). 
Indeed, cGVHD shares similarities with the mechanisms involved in several autoimmune 
disorders, namely collagen-vascular diseases (38,39). The up-regulation of the Th1 cytokines 
IFN-gamma and IL-12 in mononuclear cells of cGVHD patients implicates that also a Th1-
driven mechanism may be involved in the development of this chronic complication (40,41). 
Furthermore, IFN-γ plays a pivotal role in the increased collagen deposition, a characteristic 
pathologic feature of cGVHD (42,43). In view of the higher serum leptin levels after SCT and of 
its peculiar increase after cGVHD, we investigated their relationship with the Th1 and Th2 
cytokines secretion pattern and with the circulating CD4-to-CD8 ratio, which are frequently 
unbalanced following auto- and allo-SCT, especially when cGVHD is present. Among the 
cytokines secreted by type-1 and type-2 T-helper lymphocytes, serum IFN-γ and TNF-α levels 
were significantly higher in patients who developed GVHD compared with auto-transplanted 
patients and healthy controls. However, only serum IFN-γ levels correlated significantly with 
increased serum leptin in allo-SCT patients, in particular in those with increased IFN-gamma 
suggesting more close relationship when the immune system is activated.  
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Interactions between leptin and several cytokines have been previously reported. In 
particular, proinflammatory Th1 cytokines increase leptin secretion by adipose tissue (44); leptin 
in turn stimulates the production of Th1 type cytokines from stimulated lymphocytes 
(3,4,10,11,14,15,45). Furthermore, leptin regulates the balance of Th1/Th2 cytokines (13). Thus, 
it is possible that Th1 lymphocyte activation during cGVHD may account for the difference in 
leptin values observed between auto- and allo-transplanted subjects. A major increase in serum 
leptin levels in patients with cGVHD suggests that autoreactive T cells involved in cGVH 
reaction may further stimulate leptin secretion. In addition, as leptin reduces T cells apoptotic 
rate (45), one may guess that leptin allows escape of lymphocyte subpopulations with anti-host 
reactivity, thus worsening cGVHD. Minor increase in serum leptin levels and preserved 
leptin/BMI ratio observed after auto-SCT are in line with a milder immune system alteration in 
this cohort of patients, as documented by a less altered CD4-toCD8 ratio.  
Although the hypothesis that high serum leptin levels represents an epiphenomenona of 
cGVHD has also to be taken into a consideration, our data suggest that leptin increase may have 
some role in the development and maintenance of cGVHD. Previous evidence exists that leptin 
addition to MLR increases T-lymphocyte proliferation and IFN-γ secretion (10-12).  More 
recently, it has been shown that Th1 cells and macrophages secrete leptin that sustain their 
function through an autocrine loop (3,13). To investigate the involvement of immune-mediated 
abnormalities in the triggering of leptin secretion in cGVHD+ patients, we tested the role of 
leptin in the allogeneic MLR, an in vitro model of T-cell activation that takes place during 
allografting in vivo. Substantial decrease in proliferative responses by activated alloreactive T 
cells was achieved by incubating one-way MLR from 5 HLA-mismatched couples of responder 
and stimulator T-lymphocytes with a blocking anti-human leptin polyclonal antibody. These data 
suggest that 1) leptin can act as an autocrine growth factor in MLR and 2) serum leptin increase 
during cGVHD can also be ascribed to T cell-derived leptin, apart to be due to a well known 
IFN-γ and TNF-α−induced leptin production by adipose tissue. 
In conclusion, we found greater increase in serum leptin after allo-SCT than auto-SCT, 
with the highest levels in patients with cGVHD.  Loss of the physiological relationships between 
leptin, BMI and gonadal function, the correlation between serum leptin and IFN-γ levels in the 
allogeneic setting, and the marked inhibitory effect of leptin-blockade on T cell activation in 
primary MLR suggest that T-cell activation after allo-SCT may be involved in the leptin 
increase, and that the latter might subsequently contribute to the maintenance of the immune 
attack responsible for cGVHD. 
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Figure 1. Serum leptin levels are significantly increased after autologous (auto) and allogeneic (allo) stem cell transplantation (SCT). Panel a: 
serum leptin levels in the various groups studied. Black dots: allo-SCT with chronic GVHD (cGVHD). Panel b: serum leptin 
modifications in the same patients before and after SCT.  
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Figure 2. Correlation between leptin and body mass index (BMI) is preserved in auto-SCT patients and lost in allo-SCT patients. Each dot represents 
a subject studied. 
 
  
Long-lasting bone damage detected by dual energy x-ray absorptiometry, 
phalangeal osteosonogrammetry and in vitro growth of marrow stromal cells after 
allogeneic stem cell transplantation  
 
 
Introduction 
In the past few years the use of allogeneic stem cell transplant (allo-SCT) in the treatment of 
hematological diseases has grown exponentially along with a progressive improvement in patients’ 
outcome due to a fall in transplant-related mortality (1). As the population of post-transplant long-
term survivors is rapidly growing, attention is now focused on early and late complications of this 
procedure. Osteoporosis, fractures and avascular necrosis (AVN) are considered common 
complications leading to pain and disability, which negatively affect lifestyle and quality of life of 
transplanted patients (2,3). A significant decrease in bone mass has been shown in heart, kidney, 
lung and liver transplanted patients as well as in survivors after autologous and allo-SCT (4-12). 
The mechanisms of bone metabolism alteration caused by allo-SCT are multiple and not completely 
understood (13). Major risk factors for transplant-related osteoporosis include myeloablative 
conditioning regimens, cytokine storm at the time of transplantation, post-transplant long-lasting 
high-dose steroids and cyclosporin-A (CsA) therapy, immobilization and decreased kidney, liver 
and bowel function that result in reduced intake and altered metabolism of calcium and vitamin D 
(8,13-15). In addition, most women experience ovarian failure after allo-SCT (16). 
Osteoporosis is defined as compromised bone strength and increased susceptibility to 
fractures, while osteopenia represents a less severe bone abnormality (17). Altered biochemical 
markers of bone metabolism have been found early after allo-SCT, suggesting a transplant-induced 
increase in bone turnover (18-20). In line with this finding, a high prevalence of osteoporosis has 
been found at trabeculae-rich sites within 12 months after allo-SCT (9,11,21). Dual energy X-ray 
absorptiometry (DEXA) is currently the best well-referenced method to diagnose transplant-related 
bone loss; quantitative computed tomography has also been adopted in one study (10). Although 
BMD, a parameter determined by DEXA and tomography, accounts for about 70% of bone 
strength, there is increasing evidence that other structural aspects that largely contribute to fracture 
risk are not detected by these techniques (23-25). Multiple risk factors related to SCT influence both 
mineral content and cellular components of bone, which cause modification of bone 
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microarchitecture and mechanical properties (13). Phalangeal OSG, as detected by quantitative 
ultrasonometry, is a recent non-invasive and radiation-free method that provides  information on 
bone density and mechanical properties of bone including density, elasticity and width of trabeculae 
by assessing amplitude and speed of ultrasound signals crossing the bone (26-29). Phalanges show 
an equal proportion of compact and cancellous bone as well as a high metabolic turnover, which 
make them an important skeletal site for early identification of bone changes (30).  
Bone is constantly regenerated by a process of osteoclast-mediated resorption and 
osteoblast-induced replacement; alterations of this equilibrium are the primary causes of 
osteoporosis. Osteoclasts are multinucleated hemopoietic cells derived from the 
monocyte/macrophage lineage, whereas osteoblasts are mesenchymal derived marrow stromal cells 
which allow the formation and mineralization of secreted bone matrix (31). Estimation of bone 
remodeling includes quantification of marrow colony forming units-fibroblast (CFU-F) cells in 
vitro. Currently, CFU-F are believed to be the best “in vitro” surrogate for the most primitive 
precursors for osteoblasts (32). Chemotherapy used for hematological malignancies may damage 
the function of microenvironment precursors, whereas myeloablative conditioning regimens 
followed by autologous or allo-SCT seem to delay regeneration of bone microenvironment (33,34). 
The main aim of this cross-sectional study was to assess bone damage in adults with 
functioning donor marrow graft lasting more than one year.  In particular, we focused on bone 
densitometry perfomed one to ten years after allo-SCT at three skeletal sites by two different 
methods: DEXA and OSG. Finally, densitometric results were compared to in vitro recovery of 
clonogenic fibroblast progenitors, which represents a pivotal step of bone remodeling.   
 
 
Subjects and Methods 
Patients and transplantation procedures 
We evaluated bone abnormalities in forty-one consecutive patients who had been 
successfully allotransplanted at least one year before entering the study, with unmanipulated 
marrow from a HLA identical sibling. Reasons for transplant included patients with acute myeloid 
leukemia (n=18), chronic myeloid leukemia (n=17), acute lymphoblastic leukemia (n=4) and 
Hodgkin’s lymphoma (n=2). There were 20 women and 21 men, with a median age of 28.5 yr 
(range, 14 –50) at SCT, and 32 yr (range, 20-51) at time of bone evaluation. All patients had been 
conditioned with the BU-CY2 regimen (busulphan 16 mg/kg and cyclophosphamide 120 mg/kg). 
All patients had also received CsA (1 mg/kg/day by continuous i.v. infusion from day -1 to day + 
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20 and then 8 mg/kg/day orally) plus short-course methotrexate as prophylaxis for graft versus host 
disease (GVHD). No patient had received prophylactic therapy with growth factors after SCT. 
Twenty-three patients developed acute GVHD (aGVHD) of global grade I to IV and were 
successfully treated with methylprednisolone at doses ranging from 2 to 10 mg/kg, then tapered as 
tolerated. Twenty-nine patients had been or were affected by chronic GVHD (cGVHD) (10 limited 
and 19 extensive form), treated with prednisolone at doses of 1-2 mg/kg, associated with CsA at 
doses ranging from 1 to 8 mg/kg/day.  
 
Table 1.   Clinical characteristics of patients who underwent  allogeneic stem cell transplant. 
 
Values are expressed as mean ± SD. 
Abbreviations: SCT: stem cell 
transplant, AML: acute myeloid 
leukemia, CML: chronic myeloid 
leukemia, ALL: acute 
lymphoblastic leukemia, HD: 
Hodgkin’s disease. CR: complete 
remission, BU: busuphan, CY: 
cyclophosphamide, BMI: body 
mass index; GVHD: graft versus 
host disease; Symbols: *: expressed 
as prednisone equivalents. 
 
 
 
 
 
 
 
Calcium intake was estimated by description 
of the usual diet and ranged from 500 to 800 mg/day; daily supplemental calcium intake 
recommended for patients receiving steroid therapy was 1000 mg. Body mass index (BMI) was 
calculated for each patient as weight/height square (kg/m2). No patient smoked, drank alcohol or 
more than 3 cups of coffee per day. The clinical characteristics of the patients are summarized in 
Table 1. The control group consisted of 188 healthy individuals, including family members and 
donors of stem cells, matched for age, sex and BMI. Informed consent was obtained from all 
patients and controls in accordance with institutional guidelines and the  study design was made in 
accordance with the Helsinki II Declaration. 
 
Patient characteristics  n=41 
Age at SCT (yrs) 31.4±11 
Gender (F/M) 20/21 
Underlying disease   
    AML in 1st CR 18 
    CML in chronic phase 17 
    ALL in 2nd CR 4 
    HD 2 
Conditioning regimen:  
    BU-CY2 41 
Age at evaluation (yrs) 34.9±9.8 
BMI (kg/m2) 23.9±5.4 
Amenorrhea duration (months) 
 23.1±22.0 
Acute GVHD  23 
    Grade I-II/III-IV 20/3 
Chronic GVHD 29 
    Limited/extensive form 10/19 
Corticosteroid treatment   
    Duration (days) 260.8±245.0 
    Cumulative dose (g)* 6.7±5.5 
Cyclosporine A  treatment  
    Duration (days) 340.4 ±194.8 
    Cumulative dose (g)  
  66.9±46.88 
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The median cumulative dose of steroids given to this cohort of patients was equivalent to 
5.8 g of prednisone (range 0.8 - 24) for a period ranging from 3 to 36 months.  
 
Hormonal and biochemical evaluation 
Blood samples were obtained from all patients between 08:00 and 10:30 a.m every 3-6 
months after SCT. Serum FSH, LH, 17-β-estradiol and testosterone were monitored to assess 
gonadal function; measurements were performed by commercially available kits: FSH and LH with 
radioimmunoassay (RIA, Biodata, Rimini, Italy), testosterone and estradiol using solid phase 
chemoluminescent enzyme immunoassay (DPC, Los Angeles, CA, USA).  At study enter, serum 
calcium (Ca), phosphorus (P), creatinine, alkaline phosphatase (ALP), albumin, intact molecule 
parathyroid hormone (iPTH) and osteocalcin were determined after at least 8 hour fasting, while 
urinary calcium and hydroxyproline excretion were measured in 24h- urine collection, and 
corrected for creatinine excretion. Intact PTH and serum osteocalcin levels were measured by RIA 
(Nichols Institute Diagnostics, CA); the detection limit of the latter was 0.35 mg/L. Hydroxyproline 
excretion was measured by high pressure liquid chromatography. Blood chemistry profile, 
including levels of Ca, P, ALP, 24-h urinary Ca excretion and creatinine, were analyzed using a 
standard autoanalyzer.  
 
Bone density evaluation, fracture  and avascular necrosis  assessment 
Bone density was determined simultaneously at three different skeletal sites by two  
methods: DEXA and phalangeal OSG. Lumbar spine (LS) (L1-L4) and femoral neck (FN) BMD 
were measured by DEXA, using the Hologic QDR 1000 densitometer (Hologic, Inc., Waltham, 
MA).  Individual BMD values are expressed as g/cm2,  T- and Z-scores. Quality control was 
maintained by daily scanning of an anthropomorphic spine phantom.  The coefficient of variation 
for the DEXA technique was < 1% for the lumbar spine and 1.5% for the FN.   The reference 
population adopted in this study was the international pooled sample provided by the manufacturer; 
their data, however, did not differ significantly from those obtained on a local sample in a study 
performed when the device was set up (35). 
Phalangeal OSG evaluation was performed using DBM Sonic Bone Profiler (Igea, Carpi, Mo, Italy) 
as previously described (36). The amplitude-dependent speed of sound (AD-SoS) and ultrasound 
bone profile index (UBPI) were measured (27). Measurements were carried out on the 2nd to the 5th 
proximal phalanges of the non-dominant hand and the device automatically averaged the AD-SoS 
values of the four fingers. AD-SoS results were reported as m/s and as T- and Z-scores. The latter 
two parameters were calculated with the software provided by the manufacturer using 
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measurements obtained in a sample of Italian population as reference database. UBPI is an optimum 
mathematical combination of three signal parameters developed in order to better discriminate 
fracture risk (27) . It represents the probability of a single subject to belong to the nonfractured 
group; its values are normalized and range from 0 to 1, 1 being  attributed to the highest value 
obtained (37). Measurements were always performed by the same skilled operator and the 
coefficient of variation was 0.8%, determined by repeated measurements in a subgroup of 30 
subjects (3 measurement per person in 3 different days within one week). According to the World 
Health Organization (WHO) criteria, osteopenia and osteoporosis were defined by a T score below 
– 1 and –2.5 SD respectively for the DEXA technique (22). Using phalangeal OSG, osteopenia and 
osteoporosis were defined by AD-SoS T score < –1 and < –3.2 SD, according to a recent 
epidemiological study on more than 10.000 women (27). Potential asymptomatic vertebral 
compression fractures were investigated by standard spinal radiographs in all patients with BMD T-
score < -2.5 SD. AVN was detected by computed tomography or magnetic resonance imaging.  
 
CFU-F assay and stromal layer cultures 
Bone remodelling was investigated by in vitro CFU-F study in 30 transplanted patients and 
20 bone marrow donors. Mononuclear cells from BM (BMMNC) were isolated by density gradient 
centrifugation using lymphocyte separation medium. BMMNCs were washed by centrifugation at 
1200 g for 10 minutes at 20°C with phosphate buffered saline (PBS) containing 2% fetal bovine 
serum (FCS) for CFU-F assay and stromal cell cultures.  For CFU-F assay, BMMNC cells were 
resuspended at a concentration of 2 x106/mL in McCoy’s 5A modified medium containing 10% 
FBS with L-glutamine (Mesencult, StemCell Technologies, Vancouver, CA) supplemented with 1 
x10-8 mol/L dexamethasone (Sigma, St Louis, MO, USA), which allows the recruitment of bone 
marrow mesenchymal cells to the osteoblastic lineage, and plated in 25 cm2 tissue culture flasks.  
Fibroblast colony growth was evaluated after incubation at 37°C, 5% CO2 for 14 days in a 
humidified atmosphere.  Characteristic fibroblastoid  cell aggregates of > 50 cells were scored in 
situ as CFU-F under an inverted microscope. When needed, osteoblastic differentiation of the 
colonies was defined by their ability to express ALP activity, and tissue cultures were stained with 
crystal violet for scoring CFU-F. For marrow stromal layer, 5×106/mL BMMNCs were resuspended 
in a culture medium that consisted of long-term stem cell medium (Myelocult, StemCell 
Technologies, Vancouver, CA) supplemented with 1 x10-6 mol/L hydrocortisone sodium 
hemisuccinate (Sigma, St. Louis, MO, USA), plated into 25 cm2 tissue culture flasks and incubated 
in a humidified atmosphere (37°C, 5% CO2). On a weekly basis the stromal layer cultures were fed 
by complete replacement of the medium and analyzed for stromal confluence after 4 –5 weeks. All 
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cultures were performed in duplicate. Lymphocyte separation medium, HBSS and FCS were 
purchased from Life Technologies, Gaithersburg, MD, USA.  
 
Statistical analysis 
Data are expressed as mean ± SD and ± SEM as appropriate throughout the text and in 
tables. Analysis of risk factors was performed using Pearsons’s correlation coefficient for data 
expressed by parametric values, and using paired Student’s t-test for non-parametric variables. After 
grouping the patients with normal or pathological BMD parameters, χ2 test was used to assess 
association with specific clinical features. The linear regression was used to detect correlation 
between densitometer values and risk factors for bone loss. Statistical significance was considered 
for p < 0.05.  
 
 
Results 
Biochemical parameters at the time of bone density evaluation 
Serum Ca, P,  creatinine, albumin, urinary Ca excretion and iPTH were within the normal 
range in all patients and did not differ significantly from control values (Table 2). ALP was higher 
in patients than in controls likely because several  patients were affected by liver cGVHD. Mean 
serum testosterone and LH were normal in all males, whereas FSH resulted elevated in 9 men, 
suggesting spermatogenesis impairment (Table 2). Ovarian insufficiency occurred in all but two 
(90%) women.  Sixteen out of 18 amenorrhoic women were receiving  hormone replacement 
therapy (HRT) at the time of testing and gonadotropin levels were within the normal range in all 
except three, who were undertreated likely because of reduced intestinal absorption due to mild 
intestinal cGVHD. Two women were not treated by HRT because of severe liver cGVHD. 
Osteocalcin levels resulted significantly lower 
in patients than in controls (p=0.004), while hydroxyproline excretion did not differ significantly 
between these two groups. 
 
 
 
Table 2. Biochemical evaluation of transplanted patients at time of BMD testing vs controls 
Values are expressed as the means ± SD. °: during HRT treatment; *: p<0.05; ** p<0.01 vs controls. 
 
 
Bone mineral density in transplanted patients 
The median interval between SCT and bone status analysis was 36.5 months (range, 12-
120). At L1-L4 vertebrae, lumbar BMD  and Z-scores were significantly lower in patients than 
in controls (p<0.001). According to WHO criteria, seven patients (17%) had osteopenia (3M, 
4F) and 5 (12%) osteoporosis (2F, 3M) at this site. Also femoral BMD values and Z-scores 
differed significantly between patients and controls (p<0.001), 15 patients (37%) (7M, 8F) 
having osteopenia and 6 (15%) (3M, 3F) osteoporosis at this site. Phalangeal AD-SoS, Z-scores 
and UBPI were significantly lower in patients than in controls (p<0.001, all);  T-score values 
were within the range of osteopenia in 25 patients (60%) (10M, 15F) and of osteoporosis in 3 
(7%) (2M,1F). When female and male patients were compared separately to their gender-
matched controls, a significant decrease in bone density was detected at all skeletal sites 
evaluated (Table 3). OSG detected a significant difference in both Ad-SoS and UBPI. No 
significant difference in densitometric values was found between male and female patients 
(Table 3). Women with amenorrhea lasting more than 3 months had significantly lower AD-
Variable 
 
Normal ranges Patients 
(n= 41) 
Controls 
(n=188) 
Serum: 
Calcium (mmol/L) 
 
2.2-2.6 
 
2.36±0.13 
 
2.34±0.11 
Phosphorus (mmol/L)  0.7-1.35 1.08±0.17 1.1±0.18 
Alkaline phosphatase (U/L) 98-275 
     317±143 ** 88±20 
Creatinine (mol/L) <133 87±9 80±10 
Albumin (g/dl) 3,6-5,2 4.16±0.36  4.3± 0.3 
Osteocalcin (ng/ml) 2-22 13.98±6.3* 15.7± 2.5 
iPTH (ng/L) 10-75 
 39.5± 11.2  36.8± 10.7 
FSH (U/L) men/women° 2-15/0.3-9.9 15.5±9.4*/7.5±5 7.5±2.8/6.9±3.4 
LH (U/L) men/women° 
Testosterone (nmol/L) 
Estradiol (pmol/L)° 
2-10/0.5-7.7 
10.4-34 
147-918 
5.7±2.4/5.2±4 
19.1±7.3 
91.8±11* 
9.5±2.3/10.6±2.9 
19.8±7.8 
176±30 
Urinary:  
hydroxyproline excretion (µmol/m2 )  
 
60-190 
 
130±41.5 
 
125±16 
hydroxyproline/creatinine   9.1 9.5 
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SoS values (1993±80 vs 2073±53 m/s, p=0.04) and Z-scores (-1.81±1.13  vs - 0.68±0.77 SD;  
p=0.04) than women with amenorrhea for less than 3 months, while the difference  in UBPI 
levels (0.59±0.21 vs 0.76±0.13; p=0.09) did not reach significance. No difference was found 
regarding amenorrhea by the DEXA technique.  
Patients who had been affected by aGVHD had significantly lower lumbar BMD and Z-scores 
(-1.45±1.49 vs –0.25±0.57 SD) than those without this complication (p=0.01). No significant 
difference was found in BMD values regarding cGVHD occurrence when any vs no cGVHD 
were considered. AD-SoS resulted significantly lower in patients with extensive cGVHD 
compared to those not affected by any cGVHD  (2030±70 vs 2041±39 m/s, p<0.001). 
Prolonged administration of CsA (>199 days) was associated with lower BMD at lumbar spine 
(p=0.01) and longer steroid use (>210 days) with lower AD-SoS (p=0.03), while no significant 
relationship was shown between densitometric values and cumulative dose of 
immunosuppressive treatments.  
 
When bone mass was evaluated in relation to the time elapsed since transplantation, 
different findings were obtained depending on the analysis method (Figure 1). Patients who 
were evaluated >36 months after SCT had significantly higher (p< 0.001) lumbar BMD than 
patients evaluated <36 months. BMD values of the group with longer follow-up period 
overlapped with those of normal controls (p=0.16). Moreover, lumbar BMD showed a linear 
correlation with the time elapsed since SCT (p=0.008). On the other hand, no difference was 
seen in patients evaluated before or after the 36th month since SCT at the FN and phalanxes. No 
correlation was found between OSG values and months from transplant, and AD-SoS remained 
low even after more than 6 years.  Twelve patients belonging to the group evaluated <36 
months after SCT were re-evaluated after an additional period of 12 months: bone loss was 7% 
and 8% of the baseline value at the LS and FN respectively, while it exceeded 10% at the 
phalanxes. No significant difference was found in osteocalcin levels after < 3 or >3 years from 
SCT. 
  
 
Table 3. Bone mass evaluation in transplanted patients vs controls 
 
 
     Males 
           Patients                  Controls 
Females  
        Patients                     Controls 
N 21 98 20 90 
Age at evaluation  38.7 ± 10 38 ± 9.8 30.45 ± 8.4 31 ± 9 
BMI 26.2 ± 3.26 25.9 ± 3.5 23.4 ± 3.5 23.8 ± 3.5 
Lumbar BMD (g/cm2) 0.924 ± 0.2** 1.09 ± 0.08 0.98 ± 0.12* 1.045 ± 0.1 
    Z-score 
-1.06 ± 1.35** 0.018 ± 0.95 -0.705 ± 1.16** -0.02 ± 0.089 
Femoral neck BMD (g/cm2) 0.832 ± 0.12** 0.96 ± 0.1 0.763 ± 0.14** 0.884 ± 0.09 
    Z-score 
-0.713 ± 0.912** 0.336 ± 0.86 -1.36 ± 0.726** -0.02 ± 0.093 
Finger AdSoS (m/s) 2020 ± 61** 2118 ± 53 2018 ± 84.5** 2116 ± 50 
    Z-score 
-1.192 ± 0.8** -0.05 ± 0.45 -1.446 ± 1.19** -0.048 ± 0.42 
    UBPI 0.77 ± 0.19** 0.95 ± 0.05 0.636 ± 0.21** 0.91 ± 0.07 
Values are expressed as means ± SD. Abbreviations – BMI: body mass index; BMD: bone mineral density;  Ad-SoS: amplitude 
dependent speed of sound;  UBPI: Ultrasound bone Profile Index. Symbols - *: p<0.01; ** p<0.001vs respective controls. 
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Figure 1.  Densitometric values evaluated in patients <3 and >3 years from allogeneic SCT, 
expressed as Z-score. Each dot represents a subject studied.  
 
 
Incidence of avascular necrosis and fractures 
Eight patients (4F,4M) experienced bone AVN 11 to 120 months after allo-SCT. Sites 
included both femoral head in all patients with concomitant humeral involvement in three. Clinical 
features and densitometric values of the subjects with aseptic necrosis are summarized in Table 4. 
Groups with or without AVN were similar in terms of age, follow-up period and BMI. All patients 
with AVN suffered from extensive cGVHD, having received CsA (p= 0.079) and steroid (p<0.001) 
treatments for significantly longer periods than patients without this complication. The steroid dose 
received before AVN occurrence was also significantly higher (p<0.005) than that of patients 
without this complication. Lumbar and femoral BMD were significantly lower in the group with 
AVN, while mean AD-SoS value and UBPI did not differ between patients with or without AVN 
(Table 4). However, 6 /8 patients who developed AVN showed AD-SoS T-score value < -1 SD. In 
this study on a small number of cases with AVN, DEXA measurement was superior to OSG in 
identifying patients with AVN.  
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Table 4. Risk factors for avascular necrosis as assessed by the χ2 test 
Variable Avascular 
Necrosis 
No Necrosis χ2 P-value 
N 8 33 
 
  
Gender:   females         4 16   
                males 4 17 0.006  0.997 
Days on CsA therapy:     
                 < 199 days 2 18   
                 ≥ 199 days 6 15 2.250 0.325 
Cumulative dose of CsA:     
                ≤60 g 3 23   
                >60 g 5 10 2.877  0.237 
Days on steroid therapy:     
                ≤210 days 1 20   
                >210 days 7 13 5.964 0.05 
Cumulative dose of steroids:  
                < 5.8 g 
 
1 
 
20 
  
                ≥ 5.8 g 7 13 5.964 0.05 
Acute GVHD  5 18   
No acute GVHD 3 15 0.165 0.921 
Any chronic GVHD  8 21   
No chronic GVHD 0 12 4.113 0.128 
Extensive chronic GVHD 7 12   
No/limited chronic GVHD 1 22 7.063 0.029 
Lumbar BMD (g/cm2) 0.86±0.23 1.01±0.11    0.009* 
Femoral neck BMD (g/cm2) 0.73±0.17 0.823±0.1    0.045* 
Phalangeal AD-SoS (m/s) 2019±53 2022±79  0.9* 
UBPI 0.72±0.13 0.69±0.22  0.7* 
Abbreviations - CsA: cyclosporine A; GVHD: graft versus host disease; BMD: bone 
mineral density, AD-SoS: amplitude dependent speed of sound; UBPI: ultrasound bone 
profile index. *: P values were calculated by t-test. 
 
Among osteoporotic patients, multiple non traumatic vertebral fractures were detected in 2 men 
(age, 52 and 38 yrs) 18 and 30 months after SCT. Both of them were affected by chronic 
GVHD and had taken > 10 g of prednisone equivalent (for 548 and 510 days)  and CsA 51.2 
and 32.1 g (for 395 and 240 days). 
 
Marrow CFU-F and stromal layer in transplanted patients 
All transplanted patients showed complete engraftment at hemopoietic and molecular 
level at the time of analysis. Marrow compartment of stromal cells, measured as CFU-F cells, 
was decreased 2 to 3-fold in  transplanted patients compared to normal donors (22.3±3/105 
MNC plated vs 55±4; p <0.0001) (Figure 2). As some of us recently documented for the 
marrow long-term culture-initiating cell compartment (45), CFU-F cell number in transplanted 
patients was not influenced by the number of myeloid progenitors (CFU-GM) infused: using as 
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cut-off the median value (2.93x104/kg CFU-GM), there was no difference in CFU-F frequency 
between the groups of patients who had received more or less CFU-GM (p =0.74) (45). To 
analyze marrow microenvironment at a functional level, we studied the capacity of stromal 
cells to generate a confluent stromal layer, which is essential to support allogeneic 
hematopoietic progenitors growth in vitro.  After 4-5 weeks long-term cultures, marrow stromal 
cells produced a confluent marrow stroma only in 20% of cases compared to 80% of normal 
controls (data not shown).  Analyzing the effect of time elapsed since transplantation on 
marrow CFU-F number, we found marrow CFU-F compartment markedly depleted during the 
first 6 years after transplant (Figure 2). Between the 6th  and 10th  year,  the mean marrow 
CFU-C cell number tended to increase (13.28±3.48 vs 33.30±5.36 before and after 67 months, 
respectively; p=0.004), although most of the patients showed CFU-F numbers permanently 
below those observed in normal controls. cGVHD was significantly related to decreased 
number of CFU-F colonies in vitro  (46.4 ±9.31 vs 13.7±12.85, p=0.01), while no relationship 
was found in patients with or without avascular necrosis (16.4±18 vs 20.2±17). 
 
Variables predictive for bone loss and avascular necrosis 
In order to gain insight into the cause of SCT-related bone abnormalities, a univariate 
analysis was performed to assess the relationship between potential risk factors, densitometric 
values, AVN occurrence and CFU-F growth in vitro. The following risk factors were 
considered: age, gender, BMI, cumulative dose and length of steroid and CsA received, 
duration of amenorrhea and  a/cGVHD occurrence. Age at SCT correlated inversely with AD-
SoS (r= -0.43, p= 0.006), UBPI (r=-0.39, p= 0.01)  and lumbar BMD (r= -0.5, p=0.01). A 
similar correlation was also found with age at bone status evaluation (p= 0.001; p= 0.01 and 
p=0.02 respectively). Length of amenorrhea correlated with AD-SoS (r= -0.38, p= 0.03). On 
the other hand, no correlation was shown between densitometric parameters at any site and sex, 
BMI, immunosuppressive treatments  and cGVHD grading. Osteocalcin levels were inversely 
correlated with UBPI  (r=-0.7; p=0.03) and slightly with AD-SoS (r= -0.64; p=0.06). Only 
extensive cGVHD was strongly related to the onset of AVN, while steroid treatment  length 
and dose resulted borderline (p=0.05, both) (Table 4). 
CFU-F growth correlated with Ad-SoS,  its Z-score (r= 0.48; p= 0.05; r= 0.48, p=0.04, 
respectively) and with Z-scores of lumbar and FN BMD (r=0.39, p=0.03 and r= 0.55,  p<0.04, 
respectively). The grade of aGVHD did not affect CFU-F number after SCT (p=0.38; p=0.06 
and p=0.43 for grade I, II and III-IV). cGVHD alone was related to a significantly lower 
number of CFU-F colonies in vitro (r=0.55; p=0.002). 
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Discussion 
In the last few years, it has became clear that osteoporosis and osteonecrosis represent  
frequent and serious complications of allo-SCT. As already suggested by other cross-sectional 
based studies, our results document a frequent decrease in BMD (T-score < -1SD) after allo-
SCT at the lumbar spine (29% of patients) and even more at the femoral neck (51%) 
(10,21,40). A significant decrease in BMD appears early after transplant and seems to continue 
over the first 3 years with no deterioration afterwards. Only two prospective studies have 
attempted to establish the exact time when bone loss occurs after SCT.  A study by Välimäki et 
al. revealed post transplant bone loss within six months after allogenic SCT at both spine and 
femoral neck (9). A more recent and larger study by Stern et al. (11) found a significant 
decrease in lumbar and femoral BMD within 3 months, the decrease in femoral BMD 
continuing (-2.5%) between the 3rd and the 12th  month after transplantation (11). Other smaller 
studies have described bone loss, prevalent at femoral neck, within a few months after SCT 
(10,21,38-40). 
Bone strength is determined by two main features: bone density and bone quality. While 
bone density accounts for most of the strength, bone quality refers to architecture, turnover, 
damage accumulation and mineralization (41). The DEXA technique measures bone density 
and mineralization but does not provide information on architectural damage and bone 
formation. OSG may detect more physical properties of bone tissue and accounts for more 
0
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Figure 2. Clonogenic stromal 
precursors evaluated in 
patients <3 and >3 years 
from allogeneic SCT.  Bone 
marrow mononuclear cells 
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Each dot represents a 
subject studied. 
 
  103
structural changes than traditional methods (26,27).  Ultrasound velocity depends on bone 
density and elasticity, trabecular orientation and cortical-to-trabecular ratio, all of which are 
influenced by mineral content and organic matrix (26). By  phalangeal OSG (27), 61% of 
patients could be classified as having osteopenia and 7.3 % as having osteoporosis.  Although a 
positive correlation was found in healthy controls between BMD and phalangeal OSG results, 
we failed to show any correlation between these two methods after allo-SCT.  Such a lack of 
correlation likely represents further evidence that DEXA and OSG measure different 
parameters associated with bone loss.  In contrast to lumbar densitometry, femoral BMD and 
ultrasonometric parameters (AD-SoS and UBPI) were persistently decreased in patients 
suggesting that bone loss may persist for many years after transplantation or may be 
irreversible.  
Multiple atraumatic spine fractures were detected by screening in two patients who 
were osteoporotic at lumbar spine.  AVN occurred in 8 patients after 11 to 120 months since 
allografting. Men and women were equally affected, all of them having been previously 
treated with prolonged high dose steroid therapy for extensive cGVHD. Significant statistical 
association was found by the χ2 test between AVN occurrence and extensive cGVHD, while 
dose and length of steroid treatment resulted just at the significance limit (p=0.05).  
Discussion on the pathophysiology of post-transplant bone loss always rely on the 
main contributing factors: age, BMI, immunosuppressive treatment and hypogonadism.  As 
documented both in vitro and in vivo, steroids may reduce formation and increase resorption 
of bone, whereas CsA has been shown to increase both bone formation and resorption (44). In 
addition, the onset of hypogonadism leads to rapid bone loss due to osteoclasts overactivity 
(22).  
A possible recovery in lumbar BMD with time after transplant was suggested by the 
Pearson’s correlation analysis between time elapsed since SCT and lumbar BMD. Among 
different risk factors for bone loss tested by univariate analysis, age at SCT correlated 
inversely with spine BMD and phalangeal AD-SoS. The latter was inversely correlated also to 
amenorrhea length. By the χ2 test, longer CsA treatment (≥199 days) and aGVHD were 
associated with lower lumbar BMD values, whereas longer steroid treatment (>210 days) and 
amenorhea period (> 3 months) were associated with lower OSG values. No association was 
found between densitometric values and BMI, cumulative doses of steroids and CsA, and 
cGVHD.  
Mesenchymal stem cells residing in bone marrow are progenitors for osteoblasts and 
other mesenchymal cell lineage. CFU-Fs represent clonogenic mesenchymal progenitors 
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leading to precursors for stromal microenvironment and osteogenic compartment able to 
support hemopoiesis and to form bone tissue in vitro and in vivo (31-33). The origin of post-
transplant CFU-F is still controversial; a recent large study suggests a recipient origin (34). 
Under growth conditions known to promote the maturation of primitive osteogenic precursors 
in the CFU-F fraction of human bone marrow,  the numbers of marrow CFU-F in transplanted 
patients remains permanently below those observed in normal donors, although some 
recovery has been observed after 6 years post-SCT. In agreement with a recent report in a 
small group of patients evaluated  for osteoblastic precursors within the first year after SCT 
(46), we documented that impairment of osteogenic progenitors was severe and persistent 
after allo-SCT. Furthermore, bone marrow stromal cells of almost all transplanted patients 
were unable to give rise to confluent stroma in long-term cultures, implying also a long-
lasting functional damage. These findings suggest that in transplanted patients the decrease in 
bone mass could in part reflect a decreased number and function of osteoblasts due to 
transplant-related loss of osteogenic progenitors. This hypothesis is further supported by the 
correlation found between low densitometric values and marked decrease in CFU-F growth, 
and is in line with the finding of persistently low osteocalcin values. 
In conclusion, our data confirm and expand the results of previous studies showing a 
significant decrease in BMD and a reduced functional capacity of osteoblastic precursors 
after allo-SCT (11,46). Early bone loss may consist of both demineralization and organic 
matrix deficit, the first detectable by DEXA and the second by OSG. While mineralization 
seems to improve at trabecular rich sites (LS), no significant change was detected at cortical 
bone (FN). No improvement was revealed by OSG even after a prolonged follow-up. 
Phalangeal OSG and DEXA are not interchangeable methods for bone loss estimation. FN 
and phalangeal OSG may be preferable sites for investigation of transplant-related bone loss 
in patients who survive more than 3 years from allografting. Whether or not combined 
measurements from these anatomical sites improve bone loss detection still needs to be 
determined.  Although long-lasting steroid therapy for cGVHD and hypogonadism play 
major roles in determining bone loss, our study also shows a severe and permanent deficit in 
number and function of osteoblastic precursors within the stromal stem cell compartment, 
suggesting that inability to regenerate a normal osteogenic cell compartment may in part 
account for severe bone damage after allo-SCT.  
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Avascular necrosis in long-term survivors after allogeneic or autologous 
stem cell transplantation: a single centre experience and a review 
 
  
Introduction 
Avascular necrosis (AVN), a condition defined as nontraumatic ischemic necrosis of 
bone, has been described in 3-41% of patients who had received an organ transplant, 
femoral head resulting the prevalent localization (1,2). Following organ transplant, AVN is 
one of the dreadful complications negatively influencing the quality of life.  
Attention to the AVN after stem cell transplant (SCT) was first drawn by Atkinson et al. 
in 1987 (3), in a population of 50 patients surviving >2 years. Since then, studies on larger 
series of patients have been carried on, which pointed out to a number of significant risk 
factors, such as the primary disease, age, total body irradiation (TBI) and, in particular, 
corticosteroid administration.  
The pathogenesis of AVN is still matter of controversy: it is considered the result of 
multiple triggering factors such as  metabolic disorders, local vascular damage with 
temporary or permanent loss of blood supply to the bone, increased intraosseous pressure 
and mechanical stress leading to demineralization, death of trabecular bone and collapse (4-
6). The process is mostly progressive, resulting in joint destruction within three to five years 
if left untreated. Therefore, surgical treatment is frequently requested in these patients 
because of functional limitation, with further negative psycho-physical consequences.  
Although transplanted patients have multiple risk factors, prolonged high doses of 
steroids appear to be the main cause for developing AVN. On the other hand, AVN is rare in 
patients with endogenous Cushing’s syndrome, despite very high endogenous corti (7). 
Allo- and auto-transplanted patients were mostly pooled together in clinical studies on bone 
complications after SCT, whereas there could be considerable differences between these two 
settings. Essentially, the differences consist in different grade of immune system 
involvement and more prolonged use of immunosuppressive treatments in the allogeneic 
(allo-) setting. Allograft compromises the host immune system more severely than an 
autograft (auto-), due to the intense immunosuppressive effect of the conditioning regimen 
(to avoid graft rejection) and to a prolonged treatment by multiple immunosuppressive drugs 
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needed to avoid the graft-versus-host disease (GVHD). The frequent development of acute 
or chronic GVHD (aGVHD, cGVHD) after allo-SCT induces additional relevant alterations 
in the immune system (8). Finally, the patients treated by allo-transplant are generally 
younger than those auto-transplanted. 
Recently, we have found a straight relationship between AVN and cGVHD  in a population 
of long-term survivors after allo-SCT, while corticosteroid treatment duration and 
cumulative doses were at the border for statistical significance (9). In order to better 
understand the mechanisms or the precipiting conditions triggering AVN and to design a 
treatment strategy, we investigated AVN occurrence in a relatively large population of 
patients who had received auto- or allo-SCT. Clinical and radiographic features of AVN 
were compared with the type of transplant, clinical course of cGVHD, its treatments, bone 
mineral density  and the repopulating capacity of stromal stem cells after allo-SCT. 
 
Patients and methods 
Patients  
Of 255 consecutive patients who had received a SCT procedure, 207 were alive and free 
of malignancy 180 days after transplant and were included in the study. The patients were 
prospectively evaluated by two skilled hematologists (GDR and CS) up to 12 years after 
allo- (n=100, 47F and 53M; age range, 21-55 yrs, median, 32) or auto- (n=107; 49F and 
58M; age range, 18-59 yrs, median, 39) SCT.  Additional data were obtained by reviewing 
long-term follow-up medical records starting from diagnosis. The primary disease included 
acute or chronic myeloid leukemia (AML, CML), acute or chronic lymphocytic leukemia 
(ALL, CLL), Hodgkin’s disease (HD) and non-Hodgkin’s lymphoma (NHL). Allo-SCT 
recipients received unmanipulated marrow-derived stem cells from HLA-identical siblings. 
Auto-SCT patients received unmanipulated marrow cells (n=35) or mobilized peripheral 
blood stem cells. Mobilization was achieved by chemotherapy and granulocyte colony-
stimulating factor at a dose of 16 µg/kg per day by subcutaneous injection. Clinical features 
of the patients and previous treatment history for the underlying disease are summarized in 
Table 1. Informed consent was obtained by all patients and the study was designed in 
accordance with the Helsinki II Declaration on human experimentation. 
  110
Conditioning regimens,  aGVHD prophylaxis and treatment of acute and cGVHD   
Both allo- and auto-transplanted patients for acute AML, CML and ALL received the 
same conditioning regimen, including busulphan (16 mg/kg in 4 days) and 
cyclophosphamide (120 mg/kg in 2 days) (BUCY2). Patients with HD, NHL and CLL were 
conditioned with the BEAM protocol, consisting of carmustine (300 mg/m2 in 1 day), 
etoposide (200 mg/m2 in 4 days), cytarabine (400 mg/m2 in 4 days) and melphalan (140 
mg/m2 in 1 day). After allografting, aGVHD prophylaxis included cyclosporin A (1 mg/kg 
i.v. from day –1 to +21, then 10 mg/kg for 6 months orally) and short course methotrexate 
(10 mg/kg for 4 doses). Diagnosis and grading of GVHD were established according to 
clinical criteria;8 the clinical diagnosis was confirmed, if indicated, by histopathology of 
skin, liver or mucous membranes before starting immunosuppressive therapy. Acute GVHD 
was treated by pulse high-dose methylprednisolone therapy (2-10 mg/kg for 10 days), 
followed by slow dose tapering in the following 3 months, monitoring patients’ clinical 
conditions. Chronic GVHD was treated by prednisolone at doses of 1-1.5 mg/kg for 1 
month, associated with CsA at doses ranging from 4 to 8 mg/kg/day, followed by 25% 
tapering every month in the following  6 months. Each organ involved in cGVHD was 
evaluated for response to immunosuppressive therapy using the following criteria: major or 
minor responses was defined as complete resolution or improvement of cGVHD signs and 
symptoms, respectively, while on immunosuppressive therapy; no response and progression  
as no improvement or worsening in any disease signs or symptoms, respectively, despite 
immunosuppressive therapy; exacerbation as reactivation of cGVHD symptoms after initial 
improvement while on immunosuppressive therapy.   Fifty-six patients had been affected by 
aGVHD of global grade 1-3 and 58 were affected by cGVHD (25 limited and 33 extensive 
form). All these patients were treated as stated above for a period ranging 6-24 months 
(Table 1).  
 
Diagnosis of AVN 
The suspicion of AVN was posed on clinical ground by the referring physician 
during the post-transplant follow-up in our institution. Magnetic resonance imaging (MRI) 
was performed in all patients with suspicion of AVN by anterior-posterior  and lateral scans 
of T1- and T2-weighted images of the involved site. 99Tc labeled methylene bisphoshonate 
triphasic bone/joint scans were obtained in 6 patients in stage I-II. A staging system 
developed by ARCO (Association of Research Circulation Osseous) was used (10).  
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Densitometric evaluation 
Bone mineral density (BMD) was performed in a group of 100 patients (50 allo- and 
50 auto- transplanted: 46F and 54M; age, 34±10.8 yrs) which was representative of the 
whole population of long-term survivors and included all patients with AVN. In these 
patients BMD was evaluated at the moment of AVN diagnosis. Densitometric values were 
compared with those of 200 healthy subjects matched for age, gender and body mass index 
(BMI). Lumbar spine (L1-L4) and femoral neck BMD were measured by dual energy X-ray 
absorptiometry (DEXA), using Hologic QDR 1000 densitometer (Hologic, Inc., Waltham, 
MA). Individual BMD values were expressed as g/cm2, T-score and Z-scores. 
 
Colony forming-unit fibroblast (CFU-F) assay 
In vitro CFU-F growth was performed as previously described in 30 allotransplanted 
patients and 20 bone marrow donors (9). Briefly, isolated bone marrow mononuclear cells 
(BMMNC), after density gradient centrifugation using lymphocyte separation medium (Life 
Technologies, Gaithersburg, MD, USA), were resuspended at a concentration of 2 x106/mL 
in McCoy’s 5A modified medium containing 10% FBS with L-glutamine (Mesencult, 
StemCell Technologies, Vancouver, CA) supplemented with 1 x10-8 mol/L dexamethasone 
(Sigma, St Louis, MO, USA), and plated in 25 cm2 tissue culture flasks. After incubation at 
37°C, 5% CO2 for 15 days in a humidified atmosphere, characteristic fibroblastoid  cell 
aggregates of  >50 cells were scored in situ as CFU-F under inverted microscope.  All 
cultures were performed in duplicate.  
 
Statistical analysis 
Data are expressed as mean ± SD or SEM as appropriate throughout the text and in 
tables. Specific risk factors screened for AVN included gender, age, underlying diagnosis, 
corticosteroid  and cyclosporine exposure, type of transplant, BMD and GVHD occurrence. 
Analysis of risk factors was performed using Pearsons’s correlation coefficient for data 
expressed by parametric values, and using paired Student’s t-test for non-parametric 
variables. After stratifying the patients with and without AVN,  χ2 test was used to assess 
association with specific clinical features. Linear regression was used to detect correlation 
between AVN and risk factors. Statistical significance was considered for p < 0.05.  
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Table 1.   Characteristics of patients submitted to allogeneic or autologous stem cell transplantation 
(SCT) and of healthy controls 
 Allo-SCT (n= 100) Auto-SCT (n= 107) Controls  (n=200) 
Age at evaluation (years) 31 ± 10.5 39.6 ± 11.8 34.5±10.4 
Time from transplant (months) 38.9 ± 12.2 37.8 ± 12.4 - 
F/M 47/53 49/58 97/103 
BMI (kg/m2) 23.4 ± 1.7 25.9 ± 2.1 24.2±1.9 
Diagnosis:    
AML 45 50 - 
ALL 30  - 
CML 10  - 
HD 2 35 - 
NHL - 20 - 
SAA 3 -  
CLL - 2 - 
Previous treatment history:    
AML IDA/MITO/ARAC/ETO  
ALL VCR/DAUNO/CYCLO/MTX/MITO/ARAC/ASP  
CML HU/ IFN  
HD VCR/EPIR/BLEO/ETO  
NHL MTX/ADRI/CYCLO/VCR/PDN  
CLL CHL/FLUDA  
Corticosteroid dose (g/m2) 7.2 ± 2.7 7.16 ± 1.4 - 
    Treatment duration (days) 260.5 ± 32.3* 167 ± 34.8 - 
CsA dose (g/m2) 67 ± 3.42 - - 
   Treatment duration (days) 308 ± 39 - - 
Values are expressed as mean ± SD. Corticosteroid cumulative dose is expressed as prednisone equivalents. In the autologous setting, the 
cumulative doses includes steroids administered before transplant, for treatment of underlying disease. Abbreviations: BMI: body mass 
index; AML: Acute myeloid leukemia; ALL: acute lymphocytic leukemia; CML: chronic myeloid leukemia; HD: Hodgkin’s disease; 
NHL: non Hodgkin’s lymphoma; CLL: chronic lymphocytic leukemia; IDA: idarubicin; MITO: mitoxantrone; ARAC: cytarabine; ETO: 
etoposide; VNC: vincristine; DAUNO: daunorubicin; CYCLO: cyclophosphamide; MTX: methotrexate; ASP: asparaginase; HU: 
hydroxyurea; IFN: interferon-γ; EPIR: epirubicine; BLEO: bleomycin, PDN: prednisone; CHL; chlorambucil; FLUDA: fludarabine.  *: 
p<0.005 vs auto-SCT group 
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Results 
Twelve (7M, 5F) patients developed AVN after SCT: 10 in the allo-SCT group (6M; 
4F) and two in the group of auto-transplanted patients (1M, 1F) (83% vs 17%; p=0.037). 
Symptoms of AVN occurred 3 to 120 months following SCT (median, 28) constituted by 
joint pain (at rest and/or night pain) in 3 patients and joint pain plus functional limitation in 
9. A total of 25 joints were affected (mean, 2 joints/person; range, 1 to 4); the joints affected 
were hip, ankle, shoulder and knee. All patients had lower limb involvement and in 10 
patients AVN was confined to lower limbs. 
 
Diagnosis by MRI and scintigraphy  
MRI imaging was performed 1-10 months after first symptoms onset. Three patients 
with unilateral groin pain had bilateral femoral head disease at MRI (controlateral silent 
involvement). An area of low intensity signal in the femoral head and/or the “double line 
sign” were observed in  nine patients (stage I-II); collapse of femoral head (stage III-IV ) 
was present in three patients. Triphasic scintigraphy, performed in six patients, showed an 
abnormal uptake (increase uptake surrounding a cold area)(11) in five of them.  
 
AVN in auto-transplanted patients 
Two patients developed AVN 3 and 12 months after auto-SCT; the femoral head was 
affected bilaterally in both. Both patients had hypogonadism: the men was affected by 
testicular dysgenesis and the woman had post-transplant ovarian failure. Corticosteroid 
cumulative dose was 7 and 8 g in the patients with AVN and 6.76±0.11 g in 
autotransplanted patients not affected by this complication. Treatment duration was  240 and 
175 days in the two patients with AVN and 167±24.9 days in patients without AVN. 
Lumbar and femoral Z-scores were -0.03 and –2.39 SD and –1.02  and -0.76 SD, 
respectively, in patients with AVN, while patients without AVN had lumbar and femoral Z-
scores -0.23±0.04 SD and –0.48 ±0.038 SD, respectively. 
 
AVN in allo-transplanted patients  
Sites included both femoral heads in 4 patients, one femoral head in three, bilateral 
femoral head and unilateral/bilateral humeral head in two, bilateral femoral head and right 
knee in one. AVN developed 12-120 months after SCT. All but one patient affected by AVN 
were suffering from extensive cGVHD. Exacerbation or recurrence of cGVHD could be 
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documented in 8 patients shortly (1-4 months) before AVN diagnosis and all these patients 
had multi-organ involvement. Individual clinical features concerning GVHD of the allo-
transplanted patients with AVN are summarized in Table 2. Liver manifestation included 
increased liver enzymes in all patients (ALT, 112-1200 U/L; AST, 67-912 U/L; γGT, 90-350 
U/L) and signs of cholestasis (alkaline phosphatase, 487-785 U/L and  bilirubin, 5-9 mg/dl) 
in two. Skin lesions included hypercheratosis, lichen planus and focal epidermal atrophy. 
Ocular dryness (Sjögren-like syndrome) was the major ophthalmologic manifestation, while 
oral dryness and lichenoid lesions were the most frequent upper gastrointestinal tract 
symptoms.  
Prior to AVN, patients with this complication had received immunosuppressive 
treatments for longer periods than allo-transplanted patients who did not develop this 
complication (CsA, 403±89.3 vs 272±35 days; p=0.079;  corticosteroid, 448±52 vs 207±40 
days; p<0.001). The cumulative steroid dose received before AVN occurrence was also 
significantly higher (15.3±2 vs 5.9±1.15 g/m2; p<0.005) compared with patients without this 
complication. Two out of four women with osteonecrosis had not received hormone 
replacement therapy and were hypogonadic since SCT. A T-score  < -1 SD at lumbar spine 
was detected in 4 patients with AVN and at femoral neck in 8, although BMD did not differ 
significantly between allo-transplanted patients with or without AVN (lumbar, -0.7±0.53 vs 
-0.04±0.3 SD; p=0.065; femoral neck, -1.02±0.5 vs –1.07±0.3 SD; p=0.84).  
 
Marrow CFU-F in allo-transplanted patients 
Marrow compartment of stromal stem cells, measured by CFU-F assay, was 
decreased in transplanted patients compared to normal donors (22.3±3/105 MNC plated vs 
55±4; p<0.0001). We found marrow CFU-F compartment markedly depleted particularly in 
allo-transplanted patients affected by cGVHD (CFU-F: 43.2 ±9.3 vs 13.7±12.8 in allo-
transplanted patients without and with cGVHD, respectively; p=0.01). In addition, almost all 
transplanted patients with AVN showed a number of CFU-F below those observed in 
transplanted patients without this complication (CFU-F: 24.5±3.5 vs 12.4 ±4.3 in allo-
transplanted patients without and with AVN, respectively; p=0.042). 
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Table 2. GVHD state in allo-transplanted patients with avascular necrosis (AVN)  
cGVHD CGVHD state at  Patient Gender/age at 
TMO (yr) 
AVN onset 
after SCT 
(months) 
aGVHD 
grade 
CGVHD 
Form Principal site Other sites        AVN diagnosis 
1 M/37 54 - Extensive Skin Eyes, oral stable 
2 M/45 53 - Extensive Skin  Liver, oral Exacerbation 
3 F/21 10 - Extensive Liver Eyes Progression 
4 F/19 11 1-2 Extensive Liver Skin, eyes Progression 
5 M/34 24 4 Extensive Gut Skin, liver Progression 
6 F/21 114 - Extensive Liver Skin, eyes Exacerbation 
7 F/35 36 - Limited Liver Eyes Exacerbation 
8 M/19 48 2 Extensive Liver Skin, oral Exacerbation 
9 M/36 28 - Extensive Skin  Liver, eyes Progression 
10 M/23 18 2 Extensive Liver Skin stable 
 
Time since SCT means the period between SCT and AVN diagnosis 
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Risk factor assessment 
Groups with or without osteonecrosis were similar in terms of age, follow-up period 
from transplant and BMI. Steroid cumulative dose was similar in the allo- and auto-
transplant settings, while the duration of treatment was significantly longer in the allo-
transplanted group (p=0.001) (Table 1).  
Among the risk factors evaluated for AVN by the χ2 test (Table 3), this complication was 
related to steroid treatment dose and duration (p<0.0001 and p=0.0011, respectively) and to 
the type of transplant, being significantly more frequent after the allogeneic one (10% vs. 
1.9%, χ2: 6.23; p=0.044). Chronic GVHD, and, in particular its extensive form, was strongly 
related to AVN occurrence (p=0.018 and p<0.0001, respectively). A recent exacerbation or 
reactivation of cGVHD could be documented in 8/10 allo-transplanted patients who 
developed AVN, while other two had mild persistent liver cGVHD (one as extensive and 
one as limited form). Both lumbar and femoral BMD expressed as Z-score were 
significantly lower in allo- than in auto- transplanted patients (Table 4), suggesting greater 
bone loss in the allogeneic setting. Although nine out of twelve patients who developed 
AVN showed a Z-score value  at the femoral neck < -1 SD, the BMD difference between the 
groups with and without AVN did not reach significance at femoral site and was marginal at 
lumbar spine. No significant influence was found regarding gender and CsA treatment on 
AVN occurrence.  
 
Figure 1. MRI imaging of a recent bilateral femoral head osteonecrosis in a 39 year old man, who 
developed pain and functional limitation 2 months prior to imaging. Diffuse focal 
hypointense lesions in epiphyseal and metaphyseal regions on both sides in coronal T1-
weighted image (a), showing high intensity in T2-weighted image (b). 
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Table 3. Risk factors for avascular necrosis (AVN) as assessed by χ2 test  
Variable + AVN - AVN χ2 P-value 
Number of patients 12 195   
Transplant     allogeneic 10 90   
autologous 2 105 6.466 0.039 
Gender: Women 5 97   
               Men 7 98 0.295 = 0.863 
     
CsA < 199 days* 3 47   
        ≥ 199 days 7 43 1.9 = 0.385 
     
CsA ≤60 g* 3 47   
        > 60 g 7 43 1.907 = 0.385 
     
Steroid duration ≤216 days 2 101   
                           >216 days 10 94 68.8 < 0.0001 
     
Steroid cumulative dose < 6 g 1 103   
                                        ≥ 6 g 11 92 8.95 = 0.0011 
     
Acute GVHD * 6 50   
No acute GVHD* 4 40 0.274 = 0.872 
     
Any chronic GVHD*  10 49   
No chronic GVHD* 0 41 8.05 = 0.018 
     
Extensive chronic GVHD 9 24   
No/limited chronic GVHD 1 66 16.014 <0.0001 
    
 
Lumbar Z-score <-0.5 DS** 6 44  
 
                           >-0.5 DS 6 44 0.0 =1.0 
     
Femoral Z-score <-1.075** 9 41   
                            >-1.075 3 47 3.41 =0.182 
    
 
Lumbar BMD (g/cm2) 0.97±0.15 0.991±0.16 t-test =0.667 
Femoral neck BMD (g/cm2) 0.78±0.15 0.8±0.12 t-test =0.598 
*: data relative only to allo-transplanted patients; **: data relative to 50 allo- and 50 auto-
transplanted patients; Abbreviations - CsA: cyclosporine A; GVHD: graft versus host disease; BMD: 
bone mineral density 
 
 
Treatments 
According to the ARCO classification (10), AVN was diagnosed at stage I in five patients, 
at stage II in four, at stage III in two and at stage IV in one. Conservative treatment with bed 
rest, analgesics and pulsing electromagnetic fields were adopted in 7 patients in stage I-II, 
but the disease progressed in three. AVN progression occurred in patients with severe 
  118
prolonged GVHD. Six patients with femoral head involvement required surgical treatment. 
Five total hip replacements were performed in three patients (two bilateral) and core 
decompression was used in five joints in three subjects (one patient had unilateral 
replacement and controlateral decompression). Treatments in other localization included 
rest, analgesics and pulsing electromagnetic fields with significant improvement of clinical 
symptoms. 
Table 4. Bone mineral density measured in a subgroup of patients after allogeneic or autologous 
stem cell transplant (SCT)  
Variable Allo-SCT  
(n=50) 
Auto-SCT  
(n=50) 
    P value 
Age (yrs) 29.3 ± 1.6 38.9 ± 1.7 NS 
BMI (kg/m2) 23.5 ± 0.5 25.9 ± 0.6 NS 
Femoral neck Z-score (SD) 
-1.06 ± 0.14 -0.57 ± 0.17 0.041 
Lumbar spine Z-score (SD) 
-0.92 ± 0.17 -0.33 ± 0.2 0.017 
The results are expressed as mean±SEM; BMI: body mass index.  
 
 
Discussion 
Symptomatic AVN occurred in 12 of 207 long-term survivors after SCT (5.8%) 
within 3-120 months (median, 28) after grafting, all but two of them having received an allo-
transplant. Equal number of men and women were affected. A significant statistical 
association was found between AVN occurrence, allogeneic type of transplant, presence and 
grade of cGVHD, steroid treatment length and cumulative dose. These findings are 
consistent with previous reports on AVN in other series of patients after SCT, their 
frequencies ranging from 3.7 to 24% (3,12-18). All these studies point out to multiple joint 
involvement, with prevalent localization at the femoral head. The high M/F ratio (8/1) 
described in “a total of AVN population” (19,20) appears to be lost in transplanted patients 
regardless of the type of transplant (21-24). Surgical treatment was required in half of the 
patients. An additional important information emerged at first by our study is the 
relationship between AVN and decreased osteoblastic precursor regenerating capacity 
within the stromal stem cell compartment.  
Indeed, the results of the in vitro study showed reduced CFU-F growth in patients 
with AVN. CFU-F assay mirrors the osteoblastic precursor regenerating capacity. Our 
finding suggests that inability to regenerate a normal osteogenic cell compartment may in 
part account for AVN onset after allogeneic SCT. A larger number of patients and a 
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comparison with CFU-F growth in the auto-transplanted setting is needed to confirm this 
issue. Our study strongly suggests a close relationship between AVN and cGVHD. Indeed, 
a recent exacerbation or progression of cGVHD could be documented in 8/10 allo-
transplanted patients soon before AVN diagnosis. High incidence of acute and/or cGVHD 
has been previously reported in various studies, pointing out that steroid treatment of this 
disorder was the most important factor responsible for AVN onset. The relationship 
between AVN and potential risk factors emerging from previous studies is summarized in 
Table 5. A single report mentioned cGVHD exacerbation as a possible cause of AVN (25), 
while Enright et al. hypothesized an alloreactive immune response as a possible cause for 
osteonecrosis (12). In a cohort of 902 patients after allo- or auto-SCT followed up between 
1974 and 1988, the latter investigator reported an AVN incidence of 10.4% in the allo-
transplant setting and 0% in the auto-transplant one; 89% of the allo-transplanted patients 
with AVN developed GVHD, and 95% had been treated with steroids for GVHD 
prophylaxis. Older age and GVHD requiring steroid therapy were documented risk factors 
for AVN among allo-SCT recipients in the largest multicentric study by Sociè et al. (14), 
and corticosteroids resulted as independent risk factor by a multivariate analysis. This 
study confirmed the results obtained by the same authors in a previous cohort of 727 allo-
SCT recipients followed-up in a single center (13), where aGVHD resulted associated with 
increased incidence of AVN. Similarly, in a study by Fink et al. (15) AVN occurred more 
frequently in the allo- than in the auto-transplant setting (93% vs 7%). TBI has been shown 
as a possible etiologic factor for AVN by various studies, too (12, 14,15). However, similar 
AVN frequency has been observed in our cohort of patients, none of whom had been 
treated by TBI.  
In any case, the exact mechanisms and risk factors are still unknown for most non-
traumatic forms of this invalidating complication. The mechanisms mentioned as potentially 
contributing for AVN onset include dysregulation of lipid metabolism, drug-induced injury 
to the vessel wall and vasculitis (4-6,13,20). Lipid metabolism is altered by steroids and 
gonadal insufficiency, and it has been reported to remain abnormal long after SCT for 
multifactorial and not completely clarified reasons (X syndrome). Vasculitis after SCT can 
have autoimmune origin and can be related to cGVHD, as virtually any organ or tissue can 
be affected by this complication, even in absence of increased autoantibody  production. 
Moreover, AVN is common in conditions of dysregulated immune system, such as the post-
transplant period (21-23), SLE (26), but is virtually unknown in other non inflammatory 
conditions in which long-term high-dose corticosteroids have been used, such as 
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neurological degenerative disease, chronic pulmonary disease, etc. Furthermore, it has been 
difficult to reproduce steroid-induces AVN in experimental animal models, unless 
incompatible skin grafts were applied (27), perhaps simulating the allograft reactivity of the 
post-transplant state.  
Patients with cGVHD are generally those who assume higher steroid dose for longer 
periods of time. Therefore, on the bases of clinical data only, it is impossible to distinguish 
the separate effects of these two conditions. Taken into account the available data on general 
conditions facilitating AVN, the observations on AVN onset after GVHD exacerbation or 
progression, its relationship with allo- SCT and GVHD documented by this and other 
studies, we may speculate that immune system dysregulation can be involved in AVN 
development after SCT.  
Cyclosporine A was shown to increase AVN incidence after kidney transplant in a 
single study (28), while no significant relationship was found in patients after SCT. In our 
hands, significantly longer CsA treatment was found in patients affected by AVN in the allo-
SCT setting.  
On the other hand, no relationship was found with gender, age, gonadal function and 
BMD in the whole patient population. Although significantly lower BMD has been found in 
allo- than in auto-transplanted patients at both skeletal sites evaluated, no direct relationship 
could be documented between BMD values and AVN. Despite both auto- and two 
allotransplanted patients with AVN were hypogonadic for a long period, thus having 
multiple negative effects on bone status, the lack of AVN relationship with gonadal status in 
the whole population is in line with a previous evidence that AVN does not seem to be a 
complication of postmenopausal osteoporosis (19). 
Fortunately, most of patients (9/12) were diagnosed in AVN stage I-II, shortly after 
symptoms appearance. This permitted early treatment intervention.  However, surgery was 
necessary in six patients with hip replacement in three. Early diagnosis by MRI (shortly after 
the onset of symptoms) may help to detect AVN at an early stage, and early intervention and 
monitoring may prevent progression to the stages needing prothesic surgery. 
In conclusion, our results confirm those of other studies, and focus the attention on 
several aspects previously incompletely investigated. AVN occurred in 5.8% of our patients, 
even many years after SCT; allo-transplanted patients with clinical flare up of cGVHD seem 
to be at highest risk. However, the pathogenesis of this condition is likely multifactorial with 
various precipitating conditions. An involvement of corticosteroid treatments is pointed out 
by all previous studies, but the strong relationship between AVN, allo-SCT and cGVHD 
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relapse documented in this study, suggests that immune-mediated mechanisms may also 
operate in AVN development after SCT. 
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Table 5. Risk factors reported by previous major studies on avascular necrosis 
Study N° of 
patients 
Follow up 
period 
(years) 
SCT  
Type  
 
AVN prevalence Assessment  of 
corticosteroid role 
Associations found with AVN  
Atkinson et al., 19873 50 2     allo 5/50  (10%) n.r. AGVHD, cGVHD  
Enright et al., 199012 902 14 allo 
auto 
28/642  (4.4%)   
0/260  
Multivariate analysis Age, disease type, allo-SCT,TBI, cGVHD, 
alloreactivity 
Wagener et al., 199130 43 3 allo 
auto 
8/33  (24%) 
0 /10 
t-test CGVHD, allo-SCT 
Sociè et al., 199413 727 1.5 allo 27/727 (3.7%) Multivariate analysis Older age, male gender, aGVHD 
Sociè et al., 199714 4388 19 allo 77/4388 (17.5%) Multivariate analysis Age, initial diagnosis, TBI, aGVHD, 
cGVHD 
Fink et al., 199815 1939 17 allo/auto 87/1939 (5%) Logistic regression Allo- (93%) vs auto-(7%) SCT, TBI, 
aGVHD, cGVHD 
Wiesmann et al., 199817 272 n.r. allo 17/272 (6.3%) n.r. Older age, GVHD 
Ebeling et al., 199918 83 2.5 allo 
auto 
4/52 (7.7 %) 
0/31  
t-test Allo-SCT, male gender, lower BMD at 
femoral neck 
Torii Y et al., 200131 100  allo 19/100 (19%) t-test Younger age, cumulative steroid dose, 
pulse i.v. MPD therapy, cGVHD, 
AGVHD, cGVHD: acute/chronic graft-versus host disease; n.r.: data not reported; TBI: total body irradiation; BMD: bone mineral density; MPD: methylpredni
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Beneficial treatment with risedronate in long-term survivors after allo-SCT 
for haematological malignancies 
 
Introduction 
Osteoporosis is a relatively common and early complication after allogeneic stem cell 
transplantation (allo-SCT). The pathogenesis of bone loss related to allo-SCT is complex and 
still incompletely understood (1). Major risk factors include myeloablative conditioning 
regimens, huge cytokine release at the time of transplant, long-lasting high-dose steroids and 
cyclosporin-A (CsA) therapy, reduced mobility and frequent gonadal failure (1,2). Additionally, 
altered kidney, liver and bowel function result in reduced intake and abnormal metabolism of 
calcium and vitamin D (1,3). Recently, post-transplant number and function of osteoblastic 
precursors within the stromal stem cell compartment were found severely and persistently 
deficient, suggesting that the inability to regenerate a normal osteogenic cell compartment may 
partly explain the severe bone damage after allogeneic SCT (4-7). 
Välimäki et al. (8) found that patients undergoing allo-SCT have bone loss at both 
lumbar spine (5.7%) and femoral neck (6.1-8.6%) after the first six months from allo-SCT. In a 
larger case series, Stern et al. (9) found a significant BMD decrease at lumbar spine and 
femoral neck even three months after SCT in users of  hormone replacement therapy (HRT). 
BMD further decreased by 2.5% at total hip within 12 months (9). Other studies in smaller 
cohorts have also described bone loss that was prevalent at the femoral neck within a few 
months after SCT (10-14). A persistent decrease in femoral BMD was confirmed in two cross-
sectional studies evaluating BMD up to 13 years after SCT (4,15).  
The treatment of osteoporosis in allo-SCT patients has been poorly investigated. 
Calcium supplement with or without calcitonin for 12 months did not prevent bone loss within 
the first year after SCT (8), while increase in lumbar BMD by 9% was found in 13 women 
treated for 1 year with HRT (16).  
Bisphosphonates are currently employed in the treatment of postmenopausal 
osteoporosis with high success rates (17-19). These compounds are also effective in patients 
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with severe bone loss such as in endogenous or exogenous hypercortisolism (20-22). Since 
steroids are widely used in hematological malignancies before and after SCT, bisphosphonates 
might be considered as the most indicated approach to treat osteoporosis in such patients. 
Risedronate is a bisphosphonate for oral administration approved in Italy for prevention and 
treatment of osteoporosis, reported to be well tolerated in long-term treatments (17,20,23,24). 
The aim of this open, prospective and randomized study was to investigate the effectiveness of 
a treatment with risedronate on bone metabolism in allo-SCT recipients. 
 
Patients & Methods 
Fifty-five consecutive patients who had undergone allo-SCT in our institution were 
evaluated for BMD at lumbar spine, total hip and femoral neck, serum osteocalcin levels and 
urinary hydroxyproline excretion at least 6 months after SCT. Normal BMD values were 
present in 14 patients, while 41 (22F and 19 M, aged 33±9.5 yrs; range, 20-51) had a BMD T-
score at least –1 SD at one or more skeletal sites. Patients with osteoporosis affected by 
gastrointestinal graft vs. host disease (GVHD) (n= 3) initiated i.v. treatment with zoledronic 
acid; they were thus not included in this study. Thirty four patients (18 F, 16 M, aged 32±10 yr; 
range, 20-51) with a T-score < -1.5 SD at lumbar spine and/or femoral neck were enrolled in 
this study. All of them had been successfully allo-transplanted with unmanipulated marrow 
from a HLA identical sibling. Reasons for transplant included acute myeloid leukemia (n=14), 
chronic myeloid leukemia (n=9), acute lymphoblastic leukemia (n=7) and Hodgkin’s 
lymphoma (n=4). All patients had been conditioned with the BU-CY2 regimen (busulphan 16 
mg/kg and cyclophosphamide 120 mg/kg) and had received CsA (1 mg/kg/day by continuous 
i.v. infusion from day -1 to day + 20 and then 8 mg/kg/day orally) plus short-course 
methotrexate as prophylaxis for GVHD. The median cumulative dose of steroids given to this 
cohort of patients prior to study entry was equivalent to 5.7 g/kg of prednisone (range 0.8-21.2) 
for 3-30 months. Eleven patients were continuing glucocorticoid therapy (1-2.5 mg /kg/die of 
prednisone equivalent) because of persistent chronic GVHD for 2-7 months during the study.  
Thirty-four healthy subjects matched for gender, age and body mass index (BMI) were 
also studied as controls; for ethical reasons, they underwent a single biochemical and 
densitometric evaluation (Table 1). None of controls received drugs interfering with bone 
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metabolism. Informed consent was obtained from all patients in accordance with institutional 
guidelines and the study design was made in accordance with the Helsinki II Declaration. 
At study entry, bone metabolism, bone density and gonadal status was evaluated in all 
subjects and BMI in kg/m2 was calculated. None of the patients had received any previous  
Table 1. Clinical, biochemical and densitometric characteristics of patients and controls at study entry. 
 
 Patients 
(n=34) 
Controls 
(n=34) 
P 
Gender (M/F) 16/18 16/18 NS 
Age (yr) 32.7 ± 10 32.8 ± 9.5 NS 
BMI (kg/m2) 25.6 ± 2.2 25.5 ± 2.4 NS 
Time from SCT (months) 17.5 ± 7 -  
    
Calcium (mmol/l) 2.36 ± 0.13 2.34 ± 0.11 NS 
Phosphorus (mmol/l) 1.08 ± 0.17 1.09 ± 0.18 NS 
Alkaline phosphatase (U/l) 91 ± 32 88 ± 20 NS 
Creatinine (µmol/l) 86 ± 8.6 80 ± 10 NS 
Albumin (g/dl) 4.2 ± 0.36 4.3 ± 0.3 NS 
Osteocalcin (ng/ml) 13.9 ± 4.3 15.9 ± 2.5 0.04 
iPTH (ng/l) 39.7 ± 10.9 36.9 ± 10.7 NS 
Urinary hydroxyproline excretion (µmol/l/m2 ) 133.6 ± 32 122 ± 16 0.046 
Urinary hydroxyproline/creatinine 9.14 ± 0.8 9.3 ± 0.7 NS 
    
BMD at lumbar spine (g/cm2) 0.88 ± 0.1 1.05 ± 0.08 <0.001 
          T - score  (SD) -1.715 ±1.0 -0.2 ± 0.93 <0.001 
BMD at total hip (g/cm2) 0.82 ± 0.08 0.92±0.1 <0.001 
          T -  score  (SD) -1.55 ± 0.78 0.05±0.95 <0.001 
BMD at femoral neck (g/cm2) 0.77 ± 0.1 0.92 ± 0.105 <0.001 
          T - score (SD) -1.53 ± 1.0 -0.1 ± 0.9 <0.001 
Values are expressed as means ± SD; BMI: body mass index; SCT: stem cell transplantation; 
BMD: bone mineral density; Normal range, Ca: 2.2-2.6; P: 0.7-1.35; ALP: 98-275 U/L; 
creatinine: <133 µmol/L; albumin: 3,6-5,2 g/dl; Osteocalcin: 2-22 ng/ml; iPTH: 10-75 ng/L; 
Hydroxyproline excretion: 60-190µmol/m2. 
 
treatment for osteopenia/osteoporosis. Then, the patients were randomized to receive treatment 
with risedronate 5 mg orally once daily at 7.30-8.00 in the morning, at least 30 minutes before 
breakfast with at least 200 cc of water, calcium 1 g and vitamin D 800 IU once daily orally at 
18.00-19.00 daily for six months (n=17, group 1) or the same treatment with calcium and 
vitamin D without risedronate (n=17, group 2). Randomization was performed according to the 
program at the website www.randomization.com; the randomization sequence was stored by 
one of the investigators (A.C.), not directly involved in the treatment nor in the follow-up of the 
patients, and was inaccessible to the other investigators.  
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Gonadal status assessment 
In all subjects at study entry serum FSH, LH and 17-β-estradiol/testosterone were 
measured in a single sample at 8.00 a.m. In the patients, but not in the controls, the evaluation 
was repeated after six months. 
 
Bone metabolism assessment 
In both patient groups, at study entry and after 3,6 and 12 months, serum calcium, 
phosphorus, creatinine, alkaline phosphatase, intact PTH and osteocalcin values were 
determined in a single blood sample, and urinary calcium, phosphorus and hydroxyproline were 
assayed in the 24-h urinary collection. Blood samples were collected in the morning after a 12-h 
fast.  
 
Bone density assessment 
In both patient groups, bone density was determined by dual-energy x-ray 
absorptiometry (DEXA)  simultaneously at two different skeletal sites, lumbar spine (L1-L4), 
total hip  and femoral neck (FN), using Hologic QDR 1000 densitometer (Hologic, Inc., 
Waltham, MA).  Individual BMD values were considered as g/cm2 and T-score. BMD 
measurement has been performed at baseline and after 6 and 12-13 (median, 12.3) months of 
treatment. The changes are expressed as a percentage of the baseline value. Quality control was 
maintained by daily scanning of an anthropomorphic spine phantom. The coefficient of 
variation was  1.7 % for the lumbar spine and 2.1% for the hip.  The reference population 
adopted in this study was the international pooled sample provided by the manufacturer; their 
data did not differ significantly from those obtained on a local sample in a study performed 
when the device was set up (25). 
Assays  
All measurements were performed by commercially available kits: FSH and LH with 
radioimmunoassay (RIA, Biodata, Rimini, Italy), testosterone and estradiol using solid phase 
chemoluminescent enzyme immunoassay (DPC, Los Angeles, CA, USA). Intact PTH and 
serum osteocalcin levels were measured by RIA (Nichols Institute Diagnostics, CA), the 
detection limit of the latter being 0.35 mg/L. Hydroxyproline excretion was measured with high 
pressure liquid chromatography. Blood chemistry profile, including levels of Ca, P, ALP, 24-h 
urinary Ca excretion and creatinine, were analyzed using a standard autoanalyzer.  
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Statistical analysis 
Data are reported as mean±SD. Statistical analysis was performed by the Student’s t test 
for unpaired data for the intrer-group differences. Friedman’s test was used to compare the 
variables within the same group. Linear regression was used to analyze the relationship between 
increments of bone density and baseline BMD expressed both as absolute values and Z-score. 
The significance was set at 5%.  
 
Results 
After randomization, both groups were similar in terms of age, time from transplant, BMI, 
gender (Table 2) and previous treatment history. All men had normal testosterone levels, 
although it was in the lower tertile of the normal range in five of them. On the other hand, all 
but one woman had had ovarian failure after SCT. Six female patients (three in each group) 
were not receiving HRT, while all other women were on standard HRT during whole treatment 
period, the treatment had been started 6-10 months after SCT. Five patients in the group 1 and 
six in the group 2 continued corticosteroid treatment, all of them stopped the treatment during 
the study. Another patient of group 2 initiated steroid plus CsA treatment at 7th month, because 
of GVHD exacerbation. Similar daily doses were used in both groups (Table 2). Cyclosporine 
A was continued in nine patients (four in group 1 and five in group 2). Steroids were used for 2-
7 months (median, 3.6 and 4.1 months for group 1 and 2, respectively) during the study, 
whereas treatment periods for CsA lasted 3-7.5 months (median, 4.6 and 4.9 months for group 1 
and 2, respectively). 
 
Bone metabolism  
Serum and urinary calcium, serum phosphorus, creatinine and alkaline phosphatase were 
normal in all patients both at study entry and during the follow-up (Table 2). At baseline, 
osteocalcin levels were lower (p=0.04) and hydroxyproline excretion higher (p=0.046) in 
patients than in controls. Urinary hydroxyproline excretion was similar in group 1 and 2 at 
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Table 2. Variations after 12 month treatment. Group 1 received risedronate, calcium and vitamin D; group 2 only calcium and vitamin D. 
 Group 1  Group 2 
 
 basal 12-months#  Basal 12-months# 
 
Evaluable number (M/F) 8/9 7/8  8/9 8/8  
Age (yr) 32.5±10.2   33.2±10.4  
 
Time since SCT (months) 17±7   18±6  
 
BMI (kg/m2) 25.3±2.3 25.15±2.3  25.7±2.2 25.55±2.25 
 
Patients continuing steroid treatment during the study 5 -  6 1 
 
Average daily dose of corticosteroids (mg)§ 45.6±16 -  55.4±12 12.5 
 
Patients continuing cyclosporine A treatment 4   5 1 
 
Cyclosporine A average daily dose (mg) § 119.2±40 -  124±36 50 
 
Women on standard HRT 6/9 5/8  6/9 5/8 
 
Calcium (mmol/l) 2.37±0.12 2.39±0.11  2.36±0.13 2.4±0.12 
 
Phosphorus (mmol/l) 1.07±0.16 1.06±0.2  1.08±0.17 1.07±0.15 
 
Alkaline phosphatase (U/l) 93±25 96±28  90±33 93±28 
 
Creatinine (µmol/l) 86±8.5 88±8  87±9 87.5±9.5 
 
Albumin (g/dl) 4.2±0.4 4.2±0.5  4.15±0.35 4.2±0.4 
 
Osteocalcin (ng/ml) 14±4.4 14.6±5.2  13.9±4.3 14.1±4.1 
 
iPTH (ng/l) 40±10 38.5±9  39.5±11.2 38.4±10.1 
 
Urinary hydroxyproline excretion (µmol/l/m2 ) 135±31 113.3±25*  132±33.3 126±34 
 
Urinary hydroxyproline/creatinine 9.2 8.8  9.1 9.0 
 
BMD at lumbar spine (g/cm2) 0.88±0.075 0.93±0.092*  0.89±0.09 0.864±0.1a 
 
     T – score (SD) -1.71±0.85 -1.35 ±0.9  -1.7 ±1.0 -1.85 ±0.95 
 
BMD at total hip (g/cm2) 0.842±0.05 0.853 ±0.06  0.84±0.08 0.806±0.09 *a 
 
     T – score (SD) -1.5 ±0.62 -1.46 ±0.6  -1.49 ±0.7 -1.78 ±0.89 
 
BMD at femoral neck (g/cm2) 0.77±0.1 0.78±0.1  0.78±0.08 0.747±0.087 *a 
 
     T – score (SD) -1.59 ± 1.0 -1.486±0.9  -1.5 ±0.65 -1.8 ±0.8 
 
Values are expressed as means ± SD. #: 15 and 16 patients completed 6 month treatment in the group 1 and 2, respectively; §:  considered only in patients on treatment; 
Normal range, Ca: 2.2-2.6; P: 0.7-1.35; ALP: 98-275 U/L; creatinine: <133 µmol/L; albumin: 3,6-5,2 g/dl; Osteocalcin: 2-22 ng/ml; iPTH: 10-75 ng/L; 
Hydroxyproline excretion: 60-190µmol/m2; ;*: p<0.05 vs. baseline; a: p<0.05 vs. group 1. 
baseline, and decreased by 11.3±3.7% after 3 months (p=0.042) and by 16.8±3.8% (p=0.025) at 12 
months in patients of group 1. Serum osteocalcin values were similar in group 1 and 2 at baseline 
and after 3 and 12 months, without any significant change during the study period (Table 2). 
 
Bone mineral density  
At study entry, BMD was significantly lower in patients than in controls at each skeletal site 
(p< 0.001) (Table 1). After randomization, BMD was similar in  group  1 and group  2 at all 
skeletal sites considered (Table 2). Osteoporosis (T-score <-2.5SD) was found at femoral neck in 
three patients of group 1 and three of group 2 while at lumbar spine it was found in four of  group 1 
and in  two patients of group 2.  
After 6 months, lumbar BMD increased by 4.4±1.6% in patients of group 1 and decreased 
by 4.3±1.5% in those of group 2 (p<0.05, both). At femoral neck, BMD did not change significantly 
in patients of group 1, while it decreased in those of group 2; percent BMD change between the two 
groups was significantly different (1.2±1.2 vs. -4.3±2.1%; p<0.05) at this skeletal site. Similar 
findings were observed at total hip, no change in group 1 and BMD decrease (1.22 ±1.1 vs.  -
4.1±1.6%; p<0.05) in group 2. 
After 12 months, lumbar BMD increase achieved 5.9±1.7% (p<0.05)  of the baseline value 
in group 1. In the group 2, BMD increased mildly (1.3±1.4%) between the 6th and the 12th month, 
reaching - 2.9±1.4% of the baseline value. At femoral neck, BMD did not change significantly in 
patients of each group between the 6th and the 12th month. However, the percent BMD change 
between the two groups was significantly different (1.3±1.2 vs. -4.2±2.0% from the baseline; 
p<0.05) at this skeletal site. Similar BMD behavior was observed at total hip (1.35 ±1.1 vs.  -
4.1±1.6% of the baseline; p<0.05 ) (Table 2).  
Densitometric values at baseline and after 6 and 12 months are shown in Figure 1. The 
major increase in BMD at lumbar spine has occurred within the first 6 months of treatment, as the 
mean increase resulted 4.4%, then continuing a slower rise. The percent increment of lumbar BMD 
during anti-resorptive therapy was inversely correlated with baseline BMD values and Z-scores at 
the same site (r= -0.71; p=0.049 and r=-0.73; p=0.043; respectively).  
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Figure 1. The increase in BMD at lumbar spine after 6 and 12 months of treatment occurred in 
the treated group, while a decrease was observed in the untreated group at lumbar spine (panel a) 
and femoral neck (panel b). 
 
 
Tolerance to treatment  
 
Two patients in group 1 and one patient in group 2 discontinued the treatment because 
of exacerbation of chronic gastrointestinal GVHD (one in each group) or of gastric intolerance. 
The treatment was withdrawn after 2-5 months in all three patients. Mild back pain and 
arthralgia occurred in three and four patients in group 1 and in two and three in group 2. 
Kidney function parameters did not change in any group over the study period (data not 
shown). 
 
 
Discussion 
This randomized prospective study demonstrates that oral administration of risedronate 
at the dose of 5 mg daily for 12 months significantly increased BMD (by 5.9%) at the lumbar 
spine and prevented bone loss at the femoral neck. Patients treated only by calcium and vitamin 
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D supplementation lost approximately 4% of bone mass at lumbar spine and femoral neck 
during the first 6 months, while between the 6th and 12th month of study they  realized an 
increment of 1.3% at lumbar spine. No significant change occurred at femoral neck in the 
second 6-month period. Nevertheless, changes in BMD at 6  and 12 months were significantly 
different between the two groups (treated by risedronate or supplementation only) at all skeletal 
sites. 
These data confirm a previous observation of progressive bone loss up to 37 months 
after allo-SCT (4). Nevertheless, both the initial BMD and subsequent bone loss in the group 
treated by calcium and vitamin D supplementation were similar at lumbar spine and femoral 
neck during the first 6 months. These findings confirm those on insufficiency of standard 
prophylactic measures in prevention of bone loss after allo-SCT (8, 26,27). In this respect, 
more effective therapeutic strategies may be necessary to prevent bone loss and treat 
osteoporosis in this peculiar patients’ population. It should be noted that the site of prevalent 
demineralization differ in our patients population compared to the findings of other groups, as 
femoral neck was the site of prevalent BMD decrease in previous studies (9,15,26).  In our 
cross-sectional study, only the patients evaluated at least 3 years after allo-SCT had a lower 
BMD at femoral neck: we suggested  that this finding is likely due to an improvement of 
lumbar BMD rather than continuous loss at femoral neck (4). In fact, lumbar BMD started to 
improve approximately 24 months after SCT in group 2. This is in agreement with a clinical 
observation that chronic GVHD generally disappear and immunosupressive treatments are 
withdrawn 24-36 months after transplant. Differences in the populations enrolled in our and 
other studies can also be taken as partial explanation for the different sites of bone 
demineralization. In previous studies hypogonadism was replaced early after SCT in all 
subjects, while six of our female patients were still hypogonadal because of contraindication to 
HRT or its refusal. To avoid adverse effects, we used to start HRT later  (6-10 months after 
SCT) than previously described in other women, who received HRT as early as 60 days after 
SCT (9,14,15). Moreover, eleven patients were on low-dose corticosteroid treatment for 2-7 
months because of persistent skin, ocular or liver cGVHD that affects about 50% of allo-
transplanted patients (28). In this light, our observation is not surprising, as lumbar spine 
represents an early principal target of bone damage induced by glucocorticoids and gonadal 
steroids decrease, given its prevalent trabecular structure.  Additionally, the spine represents 
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also a principal target of measurable bone mass improvement during antiresorptive treatments, 
sexual hormones replacement and general conditions improvement.  
Increase in lumbar BMD was greater in our study than that described in menopausal 
and corticosteroid induced osteoporosis (CIO). Lumbar BMD increased about 3.5-4.5% overt 
a 12 –month treatment period in postmenopausal women (29-31) and about 2% in patients on 
chronic steroid treatment (22,32,33). Patients in the CIO studies were on steroid therapy when 
treated with risedronate. Contrarily, all but one of our patients have withdrawn high-dose 
(>7.5 mg of prednisone equivalent daily) corticosteroid treatment during the study or shortly 
before the enrollment. As an increase in lumbar BMD ranging from 14% to 80% (34,35) has 
been shown within 48 months in patients cured for Cushing’s syndrome, we can hypothesize 
that a part of BMD improvement observed in both groups was due to steroid withdrawal. In 
our cohort, baseline lumbar BMD was inversely correlated with percent BMD increment after 
antiresorptive therapy, a finding also observed in patients with CIO (22) and suggesting that 
the worse is baseline bone density, the greater can be BMD improvement.  
The lack of BMD increase at the femoral site during risedronate treatment can be 
related to the short course of treatment and to the small number of patients included in the 
active treatment arm. However, no significant BMD increase at femoral neck was also shown 
in patients with CIO after 1 year of treatment with risedronate (22,32). Additionally, in 
postmenopausal women the increment of bone density at femoral neck was lower than at 
lumbar spine after treatment with risedronate (28-30).  
Hydroxyproline excretion significantly decreased in group 1 after 3 and 6 months, 
indicating reduced bone resorption. Indeed, aminobisphosponates act by inhibiting bone 
resorption (36), although the complete mechanism of action has not yet been clarified. At 
tissue level, an increase in BMD has been attributed to decreased bone turnover due to 
reduced frequency and resorption depth of the bone remodeling units (37). At cellular level, 
bisphosphonates have been shown to have direct and indirect inhibitory effects on osteoclasts 
(38,39), and to stimulate proliferation and maturation of human osteoblasts. (40). We did not 
find any significant increase in circulating osteocalcin in patients treated by risedronate, 
however, this marker of bone formation was lower in patients than in controls at study entry, 
likely mirroring a decrease in osteoblast number and function previously reported in 
allogeneic SCT recipients (4-7). Studies investigating osteoblast number and function in allo-
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SCT recipients during bisphosphonate treatment may be useful in order to explain the rapid 
BMD increase. Studies evaluating peri-transplant administration of bisphosphonates in 
patients undergoing allo-SCT can be usefull. 
Aminobisphosponates are widely considered as effective treatment of post-
menopausal and glucocorticoid-induced osteoporosis (17,18,20,23,29-33), both conditions 
present after allo-SCT. Risedronate is likely to improve bone turnover very early, as shown in 
patients treated for corticosteroid-induced osteoporosis in whom the increase in lumbar BMD 
was significant even at 3 months (22).  
The gonadal status is an independent risk factor for osteoporosis, but the prevalence of 
women with gonadal insufficiency was similar in each group; due to the small number of 
cases included in this pilot study, these conditions were not considered separately. 
Furthermore, male patients were considered to have normal gonadal function, although five of 
them had testosterone values in the low-normal range. We do not know which were their 
testosterone values before the onset of the underlying disease and if eventual change in 
gonadal secretion had contributed to the bone loss. 
Risedronate was well tolerated in our patients, and the number of patients who 
withdrawn because of adverse effects possibly related to the drug (dyspepsia, gastralgia) was 
minimal (1/17) . These data agree with the results of a previous meta-analysis, showing that 
daily treatment by 5 mg of risedronate was not associated with increased frequency of adverse 
gastrointestinal tract effects, even among patients at high risk for these events (24). Back pain 
and arthralgia, reported also by other authors during the risedronate treatment (22) were 
mostly self-limited and did not lead to the treatment discontinuation. 
The study has several limitations. It was an open label and not blinded study. The 
follow-up period of 12 months is still relatively short to determine effects on BMD. 
Moreover, patients have not been evaluated before the transplant to detect the amount of bone 
loss closely related to the transplant procedure. It should be stated that current main aim of the 
treatment with biphosphonates is to decrease the fractures rate, the most disabling 
complication of osteoporosis. However, because of  the little size of each treatment arm and 
relatively short follow-up period, fracture rate was not determined in this study.  
In conclusion, the results of this study show that bone loss in long-term survivors to 
allo-SCT can be stopped and even reversed by risedronate associated with calcium and 
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vitamin D, while the only administration of calcium and vitamine D is ineffective until 
GVHD disappears and immunosuppressive treatments are withdrawn. Longer studies are 
needed to confirm these data and to investigate whether higher doses, different ways of 
bisphosphonate administration and/or more prolonged treatments time may improve the 
results. 
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Short-term zoledronic acid treatment increases bone mineral density and 
marrow clonogenic fibroblast progenitors after allogeneic stem cell  
transplantation 
 
 
Introduction 
Bone loss is recognized as one of the most frequent complications in long-term 
survivors after allogeneic stem cell transplantation (allo-SCT) (1-5). However, only little data 
is available so far on the treatment and prevention of this condition (6-8). Early diagnosis of 
osteoporosis or fast bone loss in this particular population is a major aim to promptly start 
appropriate supportive measures, such as lifestyle modification, calcium and vitamin D 
supplementation or antiresorptive therapies.  
Oral bisphosphonates are widely used for treating osteoporosis; they have been shown to 
improve bone mineral density (BMD) and decrease the rate of fractures in various patient 
populations (9-12). However, the use of these drugs may be limited by poor gastrointestinal 
tolerance, variable oral bioavailability and long-term compliance. Allo-SCT patients usually 
run into long-lasting and complex therapeutic regimens in order to prevent and treat several 
early and late complications related to the transplant procedure. About half of SCT patients 
suffer from graft-versus-host disease (GVHD), with the gastrointestinal tract being one of the 
most frequent targets. For these patients, who may have reduced drug absorption, intermittent 
intravenous administration of bisphosphonates may be the treatment of choice. Zoledronic 
acid, a third-generation nitrogen-containing bisphosphonates, is the most potent member of 
the bisphosphonates’ family ever investigated in clinical trials (13). Due to its high potency, 
small doses and long in-between intervals are sufficient enough to inhibit bone resorption, and 
can easily be added to a complex therapeutic regimen in the post-transplant period. 
Intravenous bisphosphonates have proven to be very effective in the treatment of menopausal 
and glucocorticoid-induced osteoporosis, malignant hypercalcemia and Paget’s disease (14-
19). Furthermore, the clinical benefit in patients with cancer and multiple myeloma includes 
bone pain improvement, reduction in skeletal complications and delay in time-to-first skeletal 
complication (14,19). 
Previously, we have shown that bone loss continues for three years after allo-SCT at 
both the lumbar spine (LS) and femoral neck (FN); it persisted up to 10 years at FN, while 
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improving mildly but significantly with time at LS (20). We have also documented that post-
SCT bone damage is at least in part related to a severe and long-lasting deficit in the 
regenerating capacity of bone marrow stromal stem cells (20,21).  
The present study was aimed at investigating the 12-month effect of short-term 
intravenous zoledronic acid administration on lumbar and femoral BMD, bone turnover 
markers and clonogenic fibroblast progenitors belonging to the osteogenic stromal lineage, in 
patients with low BMD or fast bone loss following allo-SCT for hematological malignancies. 
 
 
Patients and methods 
 
Patients and study design  
Thirty-two patients who had undergone allogeneic SCT at our Institution were 
evaluated for BMD at the LS and FN, body mass index (BMI, kg/m2), gonadal status, serum 
osteocalcin and urinary hydroxyproline excretion, after a median period of 12.2 months 
(range, 6-18) since transplant. Immediately following the transplant, Calcium 500 mg and 
Vitamin D 400 IU supplementation had been administered orally and once daily to all 
patients, between 07:00 p.m. and 08:00 p.m. and was continued for the whole observation 
period. The determination of densitometry and bone turnover markers was repeated after a 
median time span of 12.5 months since the first evaluation (range, 10.3-13.1). Thus, the 
median “observation” period was about 1 year. Subsequently, 15 patients (group 1) affected 
by  osteoporosis (n=7) or rapidly progressing osteopenia (i.e. bone loss > 5%/year) (n=8) 
received 4 mg of zoledronic acid (ZOMETA; Novartis Pharmaceuticals Corporation, Basel, 
Switzerland) intravenously as a 15 minute infusion every 28 days for three months; seven 
patients in this group were suffering from extensive cGVHD. Other 15 patients (group 2), 
who were similar to the zoledronic acid cohort in terms of age, time since transplant, BMI and 
gender, were re-evaluated for bone turnover and BMD after the same span of time without 
receiving zoledronic acid. Two patients  with Hodgkin’s disease who relapsed 13 and 15 
months after allo-SCT were excluded from the study (Figure 1). To better point out the 
importance of bone loss within the first year after allografting, two healthy subjects for each 
case, matched by gender, age and BMI were enrolled as controls, undergoing a single 
biochemical and densitometric evaluation. None of the controls received drugs known to 
interfere with bone metabolism. None of the participants had been given previous treatments 
for osteoporosis. Written informed consent was obtained from all patients and controls in 
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Figure 1.  Algorithm of study design. 
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accordance with the institutional guidelines and the study was designed in accordance 
with the Helsinki II Declaration on treatment of human subjects. 
 
Table 1.   Clinical features of 32 transplanted patients 
evaluated for bone mineral density changes 
Patient characteristics  Whole group (n=32) 
Age at SCT (yrs) 
      Range  
31.4±12 
(17 - 45) 
Gender (F/M) 15/17 
Underlying disease:   
    AML in 1st CR 14 
    CML in chronic phase 12 
    ALL in 2nd CR 3 
   HD 2 
    SAA 1 
Amenorrhea duration (months) 
 24±20 
Acute GVHD  14 
    Grade I-II/III-IV 10/4 
Chronic GVHD 17 
    Limited/extensive form 7/10 
Corticosteroid treatment#   
    Duration (days) 248±190 
    Cumulative dose (g)* 5.8±4 
Cyclosporin A treatment#  
    Duration (days) 338 ±180 
    Cumulative dose (g)  
  64.2±12 
Values are expressed as mean ± SD, when appropriate. 
Abbreviations: SCT: stem cell transplant, AML: acute myeloid 
leukemia, CML: chronic myeloid leukemia, ALL: acute 
lymphoblastic leukemia, HD: Hodgkin’s disease, SAA: severe 
aplastic anemia, CR: complete remission, BU: busulphan, CY: 
cyclophosphamide, BMI: body mass index; GVHD: graft versus host 
disease; Symbols: #: immunosuppressive treatments before study 
enrollment;*: cumulative dose of corticosteroids is expressed as 
prednisone equivalent.  
 
 
Transplantation procedures 
Leukemia was the most common indication for allo-SCT. All patients had been 
successfully allo-transplanted with unmanipulated marrow from a HLA identical sibling. 
All patients underwent conditioning with the BU-CY2 regimen (busulphan 16 mg/kg, 
cyclophosphamide 120 mg/kg) and received cyclosporine A (CsA) (1 mg/kg/day by 
continuous i.v. infusion from day -1 to day + 20 and then 8 mg/kg/day orally) plus short-
course methotrexate (10 mg/m2 on days +1,+3 and +6) as prophylaxis for GVHD. No 
patient had received radiation therapy. All patients with acute and chronic GVHD (a- and 
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cGVHD) were treated by methylprednisone (2 mg/kg/day and 1 mg/kg/day for 15 days in 
patients with aGVHD and cGVHD, respectively) and CsA (5 mg/kg/day) before the first 
evaluation of bone status. During the study, 53% of patients developed or had persistent 
cGVHD requiring immunosuppressive therapy as above described. As a significant 
correlation was found between corticosteroid treatment and bone damage at the initial 
evaluation, steroids were avoided whenever possible thereafter. During the study period, 
cGVHD was treated by CsA + mycophenolate mofetil at a dose of 30 mg/kg/day; low-
dose corticosteroids were continued in addition to these immunosuppressants in 8 patients 
only. The median cumulative dose of steroids given to this cohort of patients prior to 
entry was equivalent to 6.5 g of prednisone (range 0.8-22) for 3-36 months, while it was 
1.5+0.8 g for 2.5-5 months during the study. The median daily dose of prednisone 
equivalents administered during the study was 17.5 mg (range, 5-50 mg).  
 
Gonadal status assessment 
At study entry  all subjects underwent serum FSH, LH, 17-β-
estradiol/testosterone determination in a single sample at 08:00 a.m. In patients only, the 
same parameters were again evaluated every six months. All women were in the 
reproductive age. All measurements were performed by commercially available kits: 
FSH and LH with radioimmunoassay (RIA, Biodata, Rimini, Italy), testosterone and 
estradiol using solid phase chemoluminescent enzyme immunoassay (DPC, Los 
Angeles, CA, USA). All controls were eugonadal, females having regular menstrual 
cycles. 
 
Bone metabolism assessment 
Serum calcium, phosphorus, creatinine, alkaline phosphatase (ALP), intact 
parathyroid hormone (iPTH) and osteocalcin were determined in blood samples drawn 
at initial evaluation,  at the end of the longitudinal study, before zoledronic acid 
administration and after 12 months. Blood samples were collected in the morning after a 
12-h fast. Urinary calcium, phosphorus and hydroxyproline were assayed on the 24-h 
urinary collection. Standard dietary restrictions were observed by all individual tested, 
starting five days prior to urinary collection.  Intact PTH and serum osteocalcin levels 
were measured by RIA (Nichols Institute Diagnostics, CA), the detection limit of the 
latter being 0.35 mg/L. Bone alkaline phosphatase was assayed by a direct 
immunoradiometric assay (Ostease, Hybritech, San Diego, CA).  Hydroxyproline 
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excretion was measured with high pressure liquid chromatography. Blood chemistry 
profile, including Ca, P, ALP, urinary Ca excretion and creatinine levels, were analyzed 
using a standard autoanalyzer.  
 
Bone density assessment 
Bone density was determined by dual-energy x-ray absorptiometry (DEXA) at 
the lumbar spine (L1-L4) and femoral neck (FN), using Hologic QDR 1000 
densitometer (Hologic, Inc., Waltham, MA). Individual BMD values were expressed as 
g/cm2  and Z-scores. Quality control was performed by daily scanning of an 
anthropomorphic spine phantom. The coefficient of variation was  1.7% for the LS and 
2.1% for the FN.  The reference population adopted in this study was the international 
pooled sample provided by the manufacturer; their data, however, did not differ 
significantly from those obtained on a local sample in a study performed when the 
device was set up (23). 
 
Mesenchymal stem cell  enrichment 
Bone marrow was aspirated from the posterior iliac crest of 20 transplanted 
patients and 15  bone marrow donors into syringes containing heparin (O'Neil & 
Feldman, St Louis, MO). Briefly, mesenchymal stem cells were enriched by incubating 
whole bone marrow with a cocktail of antibodies against glycophoryn A, CD3, CD14, 
CD19, CD38 and CD66b for 20 minutes at 4°C, according to the manufacturer’s 
instructions (Rosette-Sep, StemCell Technologies Inc., Vancouver, Canada).  
Unagglutinated cells, following density gradient centrifugation using lymphocyte 
separation medium (Life Technologies, Gaithesburg, MD), were washed with Hanks’ 
balanced salt solution (HBSS) supplemented with 1% bovine serum albumin (BSA), 
and resuspended in HBSS 1% BSA. HBSS and BSA were purchased from Life 
Technologies, Gaithersburg, MD. 
 
Colony forming unit-fibroblast (CFU-F) assay  
In vitro CFU-F growth assay was performed using enriched mesenchymal stem 
cells as previously described (21,22). Briefly, enriched mesenchymal stem cells were 
resuspended at a concentration of 1x 106/ml in a specific medium (McCoy’s 5A modified 
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medium containing 10% fetal bovine serum with L-glutamine) formulated for optimal 
mesenchymal stem cell expansion (Mesencult, StemCell Technologies) supplemented 
with 10-8 M dexamethasone  (Sigma-Aldrich), allowing the recruitment of bone marrow 
mesenchymal cells to the osteoblastic lineage, and seeded at 4x105 cells/cm2 in 35-mm 
tissue culture plates. Fibroblast colony growth was evaluated after incubation at 37°C, 5% 
CO2 for 14 days in a humidified atmosphere. Aggregates of >50 characteristic 
fibroblastoid cells were scored in situ as CFU-F under inverted microscope. Osteogenic 
differentiation of fibroblastoid colonies was further defined by their ability to express 
phosphatase alkaline (ALP)  activity after replating for 14 days at 5% CO2 in mesencult 
medium supplemented with 10-8 M dexamethasone, 0.2 mM ascorbic acid and 10 mM β-
glycerol phosphate (Sigma-Aldrich) and re-adhesion to plastic ware. All cultures were 
performed in triplicate. 
 
Statistical analysis 
Data are reported as mean±SD unless otherwise specified. Statistical analysis 
was performed by the Student’s t-test for paired and unpaired data, as appropriate, for the 
comparison between patients and controls, and groups of treated and untreated patients. 
In the period prior to treatment, the association between BMD changes, 
immunosuppressive treatment duration and cumulative doses, and amenorrhea period 
were assessed by linear regression. Linear regression analysis was also used to analyze 
the relationship between increments of bone density and baseline BMD. Comparison of 
the variables within the same group was performed by the Friedman test. The 
significance was set at 5%.  
 
 
Results 
Clinical features and gonadal status  
In table 1 we have summarized the clinical features, underlying malignancies 
and details on previous treatments of the population of 32 patients at study entry. Ninety 
percent of women experienced ovarian failure (gonadotropin levels in the menopausal 
range and estradiol below the normal range of fertile women) with amenorrhea lasting at 
least 6 months as a consequence of chemotherapy. Eight women (53.3%) were receiving 
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hormone replacement therapy (HRT) at the time of the first testing: this treatment had 
been started 6-12 months after SCT  and was continued over the whole study period. The 
other women who were contraindicated or refused, were not given any HRT until the end 
of study. HRT consisted of oral administration of estradiol 2 mg/daily and 
dihydrogesterone 10 mg/day for 14 days a month (Femoston 2/10; Solvey Pharma SpA, 
Grugliasco, TO, Italia).  
In men, testosterone below the normal range with or without LH increase, was 
considered as a sign of hypogonadism. Eight men were hypogonadal at the initial 
evaluation; all of them being on immunosuppressive treatment for 4-8 months during 
the observation. Periods of immunosuppressive treatment mostly coincided with the 
finding of transient mildly low testosterone levels.  
 
Longitudinal evaluation of BMD after SCT   
 There were no significant changes in the biochemical parameters of bone 
turnover during the “observation” period (Table 2). Baseline BMD values in the 32 
patients were significantly lower than those of controls at both skeletal sites 
(P<0.001)(Table 2). According to the WHO criteria (22), osteoporosis was diagnosed  in 
6 patients (19%) and osteopenia in 10 (31%). 
In the whole cohort of 32 patients, the average BMD loss per year was 3.42% at 
LS and 3.8% at FN (Table 2). Although bone loss in male and female patients was not 
significantly different, males tended to lose more bone at FN (-6.4±7.4% vs.-2±8.33%), 
while bone loss in women was higher at LS (-4.16±6.3 vs. –2.41±8.56).  
In the whole group of 32 patients at the first evaluation, adjusted femoral BMD 
values correlated with age (r= -0.6; P= 0.045) and BMI (r= 0.46; P=0.013). At the second 
evaluation, femoral BMD continued to be significantly associated with BMI (r= 0.465; 
P=0.017), but not with age. In women, lumbar BMD correlated inversely with the 
duration of amenorrhea both at the first and second evaluation. A borderline correlation 
was found between femoral BMD decrease and BMI (r=-0.41; P=0.05), suggesting a mild 
protective effect of weight on FN BMD. A mild but not significant correlation was 
present between the amount of lumbar BMD decrease and cumulative dose of 
corticosteroids (r=-0.44; P=0.067). Serum osteocalcin was slightly correlated with 
baseline lumbar BMD (r=-0.62; P=0.055). 
  At study entry, lumbar BMD was lower in patients with cGVHD compared to 
patients without this complication (P<0.05), while the difference was not revealed at the 
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second evaluation. The amount of bone loss during the observation period was greater in 
patients with cGVHD, but not significantly different from those without cGVHD (data 
not shown). A correlation at the very limit of significance was detected between CsA 
treatment duration and the amount of FN BMD decrease (r=0.24; p=0.05). 
 
Effects of zoledronic acid  on bone turnover and BMD after allo-SCT  
During the treatment period, there was  a significant decrease in hydroxyproline 
excretion (P<0.0001) and an increase in bone alkaline phosphatase (p<0.05); in addition, 
there was a trend towards a negative correlation between serum osteocalcin and baseline 
lumbar spine BMD, but this correlation did not quite reach statistical significance (r=-
0.62; P=0.055) (Table 3). Twelve months after the beginning of the treatment, an  
increase in BMD was observed at both LS and FN (9.8%  and 6.47%, P<0.001 and P 
<0.005, respectively vs. baseline) (Figure 2).  
 
Figure 2.  Densitometric values at lumbar spine and femoral neck before and 12 months after 
treatment with zoledronic acid, expressed as Z-scores. The increase was significant at 
both lumbar spine (9.8±7%; p<0.001) and femoral neck (6.47±7%; p<0.005). 
Horizontal bars represent mean values, vertical bars are the standard error of mean. 
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Table 2. Results of the longitudinal evaluation in 32 long-term survivors after allogeneic SCT, before entering the trial with zoledronic acid  
Variable First  evaluation Second  evaluation Controls (n=64) 
    
Gender (F/M) 15/17 15/17 28/32 
BMI (kg/m2) 25.5±2.3 25.3±2.3 24.8±3.0 
    
No. of patients continuing corticosteroids/ dose (mg/day) 8/17.5±15.1 4/12.3±10 - 
Women on HRT (n/total women) 8/15 8/15 - 
    
Calcium (mmol/l) 2.37±0.12 2.38±0.11 2.36±0.12 
Phosphorus (mmol/l) 1.07±0.16 1.06±0.2 1.0±0.18 
Bone alkaline phosphatase (mcg/l) 10.2±5.3 12.1±5.8 15.2±4.1 
Creatinine (µmol/l) 86±8.5 87±8 80±10 
Albumin (g/dl) 4.2±0.4 4.2±0.5 
 4.3± 0.3 
Osteocalcin (ng/ml) 12±4.4* 12.7±5.3* 15.8± 2.5 
iPTH (ng/l) 40±10 43±9 
 36.9± 10.6 
Urinary hydroxyproline excretion (µmol/l/m2 ) 135±31* 129.6±28* 115±15 
Urinary hydroxyproline/creatinine 9.2 8.8 8.6 
Daily calcium excretion (mmol/24h) 3.5±1.5 3.3±1.3 3.35±1.1 
    
BMD at the lumbar spine (g/cm2) 0.96±0.13* 0.93±0.15** 1.04±0.09 
    % change from baseline  -3.42±7%  
BMD at the femoral neck (g/cm2) 0.83±0.1* 0.80±0.13** 0.92±0.11 
   % change from baseline  -3.8±8.1%  
Values are expressed as means ± SD. BMI: body mass index; iPTH: intact parathyroid hormone; BMD: bone mineral density. The second 
evaluation was performed at an interval of  8-18 months (median, 12.2months), and during calcium (500 mg daily) and vitamin D (400 IU daily) 
supplementation. Previous corticosteroid and cyclosporin A cumulative dose was 5.8±4 g and 64±12 g given for 248±190 and 338±180 days, 
respectively. Normal ranges: serum calcium: 2.2-2.6 mmol/L; serum phosphorus: 0.7-1.35 mmol/L; bone alkaline phosphatase: 7-25 µg/L; 
creatinine: <133 µM/L; albumin: 3.6-5.2 gr/dL; intact osteocalcin: 2-22 ng/ml; iPTH: 10-75 ng/L; urinary hydroxyproline excretion: 60-190 
(µmol/m2 ); Ca excretion: 1.3-6.5 mmol/24h. *: p<0.05; ** p<0.01 vs. controls. 
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The percentage and absolute increase in FN BMD were inversely 
correlated with pre-treatment values at the same skeletal site (r= -0.778; P =0.014 
and r=-0.79; P=0.01, respectively), indicating greater improvement in patients 
with lower initial bone density. On the other hand, in the untreated group of 15 
patients, no significant change occurred in bone turnover markers (Table 3) and 
bone density at both LS (-2.1 %) and FN (-2.3%) (P=NS). The change in BMD 
between the  treated and untreated groups was significant at both LS and FN 
(P<0.00001), as was the difference in absolute BMD values after the 12 month 
treatment (P<0.001 and P<0.05 for LS and FN, respectively) (Table 3).  
 
Adverse effects of zoledronic acid   
Side effects, including flu-like symptoms, myalgia and nausea, occurred 
in 12 patients (80%); they were generally mild and well controlled using 15 mg 
prednisone  as pre-medication, one hour before zoledronic acid administration. 
Kidney function was carefully monitored every month and the changes did not 
exceed 5% of the baseline levels over the whole observation period (Table 3). 
 
 
Effects of zoledronic acid on marrow CFU-F cells  
We have recently documented a severe and long-lasting decrease in 
marrow CFU-F cells after allogeneic SCT (20). In the present study, enriched 
mesenchymal stem cells were used to obtain CFU-F cells. At the baseline 
evaluation, the marrow compartment of CFU-F cells, resulted reduced 3- to 4-fold 
in transplanted patients compared to normal donors [mean CFU-F/106 cells plated 
± SEM: 9.9±2.9  (range: 0-46) (n=19) vs 46.8±4.4 (range: 29-59) (n=15); 
P=0.000009] (Figure 3).  
Zoledronic acid significantly improved in vitro growth of marrow CFU-F 
cells in the whole group of 12 patients (mean CFU-F/106 cells plated ± SEM: 
8.7±1.7  vs 21.9±3.5 before and after treatment, respectively; P=0.002).  However, 
in 7/12 patients the number of colonies in the CFU-F assay still remained below 
the normal range.  In six patients we performed CFU-F colony assays also 3 and 6 
months after the beginning of zoledronic acid treatment, and the number of their 
colonies progressively increased from the 3rd  to the 12th  month (mean CFU-F/106 
cells plated ± SEM: 12.1±3, 16 ±8 and 23.2±4 at 3, 6 and 12 months after 
zoledronic acid introduction, respectively), suggesting a continuous positive effect 
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of zoledronic acid on CFU-F colonies up to nine months after the withdrawal of 
treatment. These CFU-F cells clearly showed osteoblastic differentiation as 
documented by positivity to ALP staining after their replating in the 
osteoinductive conditions described in the Method section. On the contrary, only a 
marginal increase in the CFU-F cells was detected in 10 untreated patients who 
were evaluated after an interval of time similar to that of the zoledronic acid-
treated cohort (12±2 and 11±2 months in the untreated and treated cohorts, 
respectively): mean CFU-F/106 cells plated ± SEM: 7.1±1.6  vs 8.9±2.0, 
respectively; P =0.48 (Figure 3). The difference in CFU-F cells at the second 
evaluation between treated and untreated  patients was highly significant 
(P<0.00001).  
Figure 3. Clonogenic fibroblast progenitors in transplanted patients. Bone marrow 
enriched mesenchymal cells were used for colony forming unit-fibroblast (CFU-F) assay. 
CFU-F assay was repeated after 12±2 months from the beginning of zoledronic acid 
treatment in 12 patients and after 11±4 months in 10 untreated patients. A significant 
increase in CFU-F cells was found in the treatment group, while only a marginal increase 
was shown in a single patient in the untreated group. Shaded area: range values obtained 
in 15 normal individuals (bone marrow donors). Horizontal bars represent mean values, 
vertical bars represent the standard error of mean. 
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after zoledronic acid treatmentCFU-F - immunostaining for ALP:
prior to zoledronic acid treatment
Untreated patient at baseline after 12 months
 
Figure 4. Immunostaining for ALP at baseline and after 12 months in a patient treated with    
                 zoledronic acid and in an untreated patient.  
 
Discussion 
In this longitudinal study, we have confirmed our previous finding on persistent 
bone loss up to 3 years after allo-SCT (20,21). Age, time since SCT, hypogonadism, 
presence of cGHVD and its steroid treatment were all related in some way to bone loss; 
however, one of the most important roles in persistent bone loss seems to be played by 
the transplant procedure itself, possibly through persistently reduced regenerative 
capacity of osteoblastic precursors (20,21,24,25). Femoral BMD was more strongly 
influenced by BMI than the lumbar one, while the latter was related to amenorrhea 
duration and corticosteroid exposure. The major exposure to glucocorticoids and other 
immunosuppressive treatments in allo-SCT recipients occurs early after transplant for the 
prevention and treatment of GVHD. Since the repopulating capacity of osteoblast 
precursors has also been proven to be related to cGVHD (20);  patients affected by this 
complication seem to have multiple risk factors that predispose them to continuous bone 
loss (26).  Moreover, all male patients on glucocorticoid treatment presented inhibited 
gonadal axis with consequently transient but likely metabolically relevant hypogonadism. 
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Table 3. Characteristics of patients treated with zoledronic acid vs. non treated group. Both groups were receiving calcium and vitamin D 
supplementation since the first evaluation 
 
 Treated with zoledronic acid 
(n=15) 
 
Non treated group  
(n=15) 
 
  Pre-treatment  After 12-month   Baseline After 12 months 
      
 
Gender (F/M)  7/8 7/8  7/8 7/8 
BMI (kg/m2)  25.4±2.3 25.3±2.5  25.75±2.25 25.6±2.6 
      
 
No. of patients on corticosteroids/ dose taken (g/m2)  5/7.2±5.5 4/8.1±5.8  4/6.9±5.5 3/7.4±5.7 
Women on HRT (no./total women)  4/7 4/7  4/7 4/7 
       
Calcium (mmol/l)  2.38±0.11 2.35±0.11   2.38±0.12 2.37±0.12 
Phosphorus (mmol/l)  1.06±0.2 1.05±0.2  1.07±0.15 1.06±0.2 
Bone alkaline phosphatase (mcg/l)  11.2±4.8 15.2±5.6*  13.3±4.9 12±5.3 
Creatinine (µmol/l)  87±8 91±9  87.5±9.5 87±9 
Albumin (g/dl)  4.2±0.5 4.3±0.4  4.2±0.4 4.2±0.4 
Osteocalcin (ng/ml)  11±7.2 16±6.3  13.3±4.2 13.7±4.1 
Parathyroid hormone (ng/l)  41±9 38.5±10  38.3±10.5 40±10 
Urinary hydroxyproline excretion (µmol/l/m2 )  129.6±28 76±25**  130±34 126±33 
Urinary hydroxyproline/creatinine  8.8 8.5  9.0 8.9 
Urinary calcium excretion (mmol/24h)  3.4±1.5 3.2±1.4  3.18±1.6 3.19±1.6 
       
BMD at lumbar spine (g/cm2)  0.89±0.1 0.98±0.1**  0.93±0.12 0.89±0.03a a 
    % change    9.8±7%   -2.1±3% a aa 
BMD at femoral neck (g/cm2)  0.74±0.1 0.82±0.1*  0.78±0.09 0.76±0.04 a 
   % change   6.47±7%   -2.3±3.5% a aa 
Zoledronic acid was administered at a dose of 4 mg intravenously every 28 days for three consecutive months. Values are expressed as mean ± SD. Abbreviations: BMI: body 
mass index; HRT: hormone replacement therapy; BMD: bone mineral density. For normal ranges see legend to Table 2; *: p<0.005; **: p<0.001 vs. baseline; a :p<0.05, a 
a:p<0.01 and a aa :p<0.0001 vs. treated group.
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The condition of hypogonadism and cGVHD largely overlapped in the whole population. 
Thus, it is difficult to evaluate the effects of these two factors separately, especially in men, 
where hypogonadism has a shorter duration and is milder  than in women. Since the liver is 
one of the most frequent targets of cGVHD, an increase in liver enzymes often does not 
permit the introduction of replacement therapy for hypogonadism. Furthermore, currently 
there is a recommendation to not treat mild transient male hypogonadism. 
Stern et al. specifically evaluated the effects of cGVHD on bone mass over a 9 month 
period (27). An important average bone loss was shown in 9 patients, (decrease, -9.5%)  and 
was characterized by great individual variability (range, +0.85%  to -21.55%). Surprisingly, 
while the initial amount of bone loss was related to cGVHD presence in our study, the 
relationship was lost at the longitudinal evaluation. After the initial observation of a 
relationship between BMD reduction and glucocorticoid exposure (20,21), we started to treat 
cGVHD with the new immunosuppressive agent mycophenolate mofetil, known to cause less 
bone loss (28,29). The most plausible hypothesis on the loss of the relationship between BMD 
values and GVHD consists of variable bone effects of different immunosuppressive regimens. 
Other factors can be represented by a relatively short observation period (12 months) for an 
unsevere GVHD. The only correlation at the limit of significance was found between the 
amount of FN bone loss and CsA treatment duration.  
Most of the longitudinal studies investigated bone loss during the first year after SCT, 
comparing post-transplant BMD with pre-transplant values. The sharpest bone loss at 
trabecular and cortical sites occured within the first 6-12 months after allo-SCT.  In our study, 
bone loss was evaluated comparing two BMD measurements performed after the transplant. 
The baseline evaluation that was done in the later  stage after SCT can explain the lower rate 
of subsequent bone loss found in this study.  
Considering previous data on the ineffectiveness of common intervention in preventing 
bone loss (6), transplanted patients need to be treated by highly potent, specific agents. Our 
study aimed to investigate the bone effects of intravenous zoledronic acid given as three 
monthly doses of 4 mg each in patients who had undergone allogeneic SCT. This produced 
beneficial effects on lumbar and femoral BMD, largely higher than the one obtained by an 
oral bisphosphonate (30). Indeed, in our previous study a treatment with risedronate for 12 
months increased BMD at the LS by 5.9% and prevented bone loss at the femoral neck (30). 
Zoledronic acid improved bone density also at cortical rich bone (11). 
In this study, zoledronic acid was given as three consecutive doses of 4 mg each 
because of the evidence of multifactorial, conspicuous and persistent bone loss in long–term 
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survivors after allo-SCT. With this schedule we had tried to obtain rapid and measurable 
effects on bone mass. Given the persistent bone loss at trabecular and cortical rich skeletal 
sites in transplant recipients, zoledronic acid may be considered the treatment of choice in the 
near-transplant period for the prevention of bone loss. Moreover, given as intermittent short-
lasting administration, this agent can be easily added to the complex therapeutic regimens 
generally administered to transplanted patients. Several infusion protocols have been used for 
the treatment of osteoporosis, but no standard regimen is available.  In the study by Reid et 
al., a total dose of 4 mg of zoledronic acid was administered during 1 year with different 
schedules to menopausal women with low BMD. This caused a 4.3 to 5.1% and a 2.7 to 3.1% 
increase in LS and FN BMD, respectively, and was associated with a significant suppression 
of bone turnover markers (16). Another regimen was used in a multicenter study by Smith et 
al., who investigated the effects of 4 mg of zoledronic acid repeated at 3-month intervals for 
one year in men with non-metastatic prostate cancer during androgen deprivation therapy;  a 
5.6% increase in lumbar BMD was observed (11). 
Side effects were generally mild and well controlled by low-dose steroid pre-
medication. No alteration in kidney function was detected at any time point during the study, 
and liver enzymes did not worsen during the treatment period. As a matter of fact, zoledronic 
acid has proven to have a lower nephrotoxic potential than pamidronate in rat models (31).  
No conclusion can be made about fracture risk because this study is not sufficiently 
powerful to evaluate fracture incidence as a clinical end-point. Whether any treatment is able 
to reduce fracture risk after transplant still remains to be determined. 
Beneficial effects on lumbar and femoral BMD of zoledronic acid treatment in our 
transplanted patients was associated with a significant improvement of the clonogenic 
fibroblast progenitors belonging to the osteogenic stromal lineage. Although the specific 
mechanisms whereby bisphosphonates exert their beneficial osteotropic effect are not yet 
completely clarified, it is  generally accepted that they have a direct effect on osteoclasts, 
inducing their apoptosis (32-34), inhibiting their bone-resorbing activity (35) and blocking 
their precursor proliferation (36-38). This bisphosphonate-mediated anti-resorptive action has 
been reported to be related to the inhibition of the osteoclastic mevalonate pathway (34). In 
addition, recent in vitro findings suggest that bisphosphonates have multiple effects on bone 
turnover, in fact, they may directly enhance osteoblast proliferation and differentiation 
(39,40), prevent osteoblast apoptosis (41) and regulate osteoblast production of extracellular 
matrix proteins (42). All of these mechanisms further contribute to the inhibitory effect on 
bone turnover. Moreover, there is in vitro evidence that bisphosphonates increase osteoblastic 
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production of osteoprotegerin, which is needed to neutralize the receptor activator of the 
nuclear factor-kB ligand (RANKL) essential for osteoclast formation and activation (43).  
Viereck et al. have shown that in vitro pretreatment with pamidronate or zoledronate 
prevents the inhibitory effects of dexamethasone on osteoprotegerin production in the bone 
environment, suggesting that this mechanism may contribute to the bisphosphonate-induced 
enhancement of osteoclastic apoptosis in glucocorticoid-induced bone loss (43). The positive 
effects on  osteoblasts may be particularly important in allo-transplanted patients, since 
previous evidence indicated a persistently reduced regenerative and functional capacity of 
osteoblast precursors (20,26). Bisphosphonates were also demonstrated to stimulate in vitro 
formation of human and murine osteoblast precursors and of mineralized nodules, the latter 
probably through secretion of basic fibroblast growth factor stimulating CFU-F proliferation 
(42,44). Our in vitro results are in line with these studies. We have used CFU-F, as they are 
well recognized as the initial cell source of early and late osteoblast precursors (45). A 
significant improvement of in vitro growth of osteogenic progenitors was induced by in vivo 
zoledronic acid administration. In untreated patients, the number of CFU-F colonies 
marginally improved, likely due to the time elapsed from the effects of cytotoxic drugs and 
transplant-related cytokine storm. The difference between spontaneous and zoledronate-
induced improvement was highly significant. In agreement with a larger study (46), we 
documented a recipient origin of clonogenic fibroblast progenitors also after zoledronic acid 
treatment (Selleri, unpublished data). The increase in BMD and clonogenic fibroblast 
progenitors was accompanied by a significant decrease in hydroxyproline excretion and by an 
increase in serum bone alkaline phosphatase, while osteocalcin increase was just below the 
limit of statistical significance. The increase in marrow osteogenic precursors and bone 
alkaline phosphatase without significant increase in serum osteocalcin, could be explained by 
a strong  “in situ” stimulatory effect of zoledronic acid on the osteoblastic compartment 
concentrated in local niches of the stromal microenvironment. Such an effect was unable to be 
detectable as changes in serum bone formation markers. Indeed, controversial results were 
reported in serum osteocalcin levels during bisphosponate treatment for post-transplant 
osteoporosis (47-49).  
In conclusion, persistent multifactorial bone loss has been confirmed in patients up to 
36 months after allo-SCT. Most important risk factors included persistently reduced 
regenerating capacity of normal osteogenic cell compartment, ovarian failure and  the 
presence of cGVHD, requiring long-term immunosuppressive treatments. Zoledronic acid was 
easily manageable and effective in increasing densitometric values at both trabecular and 
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cortical skeletal sites. At least part of this effect can be ascribed to the ability in reversing the 
persistent post-transplant reduction of the clonogenic fibroblast progenitors belonging to the 
osteogenic stromal lineage. As intravenous bisphosphonates represent the most potent 
treatment option for post-transplant osteoporosis currently available, transplanted patients 
who are at high risk for fast and/or persistent bone loss should receive preventive treatment. 
Studies evaluating its preventive use should be carried out. Currently, the choice of 
oral/intravenous bisphosphonate administration in patients who had undergone allogeneic 
SCT should be made on the basis of individual clinical conditions, including the presence, 
grading and localization of GVHD,  and prevalent site of bone loss. 
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Effects of various anti-reabsorptive treatments on bone mineral density 
in hypogonadal young women after allogeneic stem cell  transplantation 
 
 
 
  Introduction 
Bone loss consequent to allogeneic stem cell transplantation (allo-SCT) has been 
described by many authors (1-6) as being more persistent and severe at corticacal bone 
(femoral neck) when compared to trabecular sites (lumbar spine) (4,7). Damaging effects on 
bone mass were attributed to hypogonadism, immunosuppressive and myeloablative 
treatments, immobilization, increased cytokine release, reduced dietary intake and metabolic 
alterations of calcium and vitamin D (5,6). One of the most important risk factors for bone 
loss is represented by precocious ovarian failure (POF), which is also the most common 
complication of allo-SCT (8-10). Calcium and vitamin D supplementation and hypogonadism 
replacement are commonly used in clinical practice after SCT, while bisphosphonates are 
added only in patients with osteoporosis. Little data is available so far on the effects of 
preventive or therapeutic intervention on post-transplant bone loss (1,11-13). To the best of 
our knowledge, no systematic evaluation has been performed to compare the effects of 
different agents for prevention or treatment and of osteoporosis consequent to allo-SCT. All 
commonly employed antireabsorptive treatments have been shown to improve bone mineral 
density (BMD) and decrease the rate of fractures in post-menopausal and glucocorticoid-
induced osteoporosis (14-17). However, the use of these treatments in transplanted patients 
may be limited by the general health conditions and by the simultaneous presence of other 
complications, including acute and chronic graft-versus-host disease (a- and cGVHD). Liver, 
skin and gastrointestinal tract are the most common localization of cGVHD (18) and in the 
active phase may represent a contraindication for the use of oral or trans-dermal therapies; 
even a mild chronic GVHD  may reduce gastrointestinal or dermal drug absorption. 
Furthermore, allo-SCT patients usually run into long-lasting and complex therapeutic 
regimens in order to prevent or treat other complications; thus, the management of 
osteoporosis can be difficult in some of them. 
The present study was aimed at investigating the 12-month effects of various 
antiresorptive treatments on lumbar and femoral BMD and bone turnover markers in female 
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patients with ovarian failure and low BMD following allo-SCT for hematological 
malignancies. 
 
Patients and methods 
 
Patients and study design  
Sixty women who had undergone allogeneic SCT at our Institution were enrolled in this 
study. Persistent amenorrhea occurred in all of them, as a consequence of chemotherapy. 
Precocious ovarian failure (POF) was diagnosed when gonadotropin levels were in the 
menopausal range and estradiol below the normal range of fertile women.  
All women were evaluated for BMD at the lumbar spine (LS) and femoral neck (FN), body 
mass index (BMI, kg/m2), serum osteocalcin and urinary hydroxyproline excretion, after a 
median period of 8 months (range, 3-17) since the transplant. Endocrine parameters regarding 
the reproductive function were also investigated. After the initial evaluation, the patients were 
divided into four groups of 15 women each. All the patients received calcium 1000 mg and 
vitamin D 800 IU supplementation that was administered orally once daily, between 07:00 p.m. 
and 08:00 p.m. Group 1 received only calcium and vitamin D during the whole observational 
period. In group 2, estradiol 2 mg daily and dihydroprogesterone 10 mg for 14 days a month 
were added for 12 consecutive cycles. Group 3 was treated with risedronate (35 mg weekly, 
orally) for 12 months and group 4 by zoledronic acid at the dose of 4 mg i.v. every 28 days for 3 
consecutive months. The four groups were all similar in age, BMI, underlying disease, time 
elapsed from transplant, amenorrhea duration and cGVHD features (Table 1). 
The determination of densitometry and bone turnover markers was repeated 12 months 
after the first evaluation. None of the participants had been given previous treatments for 
osteoporosis. Written informed consent was obtained from all of the patients in accordance with 
the institutional guidelines; the study was designed in accordance with the Helsinki II 
Declaration on treatment of human subjects. 
 
 
Transplantation procedure 
All patients had been successfully allo-transplanted with unmanipulated marrow from a HLA 
identical sibling. Leukemia was the most common indication for  allo-SCT. All patients had 
undergone conditioning with the BU-CY2 regimen (busulphan 16 mg/kg, cyclophosphamide 120 
mg/kg) and had received cyclosporine A (CsA) (1 mg/kg/day by continuous i.v. infusion from 
day -1 to day + 20 and then 8 mg/kg/day orally) plus short-course methotrexate (10 mg/m2 on 
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days +1,+3 and +6) as prophylaxis for GVHD. No patient had received radiation therapy. 
Patients with a- and cGVHD had been treated by methylprednisone (2 mg/kg/day or 1 mg/kg/day 
for 15 days in patients with aGVHD and cGVHD, respectively) and CsA (5 mg/kg/day) before 
the first evaluation of bone status. During the study, 53% of patients developed or had persistent 
cGVHD requiring immunosuppressive therapy as above described. As a significant correlation 
was found between corticosteroid treatment and bone damage at the initial evaluation, steroids 
were avoided whenever possible thereafter. During the study period,  cGVHD was treated by 
CsA + mycophenolate mofetil at a dose of 30 mg/kg/day; low-dose corticosteroids were 
continued in addition to these immunosuppressants in 11 patients only. The median cumulative 
dose of steroids given to this cohort of patients prior to study entry was equivalent to 6.4 g of 
prednisone (range 0.9-20) for 3-36 months, while the average dose administered  during the 
study was 1.3 ± 0.9 g for 3-10 months. The number of patients treated by steroids and the dose 
used during the study was similar among the four groups.   
 
Gonadal status assessment 
At study entry, all of the women underwent measurement of serum FSH, LH, 17-β-
estradiol, testosterone and dehydroepiandrosterone-sulphate (DHEA-S) in a single sample taken 
at 08:00 a.m. The same parameters were again evaluated after six and 12 months. All 
measurements were performed by commercially available kits: FSH and LH with 
radioimmunoassay (RIA, Biodata, Rimini, Italy), testosterone, DHEA-S and estradiol using 
Immulite, solid phase chemoluminescent enzyme immunoassay (DPC, Los Angeles, CA, USA).  
 
Bone metabolism assessment 
Serum calcium, phosphorus, creatinine, bone alkaline phosphatase (ALP), intact 
parathyroid hormone (iPTH) and osteocalcin were determined in blood samples drawn at initial 
evaluation  and after 6 and 12 months. Blood samples were collected in the morning after a 12-h 
fast. Urinary calcium, phosphorus and hydroxyproline were assayed on a 24-h urinary collection. 
Standard dietary restrictions were observed by all the individuals tested, starting five days prior 
to urinary collection.  Intact PTH and serum osteocalcin levels were measured by RIA (Nichols 
Institute Diagnostics, CA), the detection limit of the latter being 0.35 mg/L. Bone alkaline 
phosphatase was assayed by a direct immunoradiometric assay (Ostease, Hybritech, San Diego, 
CA).  Hydroxyproline excretion was measured by high pressure liquid chromatography. Blood 
chemistry profile, including Ca, P, ALP, urinary Ca excretion and creatinine levels, were 
analyzed using a standard autoanalyzer.  
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Table 1.  Clinical features of 60 transplanted female patients – women long-term survivors after allogeneic SCT 
Variable Group 1  Group 2  Group 3  Group 4  
N° of patients 15 15 15 15 
Age (yrs) 26.1 ± 9 26.8 ± 8.6 24.8 ± 7.8 27 ± 9 
BMI (kg/m2) 23.5 ± 2.3 23.8 ± 2.4 24.1 ± 3.0 23.2 ± 2.6 
Underlying disease:      
     AML in 1st CR/ CML in chronic phase 8/5/2/-/- 7/6/1/-/1 7/6/1/1/- 7/6/1/1/- 
     ALL in 2nd CR/ HD/ SAA     
Amenorrhea duration (months) 10.3 ±10 9 ± 9.2 10.8 ± 11 9.5 ± 10.2 
Acute GVHD  6 6 7 8 
    Grade I-II/III-IV 5/1 4/2 5/2 6/2 
Chronic GVHD 7 8 8 9 
    Limited/extensive form 4/3 4/4 3/5 3/6 
Corticosteroid treatment#      
    Duration (days) 216 ± 160 198 ± 143 247 ± 178 255 ± 150 
    Cumulative dose (g)* 6.9 ± 5 7.0 ± 5.4 7.7 ± 4.9 8.2 ± 4.5 
Cyclosporin A treatment#     
    Duration (days) 339 ± 176 351 ± 165 328 ± 140 349 ± 170 
    Cumulative dose (g)  61 ± 13 58 ± 14 64 ± 12 67 ± 15 
Values are expressed as mean ± SD, when appropriate. Abbreviations: SCT: stem cell transplant, BMI: body mass index, AML: acute myeloid 
leukemia, CML: chronic myeloid leukemia, ALL: acute lymphoblastic leukemia, HD: Hodgkin’s disease, SAA: severe aplastic anemia, CR: 
complete remission, GVHD: graft versus host disease; Symbols: #: immunosuppressive treatments before study enrollment;*: cumulative dose 
of corticosteroids is expressed as prednisone equivalent.  
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Bone density  and fracture assessment 
Bone density was determined by dual-energy x-ray absorptiometry (DEXA) at the lumbar 
spine (L1-L4) and femoral neck (FN), using Hologic QDR 1000 densitometer (Hologic, Inc., 
Waltham, MA). Individual BMD values were expressed as g/cm2  and T, Z-scores. Quality 
control was performed by daily scanning of an anthropomorphic spine phantom. The coefficient 
of variation was  1.8% for the LS and 2.2% for the FN.  The reference population adopted in this 
study was the international pooled sample provided by the manufacturer; their data, however, did 
not differ significantly from those obtained on a local sample in a study performed when the 
device was set up (19). 
Standard spinal radiographs in anterior-posterior and lateral positions of vertebrae Th4 - L4 
was performed in all patients at baseline and after 12 months.  At baseline, two women from 
group 3 and three from group 4 had prevalent fractures, determined as a 20% difference in 
antero-posterior, middle-posterior or posterior-posterior adjacent ratio (20). 
 
Statistical analysis 
Data are reported as mean ± SD unless otherwise specified. The normal data distribution 
was tested by Wilk-Shapiro’s test. Statistical analysis was performed by the Student’s t-test for 
paired and unpaired data, as appropriate, for comparison between groups treated by different 
regimens. At pre-treatment evaluation, the association between BMD values, 
immunosuppressive treatment duration and cumulative doses, and amenorrhea period were 
assessed by linear regression. Comparison of the variables within the same group was performed 
by the Friedman test. The significance was set at 5%.  
 
 
Results 
Clinical features and gonadal status  
Clinical features at study entry, underlying malignancies and details on previous 
treatments are summarized in Table 2. Women who did not undergo HRT did not experienced 
recovery of spontaneous menstrual cycles during the observational period. None of the women 
from group 2 reported menstrual cycles within 60 days after HRT withdrawal at the end of the 
study, their gonadotropins and estradiol being still in the postmenopausal range.  
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Baseline  evaluation of bone turnover and BMD after SCT   
Gonadotropin values were in the menopausal range, while estradiol, testosterone and 
DHEA-S were significantly lower than the normal range for reproductive aged women. 
Baseline endocrine parameters, BMD values at both skeletal sites and bone turnover markers 
were similar in all groups of patients (Table 2). According to the WHO criteria (21), 
osteoporosis was diagnosed in 4 patients of group 1, 5 of group 2, 5 of group 3 and 6 of group 
4. 
Baseline lumbar BMD correlated inversely with the duration of amenorrhea (r=-0.47; P 
=0.045). Serum osteocalcin correlated with baseline lumbar BMD (r=0.61; P=0.048). A 
borderline correlation was present between lumbar BMD and cumulative dose of 
corticosteroids used prior to the study entry (r=-0.49; P=0.05).  
 
Treatment effects on endocrine parameters, bone turnover and BMD  
Mean gonadotropin, estradiol, testosterone and DHEA-S levels did not change 
significantly in groups 1, 3 and 4. Gonadotropins decreased (FSH by 60%, LH by 64%) and 
estradiol increased (by 387%) in group 2 during HRT (P<0.0001, all), whereas testosterone and 
DHEA-S did not change; nevertheless, gonadotropins still remained  above and estradiol below 
their normal ranges for reproductive aged women.  
There were no significant changes in BMI, serum levels of calcium, phosphorus, 
albumin, calcium urinary excretion and iPTH in any group during the 12 month observation 
period. 
When concerning with bone turnover markers, in groups 3 and 4 hydroxyproline 
excretion significantly decreased at 3, 6 and 12 months, when compared with baseline values 
(P<0.001)(Figure 1). Bone alkaline phosphatase and osteocalcin did not change in groups 1,2 
and 3; they were found slightly but significantly increased in group 4 (P= 0.038 and P=0.032, 
respectively).  
Two incident subclinical vertebral fractures in group 1 and one in group 2 were detected at the 
12th month radiological evaluation of the spine. No non-vertebral fracture occurred during the 
observation period.  
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Table 2. Results of the initial evaluation of biochemical parameters and bone density in 60 women long-term survivors after 
allogeneic SCT 
Variable Group 1 (n=15) Group 2 (n=15) Group 3 (n=15) Group 4 (n=15) Normal range 
Age (yrs) 26.1 ± 9 26.8 ± 8.6 24.8 ± 7.8 27 ± 9  
BMI (kg/m2) 23.5 ± 2.3 23.8 ± 2.4 24.1 ± 3.0 23.2 ± 2.6  
FSH (U/L) 112 ± 51 103 ± 42 123 ± 39 115 ± 45  
LH (U/L) 62.5 ± 23 70 ± 19 58 ± 20 68 ± 18  
Estradiol (pg/ml)  21 ± 12 16 ± 14 23 ± 9 15 ± 10  
Testosterone (pg/ml) 0.35 ± 0.4 0.2 ± 0.3 0.3 ± 0.3 0.34 ± 0.5  
DHEAS (µg/dl) 130 ± 62 140 ± 67 110 ± 57 125 ± 39  
      
Calcium (mmol/l) 2.37 ± 0.12 2.38 ± 0.11 2.36 ± 0.12 2.37 ± 0.13  
Phosphorus (mmol/l) 1.07 ± 0.16 1.06 ± 0.2 1.1 ± 0.18 1.05 ± 0.21  
Bone alkaline phosphatase (mcg/l) 10.3 ± 5.5 12.1 ± 5.8 11.3 ± 4.1 11.2 ± 4.4  
Creatinine (µmol/l) 85 ± 8.5 87 ± 8 82 ± 10 83 ± 9  
Albumin (g/dl) 3.95 ± 0.4 3.93 ±0.38  3.9 ± 0.43  4.0 ± 0.5  
Osteocalcin (ng/ml) 12.2 ± 4.4 12.7 ± 5.3 13.3 ± 4.5 11.8 ± 3.5  
iPTH (ng/l) 34 ± 12 38 ± 9.2 
 39.9 ± 10.6  36.6 ± 11.3  
Urinary hydroxyproline excretion (µmol/l/m2 ) 136 ± 32 129 ± 27 125 ± 25 131 ± 22  
Daily calcium excretion (mmol/24h) 3.6 ± 1.4 3.4 ± 1.4 3.35 ± 1.1 3.5 ± 1.3  
 
     
BMD at the lumbar spine (g/cm2) 0.91 ± 0.14 0.89 ± 0.15 0.92 ± 0.1 0.9 ± 0.11  
  T-score (SD) -1.3 ± 1.3 -1.5 ± 1.2 -1.2 ± 1 -1.4 ± 1  
BMD at the femoral neck (g/cm2) 0.77 ± 0.12 0.78 ± 0.11 0.74 ± 0.12 0.71 ± 0.13  
   T-score (SD) -1.4 ± 1.2 -1.3 ± 1.1 -1.5 ± 1.1 -1.85 ± 1.2  
Values are expressed as means ± SD. Abbreviations: BMI: body mass index; iPTH: intact parathyroid hormone; BMD: bone mineral density. Normal ranges: FSH: 2-13 U/L; 
LH: 2-15 U/L; 17β-estradiol: 40-250 pg/ml; testosterone: 0.2-1 pg/ml, DHEAS: 80 – 560 µg/dl; serum calcium: 2.2-2.6 mmol/L; serum phosphorus: 0.7-1.35 mmol/L; bone 
alkaline phosphatase: 7-25 µg/L; creatinine: <133 µM/L; albumin: 3.6-5.2 gr/dl; intact osteocalcin: 2-22 ng/ml; iPTH: 10-75 ng/L; urinary hydroxyproline excretion: 60-190 
(µmol/m2); Ca excretion: 1.3-6.5 mmol/24h.
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Figure 1.  Bone turnover markers at months 0,3,6 and 12 of treatment. All women were treated 
with calcium (1000 mg daily) plus vitamin D (800 U.I. daily). Group 1 (n=15) received the 
supplement alone; group 2 (n=15) received  the supplement in combination with HRT; 
group 3 (n=15) was treated with oral risedronate (35 mg weekly) and group 4 (n=15) with 
zoledronic acid (4 mg i.v. every 28 days for 3 months). ALP: bone alkaline phosphatase.*: 
P< 0.05 vs. baseline. 
 
A significant decrease in lumbar and femoral BMD was observed in group 1 (-4.3 ± 2.3% 
and –4.2 ± 1.6%, P=0.046) (Figure 2), while a slight not significant decrease was found in 
group 2 (-3.1 ± 1.4% and -3.3 ± 1.5%). Risedronate treatment significantly increased lumbar 
BMD (5.8 ± 2.1%; P<0.035) and prevented bone loss at femoral neck (1.3 ± 1.2%; P=0.6 vs. 
baseline). Zoledronic acid increased significantly both lumbar and femoral BMD (8.6 ± 7%; 
P<0.01 and 5.4 ± 2.2%; P<0.039, respectively vs. baseline).  
After the 12 month treatment period, the changes in BMD between group 4 and groups 
1-2 were significant at both LS and FN (P<0.00001). Every changes between group 3 and 
groups 1-2 were significant at both LS and FN (P<0.00001). Only the difference in FN BMD 
was significant between groups 3 and 4 (P <0.0001).  
The inter-group difference in absolute BMD values at 12 months was not significant.  
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Figure 2. Densitometric values at lumbar spine and femoral neck before and 12 months after 
beginning of treatment, expressed as Z-scores. Groups 1-4 as in Figure 1. 
Horizontal bars represent mean values. *: P< 0.05 and ** P< 0.01 vs. baseline; a : 
P<0.05 vs. groups 1 and 2; b: P<0.0001 vs. group 4. 
 
Treatment adverse effects  
No patient dropped out during the 12 month treatment in any group. After HRT 
introduction in group 2, five women suffered from a moderate headache and six from breast 
tenderness. These disorders disappeared invariably within the third month of treatment. Three 
patients in  group 3 complained about mild-to-moderate gastric pain, which was well controlled 
by  addition of antacid treatment. Flu-like symptoms, including myalgia, body temperature 
increase (<37.8°C) and nausea, occurred in 12 women  (80%) treated by zoledronic acid; these 
symptoms were well controlled using 15 mg prednisone as a pre-medication, one hour before 
zoledronic acid infusion. 
Kidney and liver function was carefully monitored in all women every two months and 
did not change over  the whole observation period.  
 
Discussion 
This is a controlled study comparing different anti-reabsorptive treatments in a population 
of hypogonadal women after allogeneic stem cell transplantation. This study clearly demonstrates 
that the interventions commonly used for prevention of bone loss in the general population  have 
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no protective effects in hypogonadal transplanted women (1,22). In our experience, the 
supplementation of calcium and vitamin D, alone or together with the correction of 
hypogonadism, did not reverse bone loss in women after allo-SCT. The reasons for this may be 
related to the chronic and multifactorial nature of post-SCT bone loss. Indeed, age, time since 
SCT, degree of hypogonadism, presence of cGHVD and subsequent steroid treatments are all 
related in some way to the bone loss (1-5,13). Moreover, cytotoxic drugs have harmful effects on 
bone (23) and the transplant procedure itself negatively influences bone mass, mainly throughout 
“cytokine storm”, GVHD and persistent reduction of the regenerative capacity of the osteoblastic 
bone marrow lineage (3,24,25). Considering altogether our results and the existing data on the 
ineffectiveness of common intervention in preventing bone loss (22), transplanted patients need to 
be treated by highly potent, specific agents. 
Although calcium and vitamin D supplementation  is insufficient by itself, it is necessary 
after SCT because gastrointestinal absorption of these agents is reduced and metabolism is altered 
(2,4). All our patients were replaced with calcium and vitamin D during the whole observational 
period.  
Although virtually all women experience transient or permanent amenorrhea consequent to 
allo-SCT, little data is available on the systemic effects, the type and administration schedule of 
HRT. In women after the physiological menopause, HRT has been widely shown to be effective in 
relieving the multiple symptoms of gonadal failure, including osteoporosis (14,15). HRT was  
reported as effective in the treatment of post-transplant bone loss in a study by Castelo-Branco 
(11). We cannot confirm these results, since we could not find any improvement of BMD during 
the 12 month HRT administration; in fact,  bone loss continued. Vasomotor symptoms and 
urogenital dryness disappeared in all women, whereas endocrine parameters only improved. We 
chose the most physiological and easy to use schedule: one pill every day for 28 days in an oral 
combined sequential schedule. There are three feasible explanations for the lack of HRT’s 
protective effects in our patients: young women with precocious ovarian failure may require HRT 
with doses higher than those used for the treatment of physiological menopause; bone marrow 
transplanted women may have reduced intestinal absorption of the drugs due to persistent 
gastrointestinal system damage by the previous chemotherapy or to gastrointestinal cGVHD 
which could be mild and unrecognized. Another explanation can be the nature of post-transplant 
bone loss that could only partly be related to estrogen deficit.  
In any case, the management of HRT in allo-transplanted women is not easy, since about 
50% of patients develop chronic GVHD. HRT is contraindicated in women with abnormal liver 
function due to cGVHD. Little data is still available on HRT use in women who had undergone 
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SCT, it can be considered safe in absence of active acute or cGVHD. There is evidence that HRT 
does not increase the risk of cGVHD exacerbation and prevents some adverse effects of long-
lasting ovarian failure in young women (26,27).  
Oral bisphosphonates proved to be effective for treating post-menopausal and 
glucocorticoid-induced osteoporosis (14,15,17). In a previous study from our group, a 12-month 
treatment with a daily dose of 5 mg of risedronate increased BMD by 5.9% at the LS and 
prevented bone loss at the femoral neck in a mixed population of allo-transplanted patients (12). 
Nevertheless, gastrointestinal GVHD can impaired absorption of oral bisphosphonates, which are 
characterized by a low absorption from the gastrointestinal tract even in the general population 
(28,29). Furthermore, these agents are contraindicated in immobilized patients. Intravenous 
bisphosphonates proved to be effective in the treatment of postmenopausal and glucocorticoid-
induced osteoporosis (30,31), although their principal indications are hypercalcemia management 
in cancer patients and prevention and treatment of bone metastases of various malignancies. In our 
experience, zoledronic acid was the only agent which improved bone density at cortical rich bone 
in hypogonadal females. This drug also produced beneficial effects on lumbar and femoral BMD 
in a mixed population of hypogonadal/eugonadal allo-transplanted men and women (13). In our 
center, zoledronic acid was given as three consecutive doses of 4 mg each in order to obtain a 
rapid and consistent effect on bone mass. Several infusion protocols have been used for the 
treatment of osteoporosis, but no standard regimen is currently recommended. In different 
patients’ populations, the total dose of zoledronic acid administered over the period of one year 
ranged from 4 mg in menopausal women (30) to 16 mg in men with non-metastatic prostate 
cancer during androgen deprivation (16). These regimens caused a BMD increase that ranged 
from 4.3 to 5.6% at LS and from 2.7 to 3.1% at FN. A significant persistent suppression of bone 
turnover markers was also documented in post-menopausal women (30). An important aspect of 
zoledronic acid is the possibility of giving it as intermittent short-lasting infusion, which can be 
easily added to the complex therapeutic regimens generally used in transplanted patients.  
Bisphosphonates are currently the most effective inhibitors of bone resorption; they exert a 
direct effect on osteoclasts, inhibiting their bone-resorbing activity (32), inducing apoptosis (32-
34) and blocking their precursor proliferation (34,35). In addition, recent in vitro evidences have 
been accumulated on the anabolic bone effects of bisphosphonates. They directly enhance 
osteoblast proliferation and promote a differentiation of osteoprogenitor cells towards the 
osteoblastic pathway (36,37). Bisphosphonates also  prevent osteoblast apoptosis (38) and up-
regulate osteoblast production of extracellular matrix proteins (35). These effects have been 
proven for different members of the bisphosphonate family, including zoledronic acid, 
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pamidronate, neridronate, alendronate and risedronate (34,40,41). In a previous study, we 
documented that bone effects of zoledronic acid in transplanted patients were associated with a 
significant improvement in the regenerating capacity of osteogenic stromal lineage precursors. 
Similar findings have also been reported for risedronate in vitro: risedronate stimulated osteoblast 
proliferation in a human trabecular bone culture model. This effect was more evident and 
sustained over a wide range of time periods and drug concentration when produced by risedronate 
as opposed to alendronate (40).  
The positive effects on osteoblasts may be particularly important in allo-transplanted 
patients, since previous evidence indicated a persistently reduced regenerative and functional 
capacity of osteoblast precursors (3,23,24,41,42). Although we did not evaluate osteoblastic 
lineage behavior in patients treated by risedronate, it is likely  that BMD improvement produced 
by risedronate is at least in part related to its anabolic effects, in analogy with what we 
documented with zoledronic acid (13). As a matter of fact, the improvement observed in the 
patients treated by bisphosphonates was highly significant at both LS and FN. A significant 
decrease in hydroxyproline excretion was also observed in the groups treated by bisphosphonates. 
An increase in serum bone alkaline phosphatase and osteocalcin  was just at the limit of statistical 
significance only in the zoledronate  group. When concerning with bone formation markers in 
post-transplant osteoporosis, controversial results were reported in serum osteocalcin levels during 
bisphosphonate treatment (43,44).  
Side effects of the treatments employed were generally mild and well controlled by 
appropriate pre-medications. No alteration in kidney function was detected at any time point 
during the study, and liver enzymes did not worsen during the treatment period.  
No conclusion can be made about fracture risk reduction because this study is not sufficiently 
powerful to evaluate fracture incidence as a clinical end-point. Whether any treatment is able to 
reduce fracture risk after allo-SCT still remains to be determined. 
In conclusion, persistent multifactorial bone loss in allo-transplanted patients needs a 
specific and careful treatment. Neither calcium plus vitamin D supplementation nor its 
association with HRT were able to prevent bone loss in young adult hypogonadal women after 
allo-SCT. Bisphosphonates are currently the only treatment able to prevent and treat bone 
demineralization in this particular population of patients. Weekly oral risedronate and monthly 
i.v. zoledronic acid infusion were easily manageable and effective in increasing densitometric 
values at trabecular skeletal site. Zoledronic acid was the only therapy that improved femoral 
BMD. At least part of these effects can be ascribed to the bisphosphonates’ ability in reversing 
the persistent post-transplant reduction of  clonogenic fibroblast progenitors belonging to the 
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osteogenic stromal lineage. Currently, the choice between oral or intravenous bisphosphonate 
therapy in patients who had undergone allogeneic SCT should be made on the basis of individual 
clinical conditions, including  presence, grading and localization of GVHD,  and prevalent site of 
bone loss. The evaluation of cost-effectiveness requires the data on fracture prevention that still 
have to be produced.  
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Discussion 
 
 
Haematopoietic stem cell transplant has become a successful treatment for different 
hematological malignancies and other diseases as well, and is generally performed in young 
patients. Multiple late complications have already been described but little information on risk 
factors of these long term effects of SCT is available, except for gonadal failure. Moreover, 
frequent post-transplant endocrine and bone disorders raise an important clinical question of 
when and how to treat them. Appropriate diagnosis and treatment of post-transplant 
complications can consistently improve the quality of life and general health in long-term 
sirvovors after SCT.  
Endocrine disorders were mostly ascribed to highly aggressive chemotherapy and 
TBI. However, multiple dysfunctions were found in the endocrine system of patients not 
treated by TBI, even years after SCT. While the toxic effects of antiblastic agents have been 
widely described, the impact of immune system damage on endocrine function is less clear. 
We have focused our attention on the hypothesis that the type of transplant can be important 
for endocrine and bone disorders. In particular, thyroid and adrenal functions, and IGF-1 
impairment occur more frequently in patients after allografting than in those who have 
undergone auto-SCT. We have demonstrated that cGVHD profoundly impairs endocrine 
functions in allo-SCT recipients, also in the absence of TBI. Allogeneic bone marrow/blood 
derived stem cell transplantation is the only condition in which a great amount of donor 
immunocompetent cells are infused to a host that is recognized  as “nonself”, and thus causing 
graft-versus–tumor reaction, and GVHD. While the first is necessary for disease 
disappearance, the second represents a frequent complication that requires 
immunosuppressive treatments, which can further deregulate the function of the immune 
system. Patients developing cGVHD seem to be at a greater risk for endocrine dysfunction, 
including an increased frequency of thyroid disorders, adrenal insufficiency  and IGF-I 
reduction. Their residual gonadal function also seem to be worse. These findings suggest that 
immunosuppressive treatments and immune system derangement play an important role in the 
development of endocrine dysfunction after allografting. 
Precocious gonadal failure, adrenal insufficiency, thyroiditis and hypothyroidism 
require specific monitoring and treatment by specialized operators. Therefore, patients 
affected by these disorders require life-long monitoring to detect, prevent and treat their 
symptoms.  
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Moreover, we found a greater increase in serum leptin after allo-SCT than after auto-
SCT, with the highest levels in patients affected by cGVHD. The physiological relationship 
between leptin, body mass and gonadal function was lost in allotransplanted setting, while  a 
close relationship between leptin and IFN-gamma was documented in allotransplanted 
patients. A closer relationship between these two parameters was observed in subjects with 
increased IFN-gamma, suggesting that a higher degree of immune system activation can 
trigger leptin production in the post-transplant period. Since leptin regulates the balance of 
Th1/Th2 cytokines, it is possible that Th1 lymphocyte activation during cGVHD may account 
for the difference in leptin values observed between auto- and allo-transplanted subjects. A 
major increase in serum leptin in patients with cGVHD suggests that autoreactive T cells 
involved in cGVH reaction may further stimulate leptin secretion. A minor increase in serum 
leptin levels and preserved leptin/BMI ratio observed after auto-SCT are in line with a milder 
immune system alteration in this cohort of patients. These results further confirm a close 
relationship between the immune and endocrine systems. 
When regards to bone loss conseguent to SCT, patients who underwent allogeneic 
transplant are at a higher risk for bone loss than those autotransplanted. Bone mass at either 
cancelous or cortical rich sites usually improves with time after autografting, while 
allotransplanted patients can continue to lose cortical bone even years after the transplant. Our 
treatment experience in the allogeneic setting clearly confirms prior evidence on the inability 
of  conventional interventions used to prevent bone loss in the general population in 
transplanted patients. The supplementation of calcium and vitamin D, alone or together with 
the correction of hypogonadism, did not reverse bone loss in our women after allo-SCT. The 
reasons for this may be related to the chronic and multifactorial nature of post-SCT bone loss. 
Indeed, age, time elapsed since SCT, degree of hypogonadism, presence of cGHVD and 
subsequent steroid treatments are all in some way related to bone loss. Moreover, cytotoxic 
drugs have harmful effects on the bone, and the transplant procedure itself negatively 
influences bone mass, mainly throughout “cytokine storm,” GVHD and persistent reduction 
of the regenerative capacity of the osteoblastic bone marrow lineage. Considering our results 
altogether with the existing data on the ineffectiveness of common intervention in preventing 
bone loss, transplanted patients need to be treated by highly potent and specific agents. The 
most potent agents that are currently available on the market for the treatment of osteoporosis 
are bisphosphonates. Although they are considered as antireabsorbtive drugs, a huge amount 
of evidence has been accumulated in vitro, showing that they stimulate proliferation and 
differentiation of the osteoblastic precursors at lower concentrations. On the contrary, at  
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higher concentrations, the bisphoshonates have prevalent inhibitory effects on osteoclasts. For 
the first time, we have documented a significant improvement of the repopulation capacity of 
osteoblastic precursors in vitro that was obtained by the administration of zoledronic acid in 
vivo. The anabolic effect on osteoblasts can be particularly useful in allotrasnplanted patients 
that have inhibited the repopulating capacity of the osteoblastic lineage.    
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Conclusion 
Complications of the endocrine and muscoloschelettal systems were more frequent, 
more severe and more closely related to the degree of immunological deregulation in the 
allogeneic setting than in the autologous one. If they are left untreated, they can worsen the 
quality of life and sometimes shorten the overall survival. 
Persistent endocrine disorders were observed in the allogeneic setting even years 
after the transplant. Frequent endocrine disorders were revealed during the first year after 
autologous stem cell transplant; despite the tendency to improve, in more than half of the 
cases, the complications persisted over one year. Multiple risk factors including previous 
antiblastic, corticosteroid and radiation treatments, an abnormal immunological condition and 
general health status are likely responsible for the onset of endocrine disorders.  
Persistent bone loss at cortical bone has a multifactorial origin in patients after 
allogeneic stem cell transplant, and seems to be in great part related to the transplant 
procedure itself. It tended to improve in patients cured from the underlying disease by the 
autolgous SCT. Bone density should be monitored in all subjects during the first year after 
autologous SCT. Bone loss should be periodically investigated in all allotransplanted patients during 
life-long follow-up. Any significant decrease in bone mass should be treated by specific potent agents 
with a possible anabolic effect on the osteoblastic production.  
In conclusion, periodical screening for endocrine disorders and bone loss is 
necessary in long-term survivors  after allogeneic stem cell transplant. In the autologous 
setting, all the patients should be evaluated for both endocrine disorders and bone loss at least 
during the first year after transplant and thereafter, according to their clinical conditions, underlying 
disease and previous treatments.  
 
